<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>

<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp. - Form 10-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C.
20549</P>
<P align=center><B><FONT size=5>FORM 10-K</FONT></B></P>
<P align=center>(Mark One)</P>
<P align=center>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 <br>
For the fiscal year ended <B><U>September 30, 2012</U></B></P>
<P align=center>[&nbsp; &nbsp;] TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 <br>
For the transition period from ________________
to________________</P>
<P align=center>Commission file number<B>: </B><B><U>000-51652</U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES
CORP.</FONT></U></B><BR>(Exact name of registrant as specified in its
charter)</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD width="50%" align=center><B><U>20-8365999 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of incorporation or
      organization) </TD>
    <TD width="50%" align=center>(I.R.S. Employer Identification No.) </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center><B><U>1620 &#150; 609 Granville Street, Vancouver BC Canada
      </U></B></TD>
    <TD width="50%" align=center><B><U>V7Y 1C3 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD width="50%" align=center>(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code
<U><STRONG>1-800-689-3939</STRONG></U></P>
<P align=center>Securities registered under Section 12(b) of the Act:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=center><U><B>None </B></U></TD>
  <TD width="50%" align=center><U><B>N/A </B></U></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>Title of each class </TD>
    <TD width="50%" align=center>Name of each exchange on which registered  </TD>
  </TR></TABLE>
<P align=center>Securities registered pursuant to Section 12(g) of the
Act:<BR><B><U>Common Stock, $0.001 par value</U></B><BR>(Title of class)<BR></P>
<P align=justify>Indicate by checkmark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. <BR>Yes[&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No[X]</P>
<P align=justify>Indicate by checkmark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Act. <BR>Yes[&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No [X]</P>
<P align=justify>Indicate by checkmark whether the registrant has (1) filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.<BR>Yes[X]&nbsp;&nbsp;&nbsp;&nbsp;
No[&nbsp;&nbsp; ]</P>
<P align=justify>Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such
files).<BR>Yes[X]&nbsp;&nbsp;&nbsp;&nbsp; No[&nbsp; &nbsp;]</P>
<P align=center>i</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_2></A>
<P align=justify>Indicate by checkmark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&#146;s
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
[X]</P>
<P align=justify>Indicate by checkmark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act.</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=left>Large accelerated filer [&nbsp;&nbsp; ] </TD>
    <TD width="44%" align=left>&nbsp; </TD>
    <TD width="27%" align=left>Accelerated
      filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      [&nbsp;&nbsp; ] </TD></TR>
  <TR vAlign=top>
    <TD align=left>Non-accelerated filer&nbsp; &nbsp;[&nbsp; &nbsp;] </TD>
    <TD width="44%" align=left>(Do not check if a smaller reporting company)
    </TD>
    <TD width="27%" align=left>Smaller reporting company [X]
</TD></TR></TABLE></DIV>
<P align=justify>Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Act). <BR>Yes[&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No[X]</P>
<P align=justify>State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such
common equity, as of the last business day of the registrant&#146;s most recently
completed second fiscal quarter: $25,213,463 based on a price of $1.25 per
share, being the closing price of the registrant&#146;s common stock on March 30,
2012.</P>
<P align=justify>Indicate the number of shares outstanding of each of the
registrant&#146;s classes of common stock, as of the latest practicable date.
30,240,687 issued and outstanding as of December 28, 2012.</P>
<P align=justify>DOCUMENTS INCORPORATED BY REFERENCE</P>
<P align=justify>None</P>
<P align=center>ii</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_3></A>
<P align=center><B><U>TABLE OF CONTENTS</U></B></P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_6"><B>PART
      I</B> </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left >&nbsp; </TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_6">Item
      1. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_6">Business
      </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_14">Item
      1A. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_14">Risk
      Factors </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_26">Item
      1B. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_26">Unresolved
      Staff Comments </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_26">Item
      2. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_26">Properties.
      </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_27">Item
      3. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_27">Legal
      Proceedings. </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_27">Item
      4. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_27">Mine
      safety disclosures. </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_27"><B>PART
      II</B> </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left >&nbsp; </TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_27">Item
      5. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_27">Market
      for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer
      Purchases of Equity Securities </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_30">Item
      6. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_30">Selected
      Financial Data </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_30">Item
      7. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_30">Management's
      Discussion and Analysis of Financial Condition and Results of Operations.
      </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_36">Item
      7A. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_36">Quantitative
      and Qualitative Disclosures about Market Risk. </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_36">Item
      8. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_36">Financial
      Statements and Supplementary Data. </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_38">Item
      9. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_38">Changes
      In and Disagreements with Accountants on Accounting and Financial
      Disclosure. </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_38">Item
      9A </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_38">Controls
      and Procedures</A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_40">Item
      9B </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_40">Other
      Information</A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_41"><B>PART
      III</B> </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left >&nbsp; </TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_41">Item
      10. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_41">Directors,
      Executive Officers and Corporate Governance </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_44">Item
      11. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_44">Executive
      Compensation. </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_48">Item
      12. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_48">Security
      Ownership of Certain Beneficial Owners and Management and Related
      Stockholder Matters </A></TD></TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_50">Item
      13. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_50">Certain
      Relationships and Related Transactions, and Director Independence
  </A></TD></TR></TABLE>
<P align=center>iii</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_4></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_52">Item
      14. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_52">Principal
      Accountant Fees and Services </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_53"><B>PART
      IV</B> </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left >&nbsp; </TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_53">Item
      15. </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left ><A
      href="#page_53">Exhibits
      and Financial Statement Schedules </A></TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><A
      href="#page_59">Signatures
      </A></TD>
    <TD bgColor=#eeeeee width="90%" align=left >&nbsp;</TD>
  </TR></TABLE>
<P align=center>iv</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_5></A>
<P align=justify><B>Forward Looking Statements.</B></P>
<P align=justify>This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our
anticipated future clinical and regulatory milestone events, future financial
position, business strategy and plans and objectives of management for future
operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and similar
expressions, as they relate to us, are intended to identify forward-looking
statements. Such forward-looking statements include, without limitation,
statements regarding the anticipated start dates, durations and completion dates
of our ongoing and future clinical studies, statements regarding the anticipated
designs of our future clinical studies, statements regarding our anticipated
future regulatory submissions and statements regarding our anticipated future
cash position. We have based these forward-looking statements largely on our
current expectations and projections about future events, including the
responses we expect from the U.S. Food and Drug Administration, or FDA, and
other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and
clinical trials and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions including without
limitation the risks described in &#147;Risk Factors&#148; in Part I, Item 1A of this
Annual Report on Form 10-K. These risks are not exhaustive. Other sections of
this Annual Report on Form 10-K include additional factors which could adversely
impact our business and financial performance. Moreover, we operate in a very
competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. You should
not rely upon forward-looking statements as predictions of future events. We
cannot assure you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United
States and Canada, we assume no obligation to update or supplement
forward-looking statements.</P>
<P align=justify>As used in this annual report, the terms &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, and
&#147;Anavex&#148; mean Anavex Life Sciences Corp., unless the context clearly requires
otherwise. </P>
<P align=center>v</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_6></A>
<P align=justify><B>PART I</B></P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      1. BUSINESS </FONT></TD>
  </TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Our Current Business</FONT></I></P>
<P align=justify>We are a pharmaceutical company engaged in the development of
drug candidates. Our lead compound ANAVEX 2-73, developed to treat Alzheimer&#146;s
disease through disease modification, is in human clinical trials. </P>
<P align=justify>In pre-clinical studies conducted in France, and in Greece,
ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties.</P>
<P align=justify>Based on these preclinical studies, we sponsored a Phase 1
single ascending dose study of ANAVEX 2-73 initiated and completed in 2011. This
study was conducted in Germany in collaboration with ABX-CRO Advanced
Pharmaceutical Services (ABX-CRO). The study indicated that ANAVEX 2-73 was well
tolerated by study subjects in doses up to 55mg.</P>
<P align=justify>Despite success in trials to date, and due principally to
insufficient capital to support operations and development of our pipeline, we
have been unable to attract and retain executive management, particularly a
chief executive officer, who has experience leading a development stage
pharmaceutical company. For this reason, we intend to defer most of our research
activity until expert management evaluates our progress and proposes an
appropriate course of action, and until there is sufficient capital on hand to
effect management&#146;s plan of action.</P>
<P align=justify>In considering several different means of accomplishing our
goal of commercializing drug candidates, we have determined that pursuing a
strategic relationship with a partner, partners, or an acquirer with capable
management and sufficient capital to sponsor trials is our best course of action
at this time.</P>
<P align=justify>We intend to identify and initiate discussions with potential
partners and acquirers in the next 12 months. Further, we may acquire or develop
new intellectual property and assign, license, or otherwise transfer our
intellectual property to further our goals.</P>
<P align=justify><I><FONT color=#4f81bd>Our Pipeline</FONT></I></P>
<P align=justify>Our pipeline includes one drug candidate in human clinical
trials, and several compounds in different stages of preclinical study.</P>
<P align=justify>Our proprietary SIGMACEPTOR&#153; Discovery Platform produced small
molecule drug candidates with unique modes of action, based on our leading
understanding of sigma receptors. Sigma receptors may be targets for
therapeutics to combat many human diseases, including Alzheimer&#146;s disease. When
bound by the appropriate ligands, sigma receptors influence the functioning of
multiple biochemical signals that are involved in the pathogenesis (origin or
development) of disease.</P>
<P align=justify>Compounds that have been subjects of our research include the
following:</P>
<P align=center>1</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_7></A>
<P align=justify><B>ANAVEX 2-73</B></P>
<P align=justify>ANAVEX 2-73 may offer a disease-modifying approach in
Alzheimer&#146;s disease (AD) by using ligands that activate sigma-1 receptors.</P>
<P align=justify>In AD animal models, ANAVEX 2-73 has shown pharmacological,
histological and behavioural evidence as a potential neuroprotective,
anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its
potent affinity to sigma-1 receptors and moderate affinities to M1-4 type
muscarinic receptors. In addition, ANAVEX 2-73 has shown a potential dual
mechanism which may impact both amyloid and tau pathology. </P>
<P align=justify>Based on the results of preclinical testing, we initiated and
completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73 in
2011. In this Phase 1 SAD trial, the maximum tolerated single dose was defined
per protocol as 55-60 mg. This dose is above the equivalent dose shown to have
positive effects in mouse models of AD. There were no significant changes in
laboratory or electrocardiogram (ECG) parameters. ANAVEX 2-73 was well tolerated
below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included
headache and dizziness, which were moderate in severity and reversible. These
side effects are often seen with drugs that target central nervous system (CNS)
conditions, including AD. </P>
<P align=justify>The ANAVEX 2-73 Phase 1 SAD trial was conducted as a
randomized, placebo-controlled study. Healthy male volunteers between the ages
of 18 and 55 received single, ascending oral doses over the course of the trial.
Study endpoints included safety and tolerability together with pharmacokinetic
parameters. Pharmacokinetics includes the absorption and distribution of a drug,
the rate at which a drug enters the blood and the duration of its effect, as
well as chemical changes of the substance in the body. This study was conducted
in Germany in collaboration with ABX-CRO, a clinical research organization that
has conducted several Alzheimer&#146;s disease studies, and the Technical University
of Dresden. </P>
<P align=justify><B>ANAVEX 19-144 </B></P>
<P align=justify>ANAVEX 19-144 is the sole active metabolite of ANAVEX 2-73.
Like ANAVEX 2-73, preclinical data reveals that ANAVEX 19-144 exhibits
significant anti-amnesic, neuroprotective and anticonvulsant properties in a
variety of in vitro systems and specialized animal models. </P>
<P align=justify>In animal models, ANAVEX 19-144 controls seizures and the
epileptogenesis process. Moreover, its neuroprotective properties may prevent
the process that causes long-term damage to tissue and cells as well as
biochemical and physiological alterations to the brain from epileptic
seizures.</P>
<P align=justify><B>ANAVEX 1-41</B></P>
<P align=justify>ANAVEX 1-41 is a sigma-1 agonist. Preclinical tests revealed
significant neuroprotective benefits (i.e., protects nerve cells from
degeneration or death) through the modulation of endoplasmic reticulum,
mitochondrial and oxidative stress, which damages and destroys cells and is
believed by some scientists to be a primary cause of AD. In addition, in animal
models, ANAVEX 1-41 prevented the expression of caspase-3, an enzyme that plays
a key role in apoptosis (programmed cell death) and loss of cells in the </P>
<P align=center>2</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_8></A>
<P align=justify>hippocampus, the part of the brain that regulates learning,
emotion and memory. These activities involve both muscarinic and sigma-1
receptor systems through a novel mechanism of action.</P>
<P align=justify><B>ANAVEX 7-1037</B></P>
<P align=justify>ANAVEX 7-1037 is designed for the treatment of prostate cancer.
It is a low molecular weight, synthetic compound exhibiting high affinity for
sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2
receptors and sodium channels at micromolar levels. In advanced preclinical
studies, this compound revealed antitumor potential with no toxic side effects.
It has also been shown to selectively kill human cancer cells without affecting
normal/healthy cells and also to significantly suppress tumor growth in
immune-deficient mice models. </P>
<P align=justify>Scientific publications describe sigma receptor ligands
positively, highlighting the possibility that these ligands may stop tumor
growth and induce selective cell death in various tumor cell lines. Sigma
receptors are highly expressed in different tumor cell types. Binding by
appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In
addition, through tumor cell membrane reorganization and interactions with ion
channels, our drug candidates may play an important role in inhibiting the
processes of metastasis (spreading of cancer cells from the original site to
other parts of the body), angiogenesis (the formation of new blood vessels) and
tumor cell proliferation. </P>
<P align=justify>Our compounds are in the pre-clinical and clinical testing
stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</P>
<P align=justify><I><FONT color=#4f81bd>Our Target Indications</FONT></I></P>
<P align=justify>We have developed compounds with potential application to two
broad categories and several specific indications. The two categories are
diseases of the central nervous system, and cancer. Specific indications
include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>Alzheimer&#146;s disease &#150; In 2012, 5 million Americans suffer from Alzheimer&#146;s
  disease. The Alzheimer&#146;s Association&#174; reports that by 2025, 6.7 million
  Americans will be afflicted by the disease. Medications on the market today
  treat only the symptoms of AD and do not have the ability to stop its onset or
  its progression. There is an urgent and unmet need for a disease modifying
  cure for Alzheimer&#146;s disease.
  <LI>Depression - Depression is a major cause of morbidity worldwide according
  to the World Health Organization (&#147;WHO&#148;). Pharmaceutical treatment for
  depression is dominated by blockbuster brands, with the leading nine brands
  accounting for approximately 75% of total sales. However, the dominance of the
  leading brands is waning, largely due to the effects of patent expiration and
  generic competition. We believe the worldwide market for pharmaceutical
  treatment of depression exceeds $11 billion annually.
  <LI>Epilepsy - Epilepsy is a common chronic neurological disorder
  characterized by recurrent unprovoked seizures. These seizures are transient
  signs and/or symptoms of abnormal, excessive or synchronous neuronal activity
  in the brain. According to the Centers for Disease Control and Prevention,
  epilepsy affects 2.2 million Americans. Today, epilepsy is often </LI></UL>
<P align=center>3</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_9></A>
<UL style="TEXT-ALIGN: justify">controlled, but not cured, with medication
  that is categorized as older traditional anti epileptic drugs and second
  generation anti epileptic drugs. Because epilepsy afflicts sufferers in
  different ways, there is a need for drugs used in combination with both
  traditional anti epileptic drugs and second generations anti epileptic drugs.
  We believe the American market for pharmaceutical treatment of epilepsy
  exceeds $12 billion annually.
  <LI>Neuropathic Pain &#150; We define neuralgia, or neuropathic pain, as pain that
  is not related to activation of pain receptor cells in any part of the body.
  Neuralgia is more difficult to treat than some other types of pain because it
  does not respond well to normal pain medications. Special medications have
  become more specific to neuralgia and typically fall under the category of
  membrane stabilizing drugs or antidepressants. We believe the worldwide market
  for pharmaceutical treatment of neuropathic pain exceeds $5 billion annually.
  <LI>Malignant Melanoma - Predominantly a skin cancer, malignant melanoma can
  also occur in melanocytes found in the bowel and the eye. Malignant melanoma
  accounts for 75% of all deaths associated with skin cancer. The treatment
  includes surgical removal of the tumor, adjuvant treatment, chemo and
  immunotherapy, or radiation therapy. We believe the worldwide market for the
  pharmaceutical treatment of malignant melanoma exceeds $200 million annually.
  <LI>Prostate Cancer &#150; Specific to men, prostate cancer is a form of cancer
  that develops in the prostate, a gland in the male reproductive system. The
  cancer cells may metastasize from the prostate to other parts of the body,
  particularly the bones and lymph nodes. We believe the worldwide market for
  the pharmaceutical treatment of prostate cancer exceeds $4 billion annually.
  <LI>Pancreatic Cancer - Pancreatic cancer is a malignant neoplasm of the
  pancreas. In the United States approximately 42,000 new cases of pancreatic
  cancer were diagnosed and approximately 35,000 patients died in 2009 as a
  result of their cancer. We believe the worldwide market for the pharmaceutical
  treatment of pancreatic cancer is approximately $700 million annually.
</LI></UL>
<P align=justify><I><FONT color=#4f81bd>Competition </FONT></I></P>
<P align=justify>The pharmaceutical industry is intensely competitive.</P>
<P align=justify>At this time, we view our competition as biomedical development
companies that are trying to discover and develop compounds to be used in the
treatment of Alzheimer&#146;s disease, and those companies already doing so. Those
companies include Prana Biotechnology Limited (NASDAQ:PRAN), Elan Corporation,
PLC (NYSE:ELN), Pfizer Inc. (NYSE:PFE), Forest Pharmaceuticals, Inc. (NYSE:FRX),
Novartis AG (NYSE:NVS), GlaxoSmithKline Inc. (NYSE:GSK), Merck &amp; Co., Inc.
(NYSD:MRK), Ranbaxy Laboratories Limited (BSE:500359) and F. Hoffman-La Roche
Ltd. (SIX:ROG). </P>
<P align=justify>Each of our competitors have greater capital resources, larger
overall research and development staffs and facilities, and a longer history in
drug discovery and development, obtaining regulatory approval, and
pharmaceutical product manufacturing and marketing than we do. With these
additional resources, our competitors will be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical
industries faster than we can. Our future success will depend in large </P>
<P align=center>4</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_10></A>
<P align=justify>part on our ability to acquire funding for our research and
development. To continue to acquire funding for our research and development, we
will likely have to show progress toward our goals and we will eventually be
expected to develop a compound that may result in a transaction with another
pharmaceutical company.</P>
<P align=justify>Our research and development is highly speculative and we may
never discover or develop any compounds that we are capable of selling.</P>
<P align=justify>Rapid technological development, as well as new scientific
developments, and economic circumstances may result in our compounds becoming
obsolete before we can recover any of the expenses incurred to develop them.
</P>
<P align=justify><I><FONT color=#4f81bd>Patents, Trademarks and Intellectual
Property</FONT></I></P>
<P align=justify>We own several patents, and have filed for intellectual
property protection in several jurisdictions. Further information concerning our
patents, trademarks, and intellectual property may be found as a matter of
record in patent offices and with intellectual property registration
organizations including: the Greek National Office of Industrial Property, the
United States Patent and Trademark Office, and the World Intellectual Property
Organization.</P>
<P align=justify>Patents we currently own include:</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">
    <TR vAlign=top>
      <TD align=left>Patent <BR>
        Number </TD>
      <TD width="15%" align=left>Jurisdiction <BR></TD>
      <TD width="15%" align=left >Filing and <BR>
        Expiration Dates </TD>
      <TD width="55%" align=left >Invention Title <BR></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>1002616 </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >February 21, 1996 <BR>
        February 22, 2016 </TD>
      <TD width="55%" align=left ><FONT color=#313131>Synthesis and method of
        synthesis of a molecular</FONT> (AE 37) of anticonvulsant, antidepressant
        and neuroleptic tropic action. </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>1004208 </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >October 15, 2001 <BR>
        October 14, 2021 </TD>
      <TD width="55%" align=left ><FONT
      color=#313131>AMINOTETRAHYDROFURAN DERIVATIVES,</FONT> MUSCARINIC/SIGMA/SODIUM
        CHANNEL LIGANDS, WITH SYNERGIC SIGMA/MUSCARINIC (NEUROACTIVATING) AND
        SIGMA/SODIUM CHANNEL (NEUROPROTECTIVE) COMPONENTS, AS PROTOTYPICAL ACTIVATING
        - NEUROPROTECTORS AND NEUROREGENERATIVE DRUGS </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>1004868 </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >April 22, 2003 <BR>
        April 21, 2023 </TD>
      <TD width="55%" align=left ><FONT
      color=#313131>AMINOTETRAHYDROFURAN DERIVATIVES,</FONT> MUSCARINIC/SIGMA/SODIUM
        CHANNEL LIGANDS, ORTHO-AND ALLO-STERICALLY OPERATING, AS PROTOTYPICAL
        NEUROMEODULATING AND NEUROREGENERATIVE DRUGS. </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>1005865 </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >January 17, 2007 <BR>
        January 16, 2027 </TD>
      <TD width="55%" align=left ><FONT color=#313131>NEW SIGMA LIGANDS with anti-apoptotic
        and/or</FONT> pro-apoptotic action on the cells biochemical mechanisms
        and neuroprotective, anti-cancer, anti- metastatic, and anti-chronic inflammatory
        properties. </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>1006794 </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >February 26, 2009 <BR>
        February 27, 2029 </TD>
      <TD width="55%" align=left ><FONT color=#313131>THE NEW SIGMA(&#963;)-RECEPTOR
        LIGANDS WITH ANTI-</FONT> APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER
        CELLULAR BIOCHEMICAL MECHANISMS, WITH </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>5</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_11></A><BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="15%" align=left>&nbsp;</TD>
      <TD width="15%" align=left >&nbsp;</TD>
      <TD width="55%" align=left ><FONT
      color=#313131>NEUROPROTECTIVE, ANTI-CANCER, ANTI-</FONT> METASTATIC AND
        ANTI-(CHRONIC) INFLAMMATORY ACTION. </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left><FONT color=#313131>1007686</FONT> </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >July 8, 2011 <BR>
        July 9, 2031</TD>
      <TD width="55%" align=left ><FONT color=#313131>SYNTHESIS OF (+)- AND (-)-1-(5,5-</FONT>
        DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHYLAMINE, (+)-AND (-)-1-(2,2-
        DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHYLAMINE AND (+)- AND (-)-1-(2,2-
        DIPHENYLTETRAHYDROFURAN-3-YL)-N- METHYLMETHYLAMINE </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left><FONT color=#313131>1007322</FONT> </TD>
      <TD width="15%" align=left>Greece </TD>
      <TD width="15%" align=left >March 9, 2010 <BR>
        March 10, 2030 </TD>
      <TD width="55%" align=left ><FONT color=#313131>SYNTHESIS OF 1-METHYL-4-[4,4-DIPHENYL-4-(1-</FONT>
        ADAMANTYL)-BUTYL] PIPERAZINE AND ANALOGUES THEREOF WITH ANTI-CANCER PROPERTIES
      </TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>We regard patents and other proprietary technology rights as
corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective
development, protection, and exploitation of our intellectual property
rights.</P>
<P align=justify>In addition to filings made with intellectual property
organizations, we protect our intellectual property and confidential information
by means of carefully considered processes of communication and the sharing of
information, and by the use of confidentiality and non-disclosure agreements and
provisions for the same in contractor&#146;s agreements. While no agreement offers
absolute protection, each agreement provides us with some form of recourse in
the event of disclosure, or anticipated disclosure. Each of our officers,
directors, and third-party contractors is bound by an agreement.</P>
<P align=justify>Our patent position, like that of many biomedical companies, is
uncertain and involves complex legal and technical questions for which important
legal principles are unresolved. Our intellectual property is filed with the
Greek National Office of Industrial Property. We may file additional patent
applications in the United States, or in other jurisdictions for further
inventions. We may not be successful in obtaining critical claims or in
protecting our potential drug compounds or processes. Even if we do obtain
patents, they may not adequately protect the technology we own or have licensed.
In addition, others may challenge, seek to invalidate, infringe or circumvent
any patents we own or license, and rights we receive under those patents may not
provide competitive advantages to us. Further, the manufacture, use or sale of
our potential drug compounds may infringe the patent rights of others.</P>
<P align=justify>Our success will also depend in part on our ability to
commercialize our compounds without infringing the proprietary rights of others.
We have not conducted extensive freedom of use patent searches and no assurance
can be given that patents do not exist or could not be filed which would have an
adverse affect on our ability to market our technology or maintain our
competitive position with respect to our technology. If our compounds or other
subject matter are claimed under other existing United States or other patents
or are otherwise protected by third party proprietary rights, we may be subject
to infringement actions. In such event, we may challenge the validity of such
patents or other proprietary rights or we may be required to obtain licenses
from such companies in order to develop, manufacture or market our technology.
There can be no assurances that we would be able to obtain such licenses or </P>
<P align=center>6</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_12></A>
<P align=justify>that such licenses, if available, could be obtained on
commercially reasonable terms. Furthermore, the failure to either develop a
commercially viable alternative or obtain such licenses could result in delays
in marketing all of our potential drug compounds based on our drug technology or
the inability to proceed with the development, manufacture or sale of potential
drug compounds requiring such licenses, which could have a material adverse
affect on our business, financial condition and results of operations. If we
defend ourselves against charges of patent infringement or to protect our
proprietary rights against third parties, substantial costs will be incurred
regardless of whether we are successful. Such proceedings are typically
protracted with no certainty of success. An adverse outcome could subject us to
significant liabilities to third parties and force us to curtail or cease our
research and development of our technology.</P>
<P align=justify><I><FONT color=#4f81bd>Government Approval</FONT></I></P>
<P align=justify>Regulation by governmental authorities in the United States and
foreign countries is a significant factor in the development, manufacture, and
expected marketing of our potential drug compounds and in potential future
research and development activities. The nature and extent to which such
regulation will apply to us will vary depending on the nature of any potential
drug compounds developed. We anticipate that all of our potential drug compounds
will require regulatory approval by governmental agencies prior to
commercialization. </P>
<P align=justify>In particular, human therapeutic products are subject to
rigorous non-clinical and clinical testing and other approval procedures of the
FDA and similar regulatory authorities in other countries. Various federal
statutes and regulations also govern or influence testing, manufacturing,
safety, labeling, storage, and record-keeping related to such products and their
marketing. The process of obtaining these approvals and the subsequent
compliance with the appropriate federal statutes and regulations requires
substantial time and financial resources. Any failure by us or our collaborators
to obtain, or any delay in obtaining, regulatory approval could adversely affect
the marketing of any potential drug compounds developed by us, our ability to
receive product revenues, and our liquidity and capital resources.</P>
<P align=justify>The steps ordinarily required before a new drug may be marketed
in the United States, which are similar to steps required in most other
countries, include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>non-clinical laboratory tests, non-clinical studies in animals,
  formulation studies and the submission to the FDA of an investigational new
  drug application;
  <LI>adequate and well-controlled clinical trials to establish the safety and
  efficacy of the drug;
  <LI>the submission of a new drug application or biologic license application
  to the FDA; and
  <LI>FDA review and approval of the new drug application or biologics license
  application. </LI></UL>
<P align=justify>Non-clinical tests include laboratory evaluation of potential
drug compound chemistry, formulation and toxicity, as well as animal studies.
The results of non-clinical testing are submitted to the FDA as part of an
investigational new drug application. A 30-day waiting period after the filing
of each investigational new drug application is required prior to commencement
of clinical testing in humans. At any time </P>
<P align=center>7</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_13></A>
<P align=justify>during the 30-day period or at any time thereafter, the FDA may
halt proposed or ongoing clinical trials until the FDA authorizes trials under
specified terms. The investigational new drug application process may be
extremely costly and substantially delay the development of our potential drug
compounds. Moreover, positive results of non-clinical tests will not necessarily
indicate positive results in subsequent clinical trials. The FDA may require
additional animal testing after an initial investigational new drug application
is approved and prior to Phase III trials.</P>
<P align=justify>Clinical trials to support new drug applications are typically
conducted in three sequential phases, although the phases may overlap. During
Phase I, clinical trials are conducted with a small number of subjects to assess
metabolism, pharmacokinetics, and pharmacological actions and safety, including
side effects associated with increasing doses. Phase II usually involves studies
in a limited patient population to assess the efficacy of the drug in specific,
targeted indications; assess dosage tolerance and optimal dosage; and identify
possible adverse effects and safety risks.</P>
<P align=justify>If a compound is found to be potentially effective and to have
an acceptable safety profile in Phase I and II evaluations, Phase III trials are
undertaken to further demonstrate clinical efficacy and to further test for
safety within an expanded patient population at geographically dispersed
clinical trial sites.</P>
<P align=justify>After successful completion of the required clinical trials, a
new drug application is generally submitted. The FDA may request additional
information before accepting the new drug application for filing, in which case
the new drug application must be resubmitted with the additional information.
Once the submission has been accepted for filing, the FDA reviews the new drug
application and responds to the applicant. The FDA&#146;s requests for additional
information or clarification often significantly extends the review process. The
FDA may refer the new drug application to an appropriate advisory committee for
review, evaluation, and recommendation as to whether the new drug application
should be approved, although the FDA is not bound by the recommendation of an
advisory committee.</P>
<P align=justify>Sales outside the United States of potential drug compounds we
develop will also be subject to foreign regulatory requirements governing human
clinical trials and marketing for drugs. The requirements vary widely from
country to country, but typically the registration and approval process takes
several years and requires significant resources. In most cases, if the FDA has
not approved a potential drug compound for sale in the United States, the
potential drug compound may be exported for sale outside of the United States,
only if it has been approved in any one of the following: the European Union,
Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.
There are specific FDA regulations that govern this process.</P>
<P align=justify>We may also become subject to various federal, state, local,
and foreign laws, regulations and recommendations relating to safe working
conditions, laboratory and manufacturing practices, and the use and disposal of
hazardous or potentially hazardous substances, including radioactive compounds
and infectious disease agents, used in connection with our research. We cannot
accurately predict the extent of government regulation that might result from
future legislation or administrative action.</P>
<P align=center>8</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_14></A>
<P align=justify><I><FONT color=#4f81bd>Research and Development
Expenses</FONT></I></P>
<P align=justify>A significant portion of our operating expenses is related to
research and development. See Item 8 &#147;Financial Statements and Supplementary
Data&#148; of this Annual Report on Form 10-K for costs and expenses related to
research and development, and other financial information for fiscal years 2012
and 2011. </P>
<P align=justify><I><FONT color=#4f81bd>Scientific Advisors</FONT></I></P>
<P align=justify>We are advised by scientists and physicians with experience
relevant to our company and our product candidates. In the past twelve months,
our advisors included Alexandre Vamvakides, Ph.D., Tangui Nicolas Maurice,
Ph.D., Christopher Missling, Ph.D., Dr. Diego Garzon, Ph.D., Dr. Paul Aisen, Dr.
Rachelle Doody, and Dr. Jeffrey Cummings. </P>
<P align=justify><I><FONT color=#4f81bd>Officers</FONT></I></P>
<P align=justify>One of our directors is engaged as a consultant who acts for
our company in the capacity of president, secretary, chief operating officer and
chief financial officer.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      1 A. RISK FACTORS </FONT></TD>
  </TR></TABLE>
<P align=justify>In addition to other information in this annual report, the
following risk factors should be carefully considered in evaluating our business
because such factors may have a significant impact on our business, operating
results, liquidity and financial condition. As a result of the risk factors set
forth below, actual results could differ materially from those projected in any
forward-looking statements. Additional risks and uncertainties not presently
known to us, or that we currently consider to be immaterial, may also impact our
business, operating results, liquidity and financial condition. If any such
risks occur, our business, operating results, liquidity and financial condition
could be materially affected in an adverse manner. Under such circumstances, the
trading price of our securities could decline, and you may lose all or part of
your investment.</P>
<P align=justify><I><FONT color=#4f81bd>Risks Related to our
Company</FONT></I></P>
<P align=justify><I>We have had a history of losses and no revenue, which raise
substantial doubt about our ability to continue as a going concern.</I></P>
<P align=justify>Since inception on January 23, 2004, we have incurred aggregate
net losses of $36,954,122 from operations. We can offer no assurance that we
will ever operate profitably or that we will generate positive cash flow in the
future. To date, we have not generated any revenues from our operations. Our
history of losses and no revenues raise substantial doubt about our ability to
continue as a going concern. As a result, our management expects the business to
continue to experience negative cash flow for the foreseeable future and cannot
predict when, if ever, our business might become profitable. We will need to
raise additional funds or partner with a well capitalized organization. Neither
funds, nor </P>
<P align=center>9</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_15></A>
<P align=justify>partnership may be available on commercially acceptable terms.
If we are unable to raise funds or partner, we may not be able to execute our
business plan, take advantage of future opportunities, or respond to competitive
pressures or unanticipated requirements. This may seriously harm our business,
financial condition and results of operations. </P>
<P align=justify><I>We are an early development stage pharmaceutical research
and development company and may never be able to successfully develop marketable
products or generate any revenue. We have a very limited relevant operating
history upon which an evaluation of our performance and prospects can be made.
There is no assurance that our future operations will result in profits. If we
cannot generate sufficient revenues, we may suspend or cease operations.</I></P>
<P align=justify>We are an early development stage company and have not
generated any revenues to date and have no operating history. All of our
potential drug compounds are in the concept stage or early clinical development
stage. Moreover, we cannot be certain that our research and development efforts
will be successful or, if successful, that our potential drug compounds will
ever be approved for sales to pharmaceutical companies or will ever generate
commercial revenues. We have no relevant operating history upon which an
evaluation of our performance and prospects can be made. We are subject to all
of the business risks associated with a new enterprise, including, but not
limited to, risks of unforeseen capital requirements, failure of potential drug
compounds either in non-clinical testing or in clinical trials, failure to
establish business relationships and competitive disadvantages as against larger
and more established companies. If we fail to become profitable, we may suspend
or cease operations.</P>
<P align=justify><I>We will need additional funding and may be unable to raise
additional capital when needed, which would force us to delay, reduce or
eliminate our research and development activities.</I></P>
<P align=justify>We will need to raise additional funding, but the current
economic condition will most likely have a negative impact on our ability to
raise additional needed capital on terms that are favorable to our company or at
all. We do not anticipate that we will generate significant revenues for several
years, if at all. Until we can generate significant revenues, if ever, we expect
to satisfy our future cash needs through equity or debt financing. We cannot be
certain that additional funding will be available on acceptable terms, or at
all. If adequate funds are not available, we may be required to delay, reduce
the scope of, or eliminate one or more of our research and development
activities.</P>
<P align=justify><I>We may not be able to attract and retain qualified and
experienced directors and executive officers necessary to continue operations.
If suitable directors and officers cannot be attracted and retained we may cease
operations, and we may cease or delay our market disclosures, in which case our
securities will have little or no value.</I></P>
<P align=justify>We require skilled and experienced directors and executive
officers to continue our operations and to achieve our business plans. Skills
and qualifications include both specific pharmaceutical industry, and general
corporate knowledge and experience. Due in part to our history of raising
capital, and the value of our assets relative to our liabilities we have been
unsuccessful in attracting and retaining directors and executive officers. We
have deferred decisions concerning research activity spending until adequately
skilled and qualified directors and officers are appointed. If directors and
officers are not </P>
<P align=center>10</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_16></A>
<P align=justify>appointed, the company may cease spending, discontinue
operations entirely, and indefinitely delay filings made to regulators including
the United States Securities and Exchange Commission. Should any one, or any
combination of these factors be realized you would likely suffer a complete loss
of your investment in our securities.</P>
<P align=justify><I>We may be unable to continue as a going concern in which
case our securities will have little or no value.</I></P>
<P align=justify>Our independent auditors have noted in their report concerning
our annual financial statements for the fiscal year ended September 30, 2012
that we have incurred substantial losses since inception, which raises
substantial doubt about our ability to continue as a going concern. In the event
we are not able to continue operations you will likely suffer a complete loss of
your investment in our securities.</P>
<P align=justify><I><FONT color=#4f81bd>Risks Related to our
Business</FONT></I></P>
<P align=justify><I>Even if we are able to develop potential drug compounds, we
may not be able to receive regulatory approval, or if approved, we may not be
able to generate significant revenues or successfully commercialize our
products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and
development plans and we may be forced to cease operations.</I></P>
<P align=justify>All of our potential drug compounds will require extensive
additional research and development, including non-clinical testing and clinical
trials, as well as regulatory approvals, before we can market them. We cannot
predict if or when any potential drug compounds will be approved for marketing.
There are many reasons that we may fail in our efforts to develop our potential
drug compounds. These include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>the possibility that non-clinical testing or clinical trials may show that
  our potential drug compounds are ineffective or cause harmful side effects;
  <LI>our potential drug compounds may prove to be too expensive to manufacture
  or administer to patients;
  <LI>our potential drug compounds may fail to receive necessary regulatory
  approvals from the United States Food and Drug Administration or foreign
  regulatory authorities in a timely manner, or at all;
  <LI>even if our potential drug compounds are approved, we may not be able to
  produce them in commercial quantities or at reasonable costs;
  <LI>even if our potential drug compounds are approved, they may not achieve
  commercial acceptance;
  <LI>regulatory or governmental authorities may apply restrictions to any of
  our potential drug compounds, which could adversely affect their commercial
  success; and
  <LI>the proprietary rights of other parties may prevent us or our potential
  collaborative partners from marketing our potential drug compounds. </LI></UL>
<P align=center>11</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_17></A>
<P align=justify><I>If we fail to develop potential drug compounds, our
financial results and financial condition will be adversely affected, we will
have to delay or terminate some or all of our research and development plans and
may be forced to cease operations.</I></P>
<P align=justify>Our research and development plans will require substantial
additional management expertise and future funding which could impact our
operational and financial condition. Without sufficient expertise and additional
funds, we will likely cease operations.</P>
<P align=justify><I>It will take several years before we are able to develop
potentially marketable products, if at all. </I></P>
<P align=justify>Research and development requires substantial additional
capital, arising from costs to: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>conduct research, non-clinical testing and human studies;
  <LI>establish pilot scale and commercial scale manufacturing processes and
  facilities; and
  <LI>establish and develop quality control, regulatory, marketing, sales,
  finance and administrative capabilities to support these programs. </LI></UL>
<P align=justify>Our future operating and capital needs will depend on many
factors, including:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>the pace of scientific progress in our research and development programs
  and the magnitude of these programs;
  <LI>the scope and results of preclinical testing and human studies;
  <LI>the time and costs involved in obtaining regulatory approvals;
  <LI>the time and costs involved in preparing, filing, prosecuting, maintaining
  and enforcing patent claims;
  <LI>competing technological and market developments;
  <LI>our ability to establish additional collaborations;
  <LI>changes in our existing collaborations;
  <LI>the cost of manufacturing scale-up; and
  <LI>the effectiveness of our commercialization activities. </LI></UL>
<P align=justify>We base our outlook regarding the need for funds on many
uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct
control such as negotiations with potential strategic partners and other
factors. Any of these uncertain events can significantly change our cash
requirements as they determine such one-time events as the receipt or payment of
major milestones and other payments.</P>
<P align=justify>Additional funds will be required to support our operations and
if we are unable to obtain them on favorable terms, we may be required to cease,
delay, or reduce further research and development of our drug product programs,
assign, license, or transfer some or all of our intellectual property, merge
with another entity or cease operations. </P>
<P align=justify><I>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected.</I></P>
<P align=center>12</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_18></A>
<P align=justify>The success of our research and development efforts will be
greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical
studies involve testing potential drug compounds in appropriate non-human
disease models to demonstrate efficacy and safety. Regulatory agencies evaluate
these data carefully before they will approve clinical testing in humans. If
certain non-clinical data reveals potential safety issues or the results are
inconsistent with an expectation of the potential drug compound&#146;s efficacy in
humans, the regulatory agencies may require additional more rigorous testing,
before allowing human clinical trials. This additional testing will increase
program expenses and extend timelines. We may decide to suspend further testing
on our potential drug compounds at any time if, in our judgment, the results do
not support further development.</P>
<P align=justify>Moreover, success in non-clinical testing and early clinical
trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the
results of prior clinical trials and non-clinical testing. The clinical trial
process may fail to demonstrate that our potential drug compounds are safe for
humans and effective for indicated uses. This failure may cause us to abandon a
drug candidate and may delay development of other potential drug compounds. Any
delay in, or termination of, our non-clinical testing or clinical trials will
delay the filing of an investigational new drug application and new drug
application with the Food and Drug Administration or the equivalent applications
with pharmaceutical regulatory authorities outside the United States and,
ultimately, our ability to commercialize our potential drug compounds and
generate product revenues. In addition, we expect that our early clinical trials
will involve small patient populations. Because of the small sample size, the
results of these early clinical trials may not be indicative of future
results.</P>
<P align=justify>Following successful non-clinical testing, potential drug
compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and
licensure by regulatory agencies. From the first human trial through to
regulatory approval can take many years and 10-12 years is not unusual for
certain compounds. </P>
<P align=justify>If any of our future clinical development potential drug
compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety
concerns may arise, whether or not justified, that could lead to the suspension
or termination of our clinical programs. Examples of problems that could arise
include, among others: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>efficacy or safety concerns with the potential drug compounds, even if not
  justified;
  <LI>manufacturing difficulties or concerns;
  <LI>regulatory proceedings subjecting the potential drug compounds to
  potential recall;
  <LI>publicity affecting doctor prescription or patient use of the potential
  drug compounds;
  <LI>pressure from competitive products; or
  <LI>introduction of more effective treatments. </LI></UL>
<P align=justify>Each clinical phase is designed to test attributes of the drug
and problems that might result in the termination of the entire clinical plan
can be revealed at any time throughout the overall clinical </P>
<P align=center>13</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_19></A>
<P align=justify>program. The failure to demonstrate efficacy in our clinical
trials would have a material adverse effect on our future business prospects,
financial condition and operating results. </P>
<P align=justify><I>If we do not obtain the support of qualified scientific
collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business.</I></P>
<P align=justify>We will need to establish relationships with leading scientists
and research institutions. We believe that such relationships are pivotal to
establishing products using our technologies as a standard of care for various
indications. If we are not able to establish scientific relationships to assist
in our research and development, we may not be able to successfully develop our
potential drug compounds. If this happens, our business will be adversely
affected.</P>
<P align=justify><I>We may not be able to develop market or generate sales of
our products to the extent anticipated. Our business may fail and investors
could lose all of their investment in our company.</I></P>
<P align=justify>Assuming that we are successful in developing our potential
drug compounds and receiving regulatory clearances to market our products, our
ability to successfully penetrate the market and generate sales of those
products may be limited by a number of factors, including the following: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>If our competitors receive regulatory approvals for and begin marketing
  similar products in the United States, the European Union, Japan and other
  territories before we do, greater awareness of their products as compared to
  ours will cause our competitive position to suffer;
  <LI>Information from our competitors or the academic community indicating that
  current products or new products are more effective or offer compelling other
  benefits than our future products could impede our market penetration or
  decrease our future market share; and,
  <LI>The pricing and reimbursement environment for our future products, as well
  as pricing and reimbursement decisions by our competitors and by payers, may
  have an effect on our revenues. </LI></UL>
<P align=justify>If this happens, our business will be adversely affected.</P>
<P align=justify><I>None of our potential drug compounds may reach the
commercial market for a number of reasons and our business may fail.</I></P>
<P align=justify>Research and development of pharmaceutical products is high
risk. Most products and development candidates fail to reach the market. Our
success depends on the commercialization of drug compounds. It is possible that
our products may never reach the market for a number of reasons. They may be
found ineffective or may cause harmful side-effects during non-clinical testing
or clinical trials or fail to receive necessary regulatory approvals. We may
find that certain products cannot be manufactured at a commercial scale and,
therefore, they may not be economical to produce. Our potential products could
also fail to achieve market acceptance or be precluded from commercialization by
proprietary rights of third parties. Our patents, trademarks and other
intellectual property may be challenged and this may delay or prohibit us from
effectively commercializing our products. Furthermore, we do not expect our
potential drug compounds to be commercially available for a number of years, if
at all. If none of our </P>
<P align=center>14</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_20></A>
<P align=justify>potential drug compounds reach the commercial market, our
business will likely fail and investors will lose all of their investment in our
company. If this happens, our business will be adversely affected.</P>
<P align=justify><I>If our competitors succeed in developing products and
technologies that cost less or are more effective or with a better profile than
our own, or if scientific developments change our understanding of the potential
scope and utility of our potential products, then our technologies and future
products may be rendered undesirable or obsolete.</I></P>
<P align=justify>We face significant competition from industry participants that
are pursuing technologies in similar disease states to those that we are
pursuing and are developing pharmaceutical products that are competitive with
our products. All of our industry competitors have greater capital resources,
larger and more capable overall research and development staffs and facilities,
and a longer history in drug discovery and development, obtaining regulatory
approval and pharmaceutical product manufacturing and marketing than we do. With
these additional resources, our competitors may be able to respond to the rapid
and significant technological changes in the biotechnology and pharmaceutical
industries faster than we can. Our success depends in large part on our ability
to maintain a competitive position with respect to these companies and
technologies. Rapid technological development, as well as new scientific
developments, may result in our products becoming obsolete before we can recover
any of the expenses incurred to develop them. For example, changes in our
understanding of the appropriate population of patients who should be treated
with a targeted therapy like ours may limit the drug&#146;s market potential if it is
subsequently demonstrated that only certain subsets of patients should be
treated with the targeted therapy. </P>
<P align=justify><I>Our reliance on third parties, such as contracted
laboratories, manufacturing organizations and clinical research organizations,
may result in delays in completing, or a failure to complete, non-clinical
testing or clinical trials if their contracted work is not completed or if we do
not receive it.</I></P>
<P align=justify>In the course of product development, we may engage university
laboratories, other biotechnology companies or contract or clinical
manufacturing organizations to manufacture drug material for us to be used in
non-clinical and clinical testing and contract research organizations to conduct
and manage non-clinical and clinical studies. If we engage these organizations
to help us with our non-clinical and clinical programs, many important aspects
of this process have been and will be out of our direct control. If any of these
organizations fail to perform their obligations under our agreements with them
or fail to perform non-clinical testing and/or clinical trials in a satisfactory
manner, we may face delays in completing our clinical trials, as well as
commercialization of any of our potential drug compounds. Furthermore, any loss
or delay in obtaining or fulfilling contracts with such entities may also delay
the completion of our clinical trials, regulatory filings and the potential
market approval of our potential drug compounds. </P>
<P align=justify><I>If we fail to compete successfully with respect to
partnering, licensing, mergers, acquisitions, joint venture and other
collaboration opportunities, we may be limited in our ability to research and
develop our potential drug compounds. </I></P>
<P align=center>15</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_21></A>
<P align=justify>Our competitors compete with us to attract established
biotechnology and pharmaceutical companies or organizations for partnering,
licensing, mergers, acquisitions, joint ventures or other collaborations.
Collaborations include contracting with academic research institutions for the
performance of specific scientific testing. If our competitors successfully
enter into partnering arrangements or license agreements with academic research
institutions, we will then be precluded from pursuing those specific
opportunities. Since each of these opportunities is unique, we may not be able
to find a substitute. Other companies have already begun many drug development
programs which target diseases that we are also targeting, and have already
entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities. </P>
<P align=justify>Universities and public and private research institutions also
compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patents
that we may need for the development of our potential drug compounds. We may
attempt to license this proprietary technology, if available. These licenses may
not be available to us on acceptable terms, if at all. If we are unable to
compete successfully with respect to acquisitions, joint venture and other
collaboration opportunities, we may be limited in our ability to develop new
products. </P>
<P align=justify><I>The use of any of our products in clinical trials may expose
us to liability claims, which may cost us a significant amounts of money to
defend against or pay out, causing our business to suffer. </I></P>
<P align=justify>The nature of our business exposes us to potential liability
risks inherent in the testing, manufacturing and marketing of our products. We
currently have one drug compound in clinical trials, however, when any of our
products enter into clinical trials or become marketed products they could
potentially harm people or allegedly harm people and we may be subject to costly
and damaging product liability claims. Some participants in clinical trials are
already ill when they enter a trial or may intentionally or unintentionally fail
to meet the exclusion criteria. The waivers we obtain may not be enforceable and
may not protect us from liability or the costs of product liability litigation.
Although we intend to obtain product liability insurance that we believe is
adequate, we are subject to the risk that our insurance will not be sufficient
to cover claims. The insurance costs along with the defence or payment of
liabilities above the amount of coverage could cost us significant amounts of
money and management distraction from other elements of the business, causing
our business to suffer.</P>
<P align=justify><I>The patent positions of pharmaceutical products are complex
and uncertain and we may not be able to protect our patented or other
intellectual property. If we cannot protect this property, we may be prevented
from using it or our competitors may use it and our business could suffer
significant harm. Also, the time and money we spend on acquiring and enforcing
patents and other intellectual property will reduce the time and money we have
available for our research and development, possibly resulting in a slow down or
cessation of our research and development.</I></P>
<P align=justify>We own patents related to our potential drug compounds.
However, these patents do not ensure the protection of our intellectual property
for a number of reasons, including the following: </P>
<P align=center>16</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_22></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD vAlign=top width="5%">1. </TD>
    <TD colSpan=2>
      <P align=justify>Competitors may interfere with our patent process in a
      variety of ways. Competitors may claim that they invented the claimed
      invention prior to us. Competitors may also claim that we are infringing
      their patents and restrict our freedom to operate as claimed under our
      patents and patent applications. Competitors may also contest our patents
      and patent application, if issued, by showing the patent examiner that the
      invention was not original, was not novel or was obvious. In litigation, a
      competitor could claim that our patents and patent application are not
      valid for a number of reasons. If a court agrees, we would lose that
      patent or patent application. As a company, we have no meaningful
      experience with competitors interfering with our patents or patent
      applications.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">2. </TD>
    <TD colSpan=2>
      <P align=justify>Because of the time, money and effort involved in
      obtaining and enforcing patents, our management may spend less time and
      resources on developing potential drug compounds than they otherwise
      would, which could increase our operating expenses and delay product
      programs.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">3. </TD>
    <TD colSpan=2>
      <P align=justify>Receipt of a patent may not provide much practical
      protection. If we receive a patent with a narrow scope, then it will be
      easier for competitors to design products that do not infringe our
      patent(s).</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">4. </TD>
    <TD colSpan=2>
      <P align=justify>Our patents are not issued in all possible geographies
      where our products may be marketed. Currently, we have submitted for
      patent protection and have been issued patents for certain claims in
      Greece. We have submitted for patent protection in some of the world&#146;s
      largest markets. We may not necessarily be successful in securing patents
      for further claims and products in Greece, nor may we necessarily be
      successful in securing the existing claims and product patents in
      countries and jurisdictions where we have applied but have not yet had
      those patents issued. If we are not issued patents in these other key
      markets, our ability to advance our compounds will be severely hampered
      and we will be much less attractive to potential partners.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">5. </TD>
    <TD colSpan=2>
      <P align=justify>In addition, competitors also seek patent protection for
      their inventions. Due to the number of patents in our field, we cannot be
      certain that we do not infringe on existing patents or that we will not
      infringe on patents granted in the future. If a patent holder believes our
      potential drug compound infringes on their patent, the patent holder may
      sue us even if we have received patent protection for our technology. If
      someone else claims we infringe on their patent, we would face a number of
      issues which could cause a slow down or cessation of our research and
      development, including the following:</P></TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">a. </TD>
    <TD>
      <P align=justify>Defending a lawsuit takes significant time and can be
      very expensive.</P></TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">b. </TD>
    <TD>
      <P align=justify>If the court decides that our potential drug compound
      infringes on the competitor&#146;s patent, we may have to pay substantial
      damages for past infringement.</P></TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">c. </TD>
    <TD>
      <P align=justify>The court may prohibit us from selling or licensing the
      potential drug compound unless the patent holder licenses the patent to
      us. The patent holder is not required to grant us a license. If a license
      is available, we may have to pay substantial royalties or grant cross
      licenses to our patents.</P></TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">d. </TD>
    <TD>
      <P align=justify>Redesigning our potential drug compounds so that they do
      not infringe on other patents may not be possible or could require
      substantial funds and time.</P></TD></TR></TABLE>
<P align=center>17</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_23></A>
<P align=justify>It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our
employees or consultants may unintentionally or willfully disclose our
information to competitors. Enforcing a claim that someone else illegally
obtained and is using our trade secrets, like patent litigation, is expensive
and time consuming, and the outcome is unpredictable. In addition, courts
outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and
know-how. </P>
<P align=justify>We may also support and collaborate in research conducted by
government organizations, hospitals, universities or other educational
institutions. These research partners may be unwilling to grant us any exclusive
rights to technology or products derived from these collaborations prior to
entering into the relationship.</P>
<P align=justify>If we do not obtain required licenses or rights, we could
encounter delays in our product development efforts while we attempt to design
around other patents or even be prohibited from developing, manufacturing or
selling potential drug compounds requiring these licenses. There is also a risk
that disputes may arise as to the rights to technology or potential drug
compounds developed in collaboration with other parties.</P>
<P align=justify><I>We incur substantial costs as a result of laws and
regulations and proposed changes in laws and regulations and we cannot predict
the impact of any future changes in law. </I></P>
<P align=justify>We face burdens relating to corporate governance and financial
reporting standards. Legislations or regulations such as Section 404 of the
Sarbanes-Oxley Act of 2002 impose strict corporate governance and financial
reporting standards and have led to substantial costs of compliance including
consulting, auditing and legal fees. Any new rules could make it more difficult
or more costly for us to obtain certain types of insurance, including directors&#146;
and officers&#146; liability insurance, and we may be forced to accept reduced policy
limits and coverage or incur substantially higher costs to obtain the same or
similar coverage. The impact of these events could also make it more difficult
for us to attract and retain qualified persons to serve on our board of
directors, our board committees or as executive officers. A failure to comply
with these new laws and regulations may impact market perception of our
financial condition and could materially harm our business. Additionally, it is
unclear what additional laws or regulations may develop, and we cannot predict
the ultimate impact of any future changes in law.</P>
<P align=justify><I>Our substantial debt and other financial obligations could
impair our financial condition and our ability to fulfill our debt obligations.
Any refinancing of this substantial debt could be at significantly higher
interest rates.</I></P>
<P align=justify>As of September 30, 2012, we had total liabilities of
$2,888,324 and accumulated deficit of $37,504,926. Our substantial indebtedness
and other current financial obligations and any that we may become a party to in
the future:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>impair our ability to obtain financing for working capital, capital
  expenditures, or general corporate purposes; </LI></UL>
<P align=center>18</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_24></A>
<UL style="TEXT-ALIGN: justify">
  <LI>have a material adverse effect on us if we fail to comply with financial
  and affirmative and restrictive covenants in debt agreements and an event of
  default occurs as a result of a failure that is not cured or waived;
  <LI>require us to dedicate a substantial portion of our cash flow to interest
  payments on our indebtedness and other financial obligations, thereby reducing
  the availability of our cash flow to fund working capital and capital
  expenditures;
  <LI>limit our flexibility in planning for, or reacting to, changes in our
  business and the industry in which we operate; and
  <LI>place us at a competitive disadvantage compared to our competitors that
  have proportionally less debt. </LI></UL>
<P align=justify>If we are unable to meet our debt service obligations and other
financial obligations, we could be forced to restructure or refinance our
indebtedness and other financial transactions, seek additional equity capital or
sell our assets. We might then be unable to obtain such financing or capital or
sell our assets on satisfactory terms, if at all. Any refinancing of our
indebtedness could be at significantly higher interest rates, and/or incur
significant transaction fees.</P>
<P align=justify><I><FONT color=#4f81bd>Risks Related to our Common
Stock</FONT></I></P>
<P align=justify><I>A further decline in the price of our common stock could
affect our ability to raise further working capital and adversely impact our
operations and would severely dilute existing or future investors if we were to
raise funds at lower prices. </I></P>
<P align=justify>A further prolonged decline in the price of our common stock
could result in a reduction in our ability to raise capital. Because our
operations have been principally financed through the sale of equity securities,
a further decline in the price of our common stock could be detrimental to our
continued operations. Any reduction in our ability to raise equity capital in
the future would force us to reallocate funds from other planned uses and would
have a significant negative effect on our business plans and operations,
including our ability to develop new products and continue our current
operations. If the stock price declines, there can be no assurance that we can
raise additional capital or generate funds from operations sufficient to meet
our obligations. We believe the following factors could cause the market price
of our common stock to continue to fluctuate widely and could cause our common
stock to trade at a price below the price at which you purchase your shares of
common stock: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>actual or anticipated variations in our quarterly operating results;
  <LI>announcements of new services, products, acquisitions or strategic
  relationships by us or our competitors;
  <LI>changes in accounting treatments or principles;
  <LI>changes in earnings estimates by securities analysts and in analyst
  recommendations; and
  <LI>general political, economic, regulatory and market conditions. </LI></UL>
<P align=center>19</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_25></A>
<P align=justify>The market price for our common stock may also be affected by
our ability to meet or exceed expectations of analysts or investors. Any failure
to meet these expectations, even if minor, could materially adversely affect the
market price of our common stock. </P>
<P align=justify><I>If we issue additional shares of common stock in the future,
it will result in the dilution of our existing stockholders. </I></P>
<P align=justify>Our articles of incorporation authorize the issuance of
150,000,000 shares of common stock. Our board of directors has the authority to
issue additional shares of common stock up to the authorized capital stated in
the articles of incorporation. Our board of directors may choose to issue some
or all of such shares of common stock to acquire one or more businesses or to
provide additional financing in the future. The issuance of any such shares of
common stock will result in a reduction of the book value or market price of the
outstanding shares of our common stock. If we do issue any such additional
shares of common stock, such issuance also will cause a reduction in the
proportionate ownership and voting power of all other stockholders. Further, any
such issuance may result in a change of control of our corporation. </P>
<P align=justify><I>Trading of our common stock may be volatile and sporadic,
which could depress the market price of our common stock and make it difficult
for our stockholders to resell their shares.</I></P>
<P align=justify>There is currently a limited market for our common stock and
the volume of our common stock traded on any day may vary significantly from one
period to another. Our common stock is quoted on OTCQB. Trading in stock quoted
on OTCQB is often thin and characterized by wide fluctuations in trading prices,
due to many factors that may have little to do with our operations or business
prospects. The availability of buyers and sellers represented by this volatility
could lead to a market price for our common stock that is unrelated to operating
performance. Moreover, OTCQB is not a stock exchange, and trading of securities
quoted on OTCQB is often more sporadic than the trading of securities listed on
a stock exchange like NASDAQ. There is no assurance that a sufficient market
will develop in the stock, in which case it could be difficult for our
stockholders to resell their stock.</P>
<P align=justify><I>Our stock is classed as a &#147;penny stock&#148;. Trading of our
stock may be restricted by the Securities and Exchange Commission&#146;s penny stock
regulations which may limit a stockholder&#146;s ability to buy and sell our
stock.</I></P>
<P align=justify>Our stock is a penny stock. The Securities and Exchange
Commission has adopted Rule 15g-9 which generally defines &#147;penny stock&#148; to be
any equity security that has a market price (as defined) less than $5.00 per
share or an exercise price of less than $5.00 per share, subject to certain
exceptions. Our securities are covered by the penny stock rules, which impose
additional sales practice requirements on broker-dealers who sell to persons
other than established customers and &#147;accredited investors&#148;. The term
&#147;accredited investor&#148; refers generally to institutions with assets in excess of
$5,000,000 or individuals with a net worth in excess of $1,000,000 (excluding
the value of the primary residence of such individuals) or annual income
exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules
require a broker-dealer, prior to a transaction in a penny stock not otherwise
exempt from the rules, to deliver a standardized risk disclosure document in a
form prepared by the Securities and </P>
<P align=center>20</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_26></A>
<P align=justify>Exchange Commission which provides information about penny
stocks and the nature and level of risks in the penny stock market. The
broker-dealer also must provide the customer with current bid and offer
quotations for the penny stock, the compensation of the broker-dealer and its
salesperson in the transaction and monthly account statements showing the market
value of each penny stock held in the customer&#146;s account. The bid and offer
quotations, and the broker-dealer and salesperson compensation information, must
be given to the customer orally or in writing prior to effecting the transaction
and must be given to the customer in writing before or with the customer&#146;s
confirmation. In addition, the penny stock rules require that prior to a
transaction in a penny stock not otherwise exempt from these rules; the
broker-dealer must make a special written determination that the penny stock is
a suitable investment for the purchaser and receive the purchaser&#146;s written
agreement to the transaction. These disclosure requirements may have the effect
of reducing the level of trading activity in the secondary market for the stock
that is subject to these penny stock rules. Consequently, these penny stock
rules may affect the ability of broker-dealers to trade our securities. We
believe that the penny stock rules discourage investor interest in and limit the
marketability of our common stock.</P>
<P align=justify><I>The Financial Industry Regulatory Authority sales practice
requirements may also limit a stockholder&#146;s ability to buy and sell our
stock.</I></P>
<P align=justify>In addition to the &#147;penny stock&#148; rules described above, the
Financial Industry Regulatory Authority or FINRA has adopted rules that require
that in recommending an investment to a customer, a broker-dealer must have
reasonable grounds for believing that the investment is suitable for that
customer. Prior to recommending speculative low-priced securities to their
non-institutional customers, broker-dealers must make reasonable efforts to
obtain information about the customer&#146;s financial status, tax status, investment
objectives and other information. Under interpretations of these rules, FINRA
believes that there is a high probability that speculative low-priced securities
will not be suitable for at least some customers. The FINRA requirements make it
more difficult for broker-dealers to recommend that their customers buy our
common stock, which may limit your ability to buy and sell our stock and have an
adverse effect on the market for shares of our common stock.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      1B. UNRESOLVED STAFF COMMENTS </FONT></TD>
  </TR></TABLE>
<P align=justify>Not Applicable.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT
      color=#004080 size="4">ITEM 2. PROPERTIES </FONT></TD>
  </TR></TABLE>
<P align=justify>We do not own or lease any property.</P>
<P align=justify>Our temporary principal executive offices are contributed by
our president.</P>
<P align=justify>Effective August 1, 2012, we terminated our lease agreement
with EuroGenet Labs SA to focus on research in the United States, and to
conserve operating costs. </P>
<P align=center>21</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_27></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      3. LEGAL PROCEEDINGS </FONT></TD></TR></TABLE>
<P align=justify>We know of no material, existing or pending legal proceedings
to which we are a party or of which any of our properties is the subject. In
addition, we do not know of any such proceedings contemplated by any
governmental authorities. We know of no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder
is a party adverse to our company or has a material interest adverse to our
company. </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      4. MINE SAFETY DISCLOSURES</FONT><FONT size=4>&nbsp; </FONT></TD>
  </TR></TABLE>
<P align=justify>Not applicable.</P>
<P align=justify><B>PART II</B></P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT size=4>
      <P align=justify><font color="#004080">ITEM 5. MARKET FOR REGISTRANT&#146;S
        COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
        SECURITIES </font> </P>
      </FONT></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Market information</FONT></I></P>
<P align=justify>Our common stock is quoted on OTCQB under the symbol &#147;AVXL&#148;.
Until July 22, 2012, our common stock was quoted on the OTC Bulletin Board, but
effective July 23, 2012, our common stock was not eligible for quotation on the
OTC Bulletin Board due to quoting inactivity under Rule 15c2-11 promulgated by
the Securities and Exchange Commission.</P>
<P align=justify>The following table shows the quarterly range of high and low
bid information for our common stock over the fiscal quarters for the last two
fiscal years as quoted on OTCQB and the OTC Bulletin Board. We obtained the
following high and low bid information from OTCQB and the OTC Bulletin Board.
These over-the-counter market quotations reflect inter-dealer prices without
retail mark-up, mark-down or commission, and may not represent actual
transactions. Investors should not rely on historical prices of our common stock
as an indication of its future price performance. On December 27, 2012, the
closing price of our common stock as reported by OTCQB was $0.80 per share.</P>
<P align=center>22</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_28></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR>
    <TD  align=left>Quarter Ended</TD>
    <TD  width="33%" align=left>High</TD>
    <TD  width="33%" align=left>Low</TD></TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2012 </TD>
    <TD width="33%" align=left>$1.45 </TD>
    <TD width="33%" align=left>$0.70 </TD></TR>
  <TR vAlign=top>
    <TD align=left>June 30, 2012 </TD>
    <TD width="33%" align=left>$1.36 </TD>
    <TD width="33%" align=left>$0.50 </TD></TR>
  <TR vAlign=top>
    <TD align=left>March 31, 2012 </TD>
    <TD width="33%" align=left>$2.09 </TD>
    <TD width="33%" align=left>$1.02 </TD></TR>
  <TR vAlign=top>
    <TD align=left>December 31, 2011 </TD>
    <TD width="33%" align=left>$2.50 </TD>
    <TD width="33%" align=left>$1.11 </TD></TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2011 </TD>
    <TD width="33%" align=left>$2.50 </TD>
    <TD width="33%" align=left>$0.00 </TD></TR>
  <TR vAlign=top>
    <TD align=left>June 30, 2011 </TD>
    <TD width="33%" align=left>$3.65 </TD>
    <TD width="33%" align=left>$1.01 </TD></TR>
  <TR vAlign=top>
    <TD align=left>March 31, 2011 </TD>
    <TD width="33%" align=left>$4.45 </TD>
    <TD width="33%" align=left>$0.00 </TD></TR>
  <TR vAlign=top>
    <TD align=left>December 31, 2010 </TD>
    <TD width="33%" align=left>$4.25 </TD>
    <TD width="33%" align=left>$3.05 </TD></TR></TABLE></DIV>
<P align=justify><I><FONT color=#4f81bd>Transfer Agent</FONT></I></P>
<P align=justify>Shares of our common stock are issued in registered form. The
Nevada Agency and Trust Company, 50 West Liberty Street, Reno, Nevada
(Telephone: (775) 322-0626; Facsimile: (775) 322-5623) is the registrar and
transfer agent for shares of our common stock.</P>
<P align=justify><I><FONT color=#4f81bd>Holders of Common Stock </FONT></I></P>
<P align=justify>As of December 20, 2012, there were 81 holders of record of our
common stock. As of such date, 30,240,687 shares of our common stock were issued
and outstanding.</P>
<P align=justify><I><FONT color=#4f81bd>Dividends </FONT></I></P>
<P align=justify>We have not paid any cash dividends on our common stock and
have no intention of paying any dividends on the shares of our common stock. Our
current policy is to retain earnings, if any, for use in our operations and in
the development of our business. Our future dividend policy will be determined
from time to time by our board of directors.</P>
<P align=justify><I><FONT color=#4f81bd>Securities Authorized for Issuance under
Equity Compensation Plans or Individual Compensation Arrangements
</FONT></I></P>
<P align=justify>The following table summarizes certain information regarding
our equity compensation plan or individual compensation arrangements as at
September 30, 2012:</P>
<P align=center>23</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_29></A><BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">
    <TR vAlign=bottom>
      <TD colspan="4" align=center style="BORDER-BOTTOM: #000000 1px solid">&nbsp;Equity
        Compensation Plan Information&nbsp; </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center><BR> <BR> <BR> <BR> <BR> <BR>
        Plan Category <BR></TD>
      <TD width="25%" align=center><BR> <BR> <BR>
        Number of securities to <BR>
        be issued upon exercise <BR>
        of outstanding options, <BR>
        warrants and rights <BR>
        (a) </TD>
      <TD width="25%" align=center><BR> <BR> <BR>
        Weighted-average <BR>
        exercise price of <BR>
        outstanding options, <BR>
        warrants and rights <BR>
        (b) </TD>
      <TD width="25%" align=center>Number of securities <BR>
        remaining available for <BR>
        future issuances under <BR>
        equity compensation <BR>
        plans (excluding <BR>
        securities reflected in <BR>
        column (a)) <BR>
        (c) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Equity compensation plans approved by security holders </TD>
      <TD vAlign=bottom width="25%" align=right>1,775,000 </TD>
      <TD vAlign=bottom width="25%" align=right>2.94 </TD>
      <TD vAlign=bottom width="25%" align=right>2,225,000 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Equity compensation plans not approved by security holders
      </TD>
      <TD vAlign=bottom width="25%" align=right>Nil </TD>
      <TD vAlign=bottom width="25%" align=right>Nil </TD>
      <TD vAlign=bottom width="25%" align=right>Nil </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left><B>Total</B> </TD>
      <TD vAlign=bottom width="25%" align=right><B>1,775,000</B> </TD>
      <TD vAlign=bottom width="25%" align=right><B>2.94</B> </TD>
      <TD vAlign=bottom width="25%" align=right><B>2,225,000</B> </TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify><I><FONT color=#4f81bd>Stock Option Plan </FONT></I></P>
<P align=justify>On April 17, 2007, our directors adopted the 2007 Stock Option
Plan. On May 25, 2007, our stockholders ratified and approved the 2007 Stock
Option Plan at the annual meeting of stockholders. As of September 30, 2012,
1,775,000 options have been granted to employees, directors, officers and
consultants of our company.</P>
<P align=justify>The purpose of the 2007 Stock Option Plan is to retain the
services of valued key employees and consultants of our company and such other
persons as will be select in accordance with the 2007 Stock Option Plan, and to
encourage such persons to acquire a greater proprietary interest in our company,
thereby strengthening their incentive to achieve the objectives of the
shareholders of our company, and to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants.</P>
<P align=justify>On February 2, 2011 we amended and restated our 2007 stock
option plan to increase the number of shares authorized to be issued under the
plan to 4,000,000 </P>
<P align=justify><I><FONT color=#4f81bd>Recent Sales of Unregistered Securities
</FONT></I></P>
<P align=justify>Since the beginning of our fiscal year ended September 30,
2012, we have not sold any equity securities that were not registered under the
Securities Act of 1933 that were not previously reported in a quarterly report
on Form 10-Q or in a current report on Form 8-K. </P>
<P align=justify><I><FONT color=#4f81bd>Purchases of Equity Securities by Our
Company and Affiliated Purchasers</FONT></I></P>
<P align=justify>None.</P>
<P align=center>24</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_30></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      6 SELECTED FINANCIAL DATA </FONT></TD></TR></TABLE>
<P align=justify>Not applicable.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      7 MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
      OF OPERATION </FONT></TD></TR></TABLE>
<P align=justify>The following discussion should be read in conjunction with our
audited consolidated financial statements and notes thereto for the fiscal year
ended September 30, 2012, included elsewhere in this annual report. The
following Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations contains &#147;forward-looking statements&#148;. Forward-looking
statements are generally written in the future tense and/or are preceded by
words such as &#147;may,&#148; &#147;should,&#148; &#147;forecast,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;suggest,&#148;
&#147;believe,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; or other similar words. The
forward-looking statements contained in this annual report involve a number of
risks and uncertainties, many of which are outside of our control. Factors that
could cause actual results to differ materially from projected results include,
but are not limited to, those discussed in &#147;Risk Factors&#148; elsewhere in this
annual report. Readers are expressly advised to review and consider those Risk
Factors, which include risks associated with (1) our ability to successfully
conduct clinical and preclinical trials for our product candidates, (2) our
ability to obtain required regulatory approvals to develop and market our
product candidates, (3) our ability to raise additional capital on favorable
terms, (4) our ability to execute our development plan on time and on budget,
(5) our ability to obtain commercial partners, (6) our ability, whether alone or
with commercial partners, to successfully commercialize any of our product
candidates that may be approved for sale, and (7) our ability to identify and
obtain additional product candidates. Although we believe that the assumptions
underlying the forward-looking statements contained in this annual report are
reasonable, any of the assumptions could be inaccurate, and therefore there can
be no assurance that such statements will be accurate. In light of the
significant uncertainties inherent in the forward-looking statements included
herein, the inclusion of such information should not be regarded as a
representation by us or any other person that the results or conditions
described in such statements or our objectives and plans will be achieved.
Furthermore, past performance in operations and share price is not necessarily
indicative of future performance. Except as required by applicable laws
including the securities laws of the United States and Canada, we disclaim any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>
<P align=center>25</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_31></A>
<P align=justify><I><FONT color=#4f81bd>Our Business</FONT></I></P>
<P align=justify>We are a pharmaceutical company engaged in the development of
drug candidates. Our lead compound ANAVEX 2-73, developed to treat Alzheimer&#146;s
disease through disease modification, is in human clinical trials. </P>
<P align=justify>In pre-clinical studies conducted in France, and in Greece,
ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective properties. Based on
these preclinical studies, we sponsored a Phase 1 single ascending dose study of
ANAVEX 2-73 initiated and completed in 2011. This study was conducted in Germany
in collaboration with ABX-CRO Advanced Pharmaceutical Services. The study
indicated that ANAVEX 2-73 was well tolerated by study subjects in doses up to
55mg.</P>
<P align=justify>Despite success in trials to date, and due principally to
insufficient capital to support operations and development of our pipeline, we
have been unable to attract and retain executive management, particularly a
chief executive officer, who is experienced in leading a development stage
pharmaceutical company. For this reason, we intend to defer most of our research
activity until expert management evaluates our progress and proposes an
appropriate course of action, and until there is sufficient capital on hand to
effect management&#146;s plan of action.</P>
<P align=justify>In considering several different means of accomplishing our
goal of commercializing drug candidates, we have determined that pursuing a
strategic relationship with a partner, partners, or an acquirer with capable
management and sufficient capital to sponsor trials is our best course of action
at this time.</P>
<P align=justify>We intend to identify and initiate discussions with potential
partners and acquirers. Further, we may acquire or develop new intellectual
property and assign, license, or otherwise transfer our intellectual property to
further our goals.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080"
      size=4>Results of Operations </FONT></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Revenue</FONT></I></P>
<P align=justify>We have not earned any revenues since our inception on January
23, 2004. We are still in the development stage and do not anticipate earning
any revenues until we can establish an alliance with other companies to develop,
co-develop, license, acquire or market our products. </P>
<P align=justify><I><FONT color=#4f81bd>Expenses </FONT></I></P>
<P align=justify>Our expenses for the fiscal year ended September 30, 2012 and
2011 were as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="5%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD colspan="4" align=center>Year ended September 30, </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD colspan="4" align=center>Change </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=center>2012 </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="12%" align=center>2011 </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center></TD>
    <TD width="12%" align=center>$</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="12%" align=center>&nbsp;%&nbsp;&nbsp; </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Accounting and audit fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;139,761 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>158,225 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(18,464</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(11.7</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>Amortization </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>1,858 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>1,657 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>201 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>12.1 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Bank charges and interest </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>5,963 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>8,701 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(2,738</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(31.5</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>Consulting </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>1,155,366 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>2,757,835 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(1,602,469</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(58.1</TD>
    <TD  width="2%" align=left>) </TD>
  </TR>
</TABLE>
<P align=center>26</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_32></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Insurance </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>10,844 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>48,152 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(37,308</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(77.5</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD align=left>Investor relations </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>108,138 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>133,805 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(25,667</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(19.2</TD>
    <TD  width="2%" align=left>) </TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Legal fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>142,923 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>140,613 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>2,310 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>1.6 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD align=left>Office and miscellaneous </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>9,147 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>30,068 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(20,921</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(69.6</TD>
    <TD  width="2%" align=left>) </TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Registration and filing fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>26,794 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>58,878 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(32,084</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(54.5</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD align=left>Rent </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>63,110 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(63,110</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(100.0</TD>
    <TD  width="2%" align=left>) </TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Research and development </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>2,653,860 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>2,597,279 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>56,581 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>2.2 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD align=left>Travel </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>66,837 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>182,259 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(115,422</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>(63.3</TD>
    <TD  width="2%" align=left>) </TD></TR>
  <TR vAlign=top>
    <TD width="5%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff align=left><B>Total expenses</B> </TD>
    <TD bgColor=#e6efff  width="1%" align=left><B>$</B></TD>
    <TD bgColor=#e6efff width="12%" align=right><B>&nbsp;4,321,491$</B> </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right><B>6,180,582</B> </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right><B>(1,859,091</B></TD>
    <TD bgColor=#e6efff  width="2%" align=left><B>)</B> </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right><B>(30.1</B></TD>
  <TD bgColor=#e6efff  width="2%" align=left><B>)</B>  </TD></TR></TABLE>
<P align=justify><I>Year ended September 30, 2012 and 2011 </I></P>
<P align=justify>Expenses for the fiscal year ended September 30, 2012 decreased
by $1,859,091 over the same period in 2011. The principal contributors to the
decrease were:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>Consulting fees have decreased by $1,602,469 primarily as
      a result of decreased management infrastructure as well as a decrease in
      stock based compensation expense from stock options granted and vesting
      during the period, as compared to fiscal 2011.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>Travel expenses have decreased by $115,422 as a result of
      less international corporate travel due to cost saving initiatives in
      response to our inability to obtain sufficient financing.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>Rent expense has decreased by $63,110 as a result of our
      New Jersey office lease expiring in 2011.</P></TD></TR></TABLE>
<P align=justify><I>Other income</I></P>
<P align=justify>Other income and (loss) for the year ended September 30, 2012,
amounted to $(3,980,214) as compared to a loss of $(1,126,565) for the year
ended September 30, 2011. The increase in loss of $(2,853,649) is primarily
attributable to </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>a loss of $3,829,333 resulting from the extinguishment of
      four promissory notes totaling $1,297,889 recognized in the year ended
      September 30, 2012 compared with a loss of $198,738 recognized in the same
      period in 2011 relating to the extinguishment of promissory notes totaling
      $398,922;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>interest expense of $138,341 recognized in the year ended
      September 30, 2012 as compared to lower interest expense of $90,246
      recognized in the year ended September 30, 2011, as a result of the
      increased debt levels during the current period from the issuance of
      promissory notes in the fourth quarter of 2011 and the first quarter of
      2012;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>accretion of debt discount of $98,081 recognized in the
      year ended September 30, 2012 compared with accretion of $69,419
      recognized in the year ended September 30, 2011 in respect of a debt
      issuance in the third quarter of fiscal 2011.</P></TD></TR></TABLE>
<P align=justify>This increase in loss was also partially offset by:</P>
<P align=center>27</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_33></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>debt conversion expense of $504,160 recognized in the
      year ended September 30, 2011 compared with no similar expense for the
      same period in 2012, as a result of the Company&#146;s adjustment to conversion
      rates on convertible debt during fiscal 2011;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>loss on settlement of accounts payable of $334,053
      recognized in the year ended September 30, 2011 with no corresponding loss
      in the year ended September 30, 2012.</P></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Liquidity and Capital Resources
</FONT></I></P>
<P align=justify><I><FONT color=#4f81bd>Working Capital</FONT></I></P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=center>September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=center>September 30, 2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Current Assets </TD>
    <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="17%" align=right>12,577 </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="17%" align=right>200,605 </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%">&nbsp;</TD>
    <TD align=left>Current Liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=right>2,888,324 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=right>1,345,443 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Working Capital Deficiency </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="17%"
    align=right>&nbsp;(2,875,747</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="2%"
    align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="17%"
    align=right>(1,144,838</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="2%"
    align=left>) </TD></TR></TABLE>
<P align=justify>As of September 30, 2012, we had $11,362 in cash, a decrease of
$123,340 from September 30, 2011. The principal components of this decrease in
cash relate to a loss from operations in excess of cash generated through
financing activities from debt and equity issuances. As of September 30, 2012,
we had a working capital deficiency of $2,875,747, a decrease in deficit of
$1,730,909 from September 30, 2011. The principal component of this decrease in
working capital deficit was as a result of increased accounts payable and
accrued liabilities arising from our inability to obtain sufficient financing to
meet these debt obligations.</P>
<P align=justify>We have sufficient capital to continue basic operations until
January 2013. We anticipate that we will require $4,000,000 for the 12-month
period ending September 30, 2013 to continue our operations. If we are not able
to secure additional financing, we will not be able to implement and fund this
work.</P>
<P align=justify><I><FONT color=#4f81bd>Going Concern</FONT></I></P>
<P align=justify>At September 30, 2012, we had an accumulated deficit of
$37,504,926 since our inception and incurred a net loss of $8,301,705 for the
fiscal year ended September 30, 2012. We expect to incur further losses in the
development of our business, all of which casts substantial doubt about our
ability to continue as a going concern. Our ability to continue as a going
concern is dependent upon our ability to generate future profitable operations
and/or to obtain the necessary financing to meet our obligations and repay our
liabilities arising from normal business operations when they come due. Our
independent auditors included an explanatory paragraph regarding substantial
doubt about our ability to continue as a going concern in their report on our
annual financial statements for the fiscal year ended September 30, 2012. </P>
<P align=center>28</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_34></A>
<P align=justify><I><FONT color=#4f81bd>Future Financing</FONT></I></P>
<P align=justify>We will require additional financing to fund operations,
further strengthen our patents, secure patents for other compounds and any
further intellectual property that we may acquire, and to continue clinical
development. We currently do not have committed sources of additional financing
and may not be able to obtain additional financing, particularly, if the
volatile conditions in the stock and financial markets, and especially the
market for early development stage pharmaceutical and biotechnology research and
development company stocks persist. </P>
<P align=justify>There can be no assurance that additional financing will be
available to us when needed or, if available, that it can be obtained on
commercially reasonable terms. If we are not able to obtain the additional
financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities or
perhaps even cease the operation of our business. </P>
<P align=justify>Since inception we have funded our operations primarily through
equity and debt financings and we expect that we will continue to fund our
operations through the equity and debt financing. Our existing stockholders&#146;
ownership will be diluted if we raise additional financing by issuing equity
securities. Obtaining commercial loans, assuming those loans would be available,
will increase our liabilities and future cash commitments. </P>
<P align=justify>There is no assurance that we will be able to maintain
operations at a level sufficient for investors to obtain a return on their
investment in our common stock. Further, we may continue to be unprofitable.</P>
<P align=justify><I><FONT color=#4f81bd>Off-Balance Sheet
Arrangements</FONT></I></P>
<P align=justify>We have no off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that is material to our
stockholders.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT
      color=#004080 size="4">Application of Critical Accounting Policies </FONT></TD>
  </TR></TABLE>
<P align=justify>Our financial statements and accompanying notes are prepared in
accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, revenue and
expenses. These estimates and assumptions are affected by management&#146;s
application of accounting policies. We believe that understanding the basis and
nature of the estimates and assumptions involved with the following aspects of
our financial statements is critical to an understanding of our financials.</P>
<P align=justify>We base our assumptions and estimates on historical experience
and other sources that we believe to be reasonable at the time. Actual results
may vary from our estimates due to changes in circumstances, weather, politics,
global economics, mechanical problems, general business conditions and other
factors. Our significant estimates are related to the valuation of warrants and
options.</P>
<P align=center>29</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_35></A>
<P align=justify>There are accounting policies that we believe are significant
to the presentation of our financial statements. The most significant of these
accounting policies relates to the accounting for our research and development
expenses and stock-based compensation expense. </P>
<P align=justify><I><FONT color=#4f81bd>Research and Development
Expenses</FONT></I></P>
<P align=justify>Research and developments costs are expensed as incurred. These
expenses are comprised of the costs of our proprietary research and development
efforts, including salaries, facilities costs, overhead costs and other related
expenses as well as costs incurred in connection with third-party collaboration
efforts. Milestone payments made by us to third parties are expensed when the
specific milestone has been achieved. </P>
<P align=justify>In addition, we incur expenses in respect of the acquisition of
intellectual property relating to patents and trademarks. The probability of
success and length of time in developing commercial applications of the drugs
subject to the acquired patents and trademarks is difficult to determine and
numerous risks and uncertainties exist with respect to the timely completion of
the development projects. There is no assurance the acquired patents and
trademarks will ever be successfully commercialized. Due to these risks and
uncertainties, we expense the acquisition of patents and trademarks. </P>
<P align=justify><I><FONT color=#4f81bd>Stock-based Compensation</FONT></I></P>
<P align=justify>We account for all stock-based payments and awards under the
fair value based method.</P>
<P align=justify>Stock-based payments to non-employees are measured at the fair
value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair
value of stock-based payments to non-employees is periodically re-measured until
the counterparty performance is complete, and any change therein is recognized
over the vesting period of the award and in the same manner as if we had paid
cash instead of paying with or using equity based instruments. The cost of the
stock-based payments to non-employees that is fully vested and non-forfeitable
as at the grant date is measured and recognized at that date, unless there is a
contractual term for services in which case such compensation would be amortized
over the contractual term. </P>
<P align=justify>We account for the granting of share purchase options to
employees using the fair value method whereby all awards to employees will be
recorded at fair value on the date of the grant. The fair value of all share
purchase options are expensed over their vesting period with a corresponding
increase to additional capital surplus. Upon exercise of share purchase options,
the consideration paid by the option holder, together with the amount previously
recognized in additional capital surplus, is recorded as an increase to share
capital.</P>
<P align=justify>We use the Black-Scholes option valuation model to calculate
the fair value of share purchase options at the date of the grant. Option
pricing models require the input of highly subjective assumptions, including the
expected price volatility. Changes in assumptions can materially affect the fair
value estimate and therefore the Black-Scholes model does not necessarily
provide a reliable single measure of the fair value of our share purchase
options. </P>
<P align=center>30</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_36></A>
<P align=justify><I><FONT color=#4f81bd>Derivative Liabilities</FONT></I></P>
<P align=justify>Our convertible promissory notes included embedded conversion
options which, prior to their amendments, were required to be accounted for as
separate derivative liabilities. These liabilities were required to be measured
at fair value. These instruments were adjusted to reflect fair value at each
period end. Any increase or decrease in the fair value was recorded in results
of operations as change in fair value of derivative liabilities. In determining
the appropriate fair value, we used the binomial pricing model. </P>
<P align=justify>The debt discount arising from bifurcating the derivative
liability from the host debt instrument was accreted to income during the
period. </P>
<P align=justify><I><FONT color=#4f81bd>Recent Accounting Pronouncements
</FONT></I></P>
<P align=justify>On June 16, 2011, the FASB issued ASU No. 2011-05,
Comprehensive Income (Topic 220): Presentation of Comprehensive Income, or ASU
2011-05. ASU 2011-05 requires entities to report items of other comprehensive
income on either part of a single contiguous statement of comprehensive income
or in a separate statement of comprehensive income immediately following the
statement of income. On December 23, 2011, the FASB issued an update to this
pronouncement, ASU No. 2011-12, Comprehensive Income (Topic 220): Deferral of
the Effective Date for Amendments to the Presentation of Reclassifications of
Items out of Accumulated Other Comprehensive Income in Accounting Standards
Update No. 2011-05, or ASU 2011-12. ASU 2011-12 defers the specific requirement
to present items that are reclassified from accumulated other comprehensive
income to net income separately with their respective components of net income
and other comprehensive income. The Company has not recorded any components of
comprehensive income (loss) for the years ended September 30, 2012 and 2011 and,
as at September 30, 2012, the Company does not have a balance recorded in
respect of accumulated comprehensive income (loss).</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
  </FONT></TD></TR></TABLE>
<P align=justify>Not Applicable.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </FONT></TD></TR></TABLE>
<P align=center>31</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_37></A><A name=page_F-1></A>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B></P>
<P align=center>(A Development Stage Company)</P>
<P align=center>CONSOLIDATED FINANCIAL STATEMENTS</P>
<P align=center>September 30, 2012 and 2011</P>
<P align=center>(<U>Stated in US Dollars</U>)</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>32</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_a-1></A>&nbsp;<BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 9pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD  rowSpan=4 align=left><IMG
      src="bdo.gif" width="114" height="60" border=0></TD>
      <TD width="33%" align=left>Tel: 604 688 5421 </TD>
      <TD width="33%" align=left>BDO Canada LLP </TD>
    </TR>
    <TR vAlign=top>
      <TD width="33%" align=left>Fax: 604 688 5132 </TD>
      <TD width="33%" align=left>600 Cathedral Place </TD>
    </TR>
    <TR vAlign=top>
      <TD width="33%" align=left><B>www.bdo.ca </B></TD>
      <TD width="33%" align=left>925 West Georgia Street </TD>
    </TR>
    <TR vAlign=top>
      <TD width="33%" align=left>&nbsp;</TD>
      <TD width="33%" align=left>Vancouver BC V6C 3L2 Canada </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P align=justify>To the Directors and Stockholders,<BR>
  Anavex Life Sciences
  Corp. <BR>
  (a Development Stage Company) </P>
<P align=justify>We have audited the accompanying consolidated balance sheets of
  Anavex Life Sciences Corp. (the &#147;Company&#148;) as of September 30, 2012 and 2011,
  and the related consolidated statements of operations, cash flows and changes in
  capital deficit for the years then ended and for the period from January 23,
  2004 (date of inception) to September 30, 2012. These financial statements are
  the responsibility of the Company&#146;s management. Our responsibility is to express
  an opinion on these financial statements based on our audits. </P>
<P align=justify>We conducted our audits in accordance with the standards of the
  Public Company Accounting Oversight Board (United States). Those standards
  require that we plan and perform the audit to obtain reasonable assurance about
  whether the financial statements are free of material misstatement. The Company
  is not required to have, nor were we engaged to perform, an audit of its
  internal control over financial reporting. Our audit included consideration of
  internal control over financial reporting as a basis for designing audit
  procedures that are appropriate in the circumstances, but not for the purpose of
  expressing an opinion on the effectiveness of the Company&#146;s internal control
  over financial reporting. Accordingly, we express no such opinion. An audit also
  includes examining, on a test basis, evidence supporting the amounts and
  disclosures in the financial statements. An audit also includes assessing the
  accounting principles used and significant estimates made by management, as well
  as evaluating the overall presentation of the financial statements. We believe
  that our audits provide a reasonable basis for our opinion. </P>
<P align=justify>In our opinion, the consolidated financial statements referred
  to above present fairly, in all material respects, the financial position of
  Anavex Life Sciences Corp. at September 30, 2012 and 2011, and the results of
  its operations and its cash flows for the years then ended and for the period
  from January 23, 2004 (date of inception) to September 30, 2012, in conformity
  with accounting principles generally accepted in the United States. </P>
<P align=justify>The accompanying financial statements have been prepared
  assuming that the Company will continue as a going concern. As discussed in Note
  1 to the financial statements, the Company had an accumulated deficit of
  $37,504,926 at September 30, 2012 and incurred a net loss of $8,301,705 for the
  year then ended. These conditions raise substantial doubt about the Company&#146;s
  ability to continue as a going concern. Management&#146;s plans in regard to these
  matters are also described in Note 1. The financial statements do not include
  any adjustments that might result from the outcome of this uncertainty. </P>
<P align=justify>/s/ BDO Canada LLP </P>
<P align=justify>Chartered Accountants </P>
<P align=justify>Vancouver, Canada </P>
<P align=justify>December 28, 2012 </P>
<P align=justify>&nbsp;</P>
<P align=justify><FONT size=1>BDO Canada LLP, a Canadian limited liability
  partnership, is a member of BDO International Limited, a UK company limited by
  guarantee, and forms part of the international BDO network of independent member
  firms. </FONT></P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-2></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED BALANCE SHEETS<BR>
  September 30, 2012 and
  2011<BR>
  (<U>Stated in US Dollars</U>)</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD colspan="6" align=center><B><U>ASSETS</U></B> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Current </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash </TD>
    <TD vAlign=bottom  width="1%" align=left>$</TD>
    <TD vAlign=bottom width="12%" align=right>&nbsp;11,362 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>$</TD>
    <TD vAlign=bottom width="12%" align=right>&nbsp;134,702 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>VAT recoverable </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=right>809 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Deferred financing charge - Note 5 </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>1,215 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>55,464 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Prepaid expenses </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>9,630 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>12,577 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>200,605 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Equipment - Note 3 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>576 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>2,434 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="12%"
    align=right>&nbsp;13,153 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="12%"
    align=right>&nbsp;203,039 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD colspan="6" align=center><B><U>LIABILITIES</U></B> </TD>
    <TD vAlign=bottom  width="2%" align=center>&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Current </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Accounts payable and accrued liabilities -
      Note 7 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=right>&nbsp;2,589,324 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=right>&nbsp;410,024 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Derivative liability - Note 4 </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>67,500 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Promissory notes payable - Note 5 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>299,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>867,919 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="12%"
    align=right>2,888,324 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="12%"
    align=right>1,345,443 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD colspan="6" align="center"><B><U>CAPITAL DEFICIT</U></B> </TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%">&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Capital stock - Note 6 </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Authorized: <BR>
      150,000,000 common shares, par value $0.001 per share <BR>
      Issued and outstanding: <BR>
      30,240,687 common shares (2011 - 26,571,574) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=right>30,241 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=right>26,572 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Additional paid-in capital </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>34,599,514 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="12%" align=right>28,034,245 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Deficit accumulated during the development
      stage </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>(37,504,926</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>(29,203,221</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="12%"
    align=right>(2,875,171</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="12%"
    align=right>(1,142,404</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>&nbsp;13,153 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
    width="12%" align=right>&nbsp;203,039 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Basis of Presentation and Liquidity - Note
      1 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="12%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-3></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
  for the years ended
  September 30, 2012 and 2011<BR>
  and for the period from January 23, 2004 (Date of
  Inception) to September 30, 2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="11%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center >January 23, 2004 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD colspan="4" align=center>Years ended September 30, </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center >(Date of Inception) to </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%" align=center>2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%" align=center>2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=center
    >September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Expenses </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=left>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=left>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=left >&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Accounting and audit fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="11%" align=right>&nbsp;139,761 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="11%" align=right>&nbsp;158,225 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="15%" align=right >&nbsp;662,114 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Amortization and depreciation </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>1,858 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>1,657 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >5,055 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Bank charges and interest </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>5,963 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>8,701 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >42,307 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees - Note 7 and 8 </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>1,155,366 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>2,757,835 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >11,744,091 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Insurance </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>10,844 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>48,152 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >58,996 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Investor relations </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>108,138 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>133,805 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >831,707 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Legal fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>142,923 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>140,613 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >670,025 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Management fees </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >14,625 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Office and miscellaneous </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>9,147 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>30,068 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >147,684 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Registration and filing fees </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>26,794 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>58,878 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >154,398 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Rent and administration </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>63,110 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >224,670 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Research and development - Note 8 </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>2,653,860 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>2,597,279 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >12,558,949 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Travel </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>66,837 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>182,259 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >741,155 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Website design and maintenance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%" align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%" align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=right
    >28,417 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff width="11%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff width="11%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Loss before other income (expenses) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(4,321,491</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(6,180,582</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >(27,884,193</TD>
    <TD  width="2%" align=left>) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff width="11%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff width="11%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%">&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Other income (expenses) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=left>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=left>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=left >&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Interest and financing fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>(138,341</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>(90,246</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >(626,021</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Accretion of debt discount - Note 5 </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(98,081</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(69,419</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >(2,174,661</TD>
    <TD  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Change in fair value of derivative liability
      - Note 4 </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>67,500 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>100,000 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >(463,274</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Debt conversion expense </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(504,160</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >(504,160</TD>
    <TD  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Loss on settlement of accounts payable </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="11%" align=right>(334,053</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right >(778,053</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Loss on extinguishment of debt </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(3,829,333</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>(198,738</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right >(4,515,540</TD>
    <TD  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Foreign exchange gain (loss) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>18,041 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>(29,949</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=right >(8,220</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="11%"
    align=right>&nbsp;(8,301,705</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="11%"
    align=right>&nbsp;(7,307,147</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right >&nbsp;(36,954,122</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Basic and diluted loss per share </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="11%"
    align=right>&nbsp;(0.29</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="11%"
    align=right>&nbsp;(0.29</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=left >&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Weighted average number of shares outstanding </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="11%"
    align=right>28,168,784 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="11%"
    align=right>25,169,065 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=left >&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%"
  align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-4></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
  for the years ended
  September 30, 2012 and 2011<BR>
  and for the period from January 23, 2004 (Date of
  Inception) to September 30, 2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="11%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center >January 23, 2004 </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD colspan="4" align=center>Years ended September 30, </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center >(Date of Inception) to </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%" align=center>2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%" align=center>2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=center
    >September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Cash Flows used in Operating Activities </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=left
      >&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the period </TD>
    <TD vAlign=bottom  width="1%" align=left>$</TD>
    <TD vAlign=bottom width="11%" align=right>&nbsp;(8,301,705</TD>
    <TD vAlign=bottom  width="2%" align=left>) </TD>
    <TD vAlign=bottom  width="1%" align=left>$</TD>
    <TD vAlign=bottom width="11%" align=right>&nbsp;(7,307,147</TD>
    <TD vAlign=bottom  width="2%" align=left>) </TD>
    <TD vAlign=bottom  width="1%" align=left>$</TD>
    <TD vAlign=bottom width="15%" align=right
    >&nbsp;(36,954,122</TD>
    <TD vAlign=bottom  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Adjustments to reconcile net loss to net cash
      used in operations: </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=left
      >&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Amortization and depreciation </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>1,858 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>1,657 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >5,055 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Accretion of debt discount </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>98,081 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>69,419 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >2,174,661 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Stock-based compensation </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>302,208 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>1,273,162 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >4,842,547 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Amortization of deferred financing charge </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>62,399 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>44,536 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >162,712 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Change in fair value of derivative liability </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>(67,500</TD>
    <TD vAlign=bottom  width="2%" align=left>) </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>(100,000</TD>
    <TD vAlign=bottom  width="2%" align=left>) </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >463,274 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Consulting expense recorded in exchange for
      shares to be issued </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >236,337 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Common shares issued for consulting expenses </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>15,895 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >406,405 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Promissory note issued for severance </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >71,500 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Common shares issued for severance </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>75,000 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >415,600 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Common shares issued for research and development
      expenses </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >800,000 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Management fees contributed </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >14,625 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Debt conversion expense </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>504,160 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >504,160 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Loss on settlement of accounts payable </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>334,053 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >778,053 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Loss on extinguishment of debt </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>3,829,333 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>198,738 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >4,515,540 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Rent contributed </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >3,750 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Changes in non-cash working capital balances
      related to operations: </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right >- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>VAT recoverable </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>809 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>37,011 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Prepaid expenses </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>9,630 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>13,639 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right >- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Accounts payable and accrued liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>2,281,052 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>1,129,293 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="15%"
    align=right >5,772,548 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Net cash used in operating activities </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>(1,692,940</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>(3,801,479</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >(15,787,355</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%" >&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Cash Flows provided by Financing Activities </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=left
      >&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common shares, net of share issue costs </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>996,250 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>3,021,512 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >10,246,833 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Share subscriptions received </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>(100,000</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right >- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Proceeds from promissory notes </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>581,500 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>750,000 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >5,399,000 </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Deferred financing fee </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>(8,150</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >(108,150</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Repayment of promissory note </TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="11%" align=right>- </TD>
    <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
    <TD vAlign=bottom width="15%" align=right >(100,000</TD>
    <TD vAlign=bottom  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Due to related parties </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >33,665 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Shareholder advances </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="15%"
    align=right >333,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Net cash provided by financing activities </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>1,569,600 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>3,671,512 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >15,804,348 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%" >&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Cash Flows used in Investing Activities </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=left
      >&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Acquisition of equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="15%"
    align=right >(5,631</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Net cash used in investing activities </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>- </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >(5,631</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%" >&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Increase (decrease) in cash during the period </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>(123,340</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=right>(129,967</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=right
      >11,362 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash, beginning of period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>134,702 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="11%"
    align=right>264,669 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="15%"
    align=right >- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Cash, end of period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
    width="11%" align=right>&nbsp;11,362 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
    width="11%" align=right>&nbsp;134,702 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
    width="15%" align=right >&nbsp;11,362 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
    <TD vAlign=bottom  width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="15%" >&nbsp;</TD>
    <TD vAlign=bottom  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Supplemental Cash Flow Information - Note 10 </TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="11%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom width="15%" align=left
      >&nbsp;</TD>
    <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-5></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT<BR>
  for the
  period from January 23, 2004 (Date of Inception) to September 30,
  2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 7pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Deficit </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD colspan="10"
      align=center style="BORDER-BOTTOM: #000000 2px solid"> Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Accumulated </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>Shares </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Par Value </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Additional </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Common </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>During the </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Paid-in </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Shares to be </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Development </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Stage </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on January
        23, 2004 - at $0.0033 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>12,000,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;12,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;28,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;40,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Net loss from January 23, 2004 to September 30, 2004 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(14,395</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(14,395</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff >&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2004 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>12,000,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>12,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>28,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(14,395</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>25,605 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on December
        31, 2004 - at $0.0033 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>7,200,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>7,200 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>16,800 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>24,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Management fees contributed </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>13,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>13,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Rent contributed </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>3,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>3,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(91,625</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(91,625</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff >&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2005 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>19,200,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>19,200 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>60,800 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(106,020</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(26,020</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Management fees contributed </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,625 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,625 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Rent contributed </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>750 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>750 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Debt forgiven by directors </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>33,666 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>33,666 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(25,532</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(25,532</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff >&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2006 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>19,200,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>19,200 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>96,841 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(131,552</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(15,511</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for research and development
        services on September 24, 2007 - at $3.60 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>222,222 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>222 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>799,778 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>800,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for settlement of loan payable on September
        25, 2007 - at $3.60 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>92,500 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>93 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>332,907 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>333,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>(1,579,993</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>(1,579,993</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2007 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>19,514,722 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;19,515 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;1,229,526 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(1,711,545</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;(462,504</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-6></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT<BR>
  for the
  period from January 23, 2004 (Date of Inception) to September 30,
  2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 7pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Deficit </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD colspan="10"
      align=center style="BORDER-BOTTOM: #000000 2px solid"> Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Accumulated </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>Shares </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Par Value </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Additional </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Common </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>During the </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Paid-in </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Shares to be </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Development </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Stage </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2007 - brought forward </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>19,514,722 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;19,515 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;1,229,526 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(1,711,545</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;(462,504</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for cash on December 10, 2007 - at
        $3.50 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>150,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>150 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>524,850 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>525,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for consulting services
        on December 18, 2007 - at $3.86 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>50,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>50 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>192,950 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>193,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued in settlement of debt on December 18,
        2007 - at $4.50 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>10,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>10 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>44,990 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>45,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Stock-based compensation for shares issued
        at a discount </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>65,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>65,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for severance on May 15, 2008 - at
        $5.24 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>65,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>65 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>340,535 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>340,600 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Common shares to be issued for consulting
        services </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>252,599 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>252,599 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Common stock issued for consulting services on August 19,
        2008 - at $5.07 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>25,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>25 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>126,725 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(126,750</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on August
        19, 2008 - at $4.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>142,698 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>142 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>606,325 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>606,467 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Stock-based compensation </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,493,937 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,493,937 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>(5,351,269</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>(5,351,269</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2008 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>19,957,420 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;19,957 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;4,624,838 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;125,849 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(7,062,814</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(2,292,170</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-7></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT<BR>
  for the
  period from January 23, 2004 (Date of Inception) to September 30,
  2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 7pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Deficit </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD colspan="10"
      align=center style="BORDER-BOTTOM: #000000 2px solid"> Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Accumulated </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>Shares </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Par Value </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Additional </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Common </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>During the </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Paid-in </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Shares to be </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Development </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Stage </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2008 - brought forward </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>19,957,420 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;19,957 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;4,624,838 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;125,849 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(7,062,814</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(2,292,170</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Stock-based compensation </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>812,336 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>812,336 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for consulting services
        on November 20, 2008 - $2.63 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>25,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>65,725 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(65,750</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for consulting services on February
        20, 2009 - $2.50 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>25,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>25 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>62,475 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(62,500</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on March 6,
        2009 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>89,148 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>89 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>200,494 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>200,583 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for consulting services on March 20,
        2009 - at $2.00 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>2,500 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>3 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>4,997 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>5,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on March 20,
        2009 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>10,800 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>11 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>24,289 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>24,300 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for cash on June 11, 2009 - at $2.25 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>36,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>36 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>80,964 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>81,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for services on June
        11, 2009 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>29,227 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>29 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>65,731 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>65,760 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for cash on June 19, 2009 - at $2.25 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>495,556 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>496 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,114,504 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,115,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for finders' fees on
        June 26, 2009 - at $2.51 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>22,222 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>22 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>55,755 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>55,777 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Shares to be issued for consulting services - Note 8 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>236,337 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>236,337 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on August
        19, 2009 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>128,888 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>129 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>289,869 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>289,998 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Less: Finders fees </TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(72,850</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(72,850</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Beneficial conversion features on convertible
        debt issuances </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>333,056 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>333,056 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Extinguishment of debt </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>487,469 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>487,469 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Cancellation of common shares </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(75,000</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(75</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>234,011 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(233,936</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Share subscriptions received </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>300,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>300,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>(5,499,419</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
    width="7%" align=right>(5,499,419</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff vAlign=bottom
     width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2009 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>20,746,761 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;20,747 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;8,383,663 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;300,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(12,562,233</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(3,857,823</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-8></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT<BR>
  for the
  period from January 23, 2004 (Date of Inception) to September 30,
  2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 7pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Deficit </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD colspan="10"
      align=center style="BORDER-BOTTOM: #000000 2px solid"> Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Accumulated </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>Shares </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Par Value </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Additional </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Common </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>During the </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Paid-in </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Shares to be </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Development </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Stage </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2009 - brought forward </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>20,746,761 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;20,747 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;8,383,663 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;300,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(12,562,233</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(3,857,823</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Cumulative effect of accounting changes </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(333,056</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(550,804</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(883,860</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on October
        2, 2009 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>266,666 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>267 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>599,733 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(300,000</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>300,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued in settlement of promissory note on
        February 2, 2010 - at $2.02 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>49,505 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>49 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>99,951 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>100,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on April 9,
        2010 - at $2.60 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>92,499 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>93 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>240,405 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>240,498 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued in settlement of debt on April 30,
        2010 - at $2.85 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>9,825 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>9 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>27,991 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>28,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Finders' fees paid in cash </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(24,050</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(24,050</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for cash on June 29, 2010 - at $2.50 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>941,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>941 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>2,351,559 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>2,352,500 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Finders' fees paid in cash </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(206,500</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(206,500</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued in settlement of debt on July 5, 2010
        - at $2.50 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>400,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>400 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>999,600 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,000,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on September
        3, 2010 - at $2.75 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>163,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>163 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>448,087 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>448,250 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for finders' fees on September 3, 2010
        - at $2.75 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>9,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>9 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(9</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Finders' fees paid in cash </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(15,125</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(15,125</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Shares issud on conversion of promissory note on September
        30, 2010 - at </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>328,058 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>328 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>737,802 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>738,130 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Shares issud on conversion of promissory
        note on September 30, 2010 - at </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>510,638 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>511 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,199,489 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,200,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Reclassification of dervative liability on modification
        of note terms </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>3,144,520 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>3,144,520 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Settlement of accounts payable </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>444,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>444,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Stock-based compensation </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>770,055 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>770,055 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Equity component of convertible promissory
        note </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>44,220 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>44,220 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(8,783,037</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(8,783,037</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff >&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2010 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>23,516,952 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;23,517 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;18,912,335 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;(21,896,074</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;(2,960,222</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-9></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT<BR>
  for the
  period from January 23, 2004 (Date of Inception) to September 30,
  2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 7pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Deficit </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD colspan="10"
      align=center style="BORDER-BOTTOM: #000000 2px solid"> Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Accumulated </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>Shares </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Par Value </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Additional </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Common </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>During the </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Paid-in </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Shares to be </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Development </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Stage </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid"  width="2%"
    align=center>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
      <TD vAlign=bottom  width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp;</TD>
      <TD vAlign=bottom  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2010 - brought forward </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>23,516,952 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;23,517 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;18,912,335 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(21,896,074</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(2,960,222</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for cash on November 18, 2010 - at
        $2.75 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>393,846 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>393 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,082,682 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,083,075 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Less: Share Issue costs </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(65,363</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(65,363</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for finders' fees on November 18, 2010
        - at $2.75 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>3,636 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>4 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(4</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Shares issued on the conversion of promissory
        note on November 18, 2010 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>853,075 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>853 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,918,565 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,919,418 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Debt conversion expense </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>504,160 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>504,160 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Shares issued on the conversion of a promissory
        note on November 18, 2010 - at $4.12 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>145,063 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>145 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>597,515 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>597,660 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued in settlement of debt on November 18,
        2010 - at $4.12 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>181,818 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>182 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>748,908 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>749,090 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on November
        25, 2010 - at $3.35 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>29,851 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>30 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>99,970 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>100,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for finders' fees on on November 25,
        2010 - at $3.35 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>2,985 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>3 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>(3</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued for cash on February
        1, 2011 - at $3.75 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>61,014 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>61 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>228,739 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>228,800 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Capital stock issued for cash on May 3, 2011 - at $3.00 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>33,334 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>34 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>99,966 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>100,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Capital stock issued on exercise of warrants
        for cash on June 19, 2011 - at $2.25 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>700,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>700 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,574,300 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,575,000 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Equity units issued in settlement of an account payable
        on September 28, 2011 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>650,000 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>650 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,059,313 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=right>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="2%" align=right>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>1,059,963 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Stock-based compensation </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,273,162 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>1,273,162 </TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Net loss for the period </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(7,307,147</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(7,307,147</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
    width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff >&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="1%"
    align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom  width="2%"
    align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2011 </TD>
      <TD vAlign=bottom  width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>26,571,574 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;26,572 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;28,034,245 </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD vAlign=bottom  width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;(29,203,221</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
      <TD vAlign=bottom  width="1%" align=left>$</TD>
      <TD vAlign=bottom width="7%" align=right>&nbsp;(1,142,404</TD>
      <TD vAlign=bottom  width="2%" align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-10></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>
  (A Development Stage
  Company)<BR>
  CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT<BR>
  for the
  period from January 23, 2004 (Date of Inception) to September 30,
  2012<BR>
  (<U>Stated in US Dollars</U>)</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 7pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Deficit </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD colspan="10"
      align=center style="BORDER-BOTTOM: #000000 2px solid"> Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Accumulated </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>Shares </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Par Value </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Additional </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Common </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>During the </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Paid-in </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Shares to be </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>Development </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="7%" align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%"
      align=center>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Stage </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="7%" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 2px solid" width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="7%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Balance, September 30, 2011 - brought forward </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>26,571,574 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;26,572 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;28,034,245 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(29,203,221</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>$</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%"
    align=right>&nbsp;(1,142,404</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on December 6, 2011 - at $1.25 </TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>615,600 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>616 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>768,884 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>769,500 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Less: Share Issue costs </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(77,000</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(77,000</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on February 9, 2012 - at $1.25 </TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>270,000 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>270 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>337,230 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>337,500 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Less: Share Issue costs </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(33,750</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>) </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>(33,750</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Equity units issued for services on February 9, 2012 - at
        $1.99 </TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>8,000 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>8 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>15,888 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>15,896 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Equity units issued for settlement of loans
        payable on May 31, 2012 - Note 5</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>2,700,513 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>2,700 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>5,176,884 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>5,179,584 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for services on July 12, 2012 - at $1.00 </TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>75,000 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>75 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>74,925 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>- </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD vAlign=bottom width="7%" align=right>75,000 </TD>
      <TD vAlign=bottom width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Stock-based compensation - Note 8 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>302,208 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>- </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>302,208 </TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Net loss for the period </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(8,301,705</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="2%"
    align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="7%"
    align=right>(8,301,705</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom width="2%"
    align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="1%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="7%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff vAlign=bottom width="2%" align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="7%"
    align=right>30,240,687 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="7%"
    align=right>&nbsp;30,241 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="7%"
    align=right>&nbsp;34,599,514 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="7%"
    align=right>&nbsp;- </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="7%"
    align=right>&nbsp;(37,504,926</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="2%"
    align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="7%"
    align=right>&nbsp;(2,875,171</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom width="2%"
    align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-11></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT
      color=#17365d size="4">ANAVEX LIFE SCIENCES CORP. </FONT></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><FONT color=#002060>(A Development Stage Company) </FONT></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><FONT color=#002060>NOTES TO THE CONSOLIDATED FINANCIAL
      STATEMENTS </FONT></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><FONT color=#002060>September 30, 2012 and 2011 </FONT></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><FONT color=#002060>(</FONT><U><FONT color=#002060>Stated
      in US Dollars</FONT></U><FONT color=#002060>) </FONT></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD  align=left><EM><FONT color=#4f81bd>Note 1 </FONT></EM></TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Business
      Description, Basis of Presentation and Liquidity </FONT></I></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Business</P>
<P style="MARGIN-LEFT: 10%" align=justify>Anavex Life Sciences is a
  pharmaceutical company engaged in the development of drug candidates. Our lead
  compound ANAVEX 2-73, developed to treat Alzheimer&#146;s disease through disease
  modification, is in human clinical trials. </P>
<P style="MARGIN-LEFT: 10%" align=justify>In pre-clinical studies conducted in
  France, and in Greece ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective
  properties.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Based on these preclinical studies,
  Anavex sponsored a Phase 1 single ascending dose study of ANAVEX 2-73 initiated
  and completed in 2011. This study was conducted in Germany in collaboration with
  ABX-CRO Advanced Pharmaceutical Services. The study indicated that ANAVEX 2-73
  was well tolerated by study subjects in doses up to 55mg.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Due principally to Anavex&#146; inability
  to obtain sufficient funding to support operations and development of our
  pipeline, it has been unable to attract and retain executive management that is
  experienced in leading a development stage pharmaceutical company. For this
  reason, the company is deferring research into drug candidates until expert
  management evaluates the company&#146;s progress and determines an appropriate course
  of action, and there is capital to effect management&#146;s plan of action.</P>
<P style="MARGIN-LEFT: 10%" align=justify>In considering several different means
  of accomplishing Anavex&#146; goal of commercializing a treatment for Alzheimer&#146;s
  disease, its officers and directors have determined that pursuing a strategic
  relationship with a partner, partners, or an acquirer with capable management
  and sufficient capital to sponsor trials is the company&#146;s best course of action
  at this time. Further, Anavex may acquire or develop new intellectual property
  and assign, license, or otherwise transfer its intellectual property to further
  its plan.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Basis of Presentation and Liquidity </P>
<P style="MARGIN-LEFT: 10%" align=justify>These financial statements have been
  prepared in accordance with generally accepted accounting principles in the
  United States of America and the instructions to Form 10-K.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-12></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 2</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 1 </FONT></I></TD>
    <TD  width="90%" align=left ><EM><FONT
      color=#4f81bd>Business Description, Basis of Presentation and Liquidity &#150;
      (cont&#146;d)</FONT></EM> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>These financial statements have been prepared in
      accordance with generally accepted accounting principles in the United
      States of America on a going concern basis, which assumes that the Company
      will continue to realize its assets and discharge its obligations and
      commitments in the normal course of operations. Realization values may be
      substantially different from carrying values as shown and these financial
      statements do not give effect to adjustments that would be necessary to
      the carrying values and classification of assets and liabilities should
      the Company be unable to continue as a going concern. At September 30,
      2012, the Company had an accumulated deficit of $37,504,926 (2011 -
      $29,203,221), had a working capital deficit of $2,875,747 and expects to
      incur further losses in the development of its business, all of which
      casts substantial doubt about the Company&#146;s ability to continue as a going
      concern. The Company&#146;s ability to continue as a going concern is dependent
      upon its ability to generate future profitable operations and/or to obtain
      the necessary financing to meet its obligations and repay its liabilities
      arising from normal business operations when they come due. Management has
      no formal plan in place to address this but considers obtaining additional
      funds by equity financing and/or from issuing promissory notes. Management
      expects the Company&#146;s cash requirement over the next twelve months to be
      approximately $4,000,000. While the Company is expending best efforts to
      achieve the above plans, there is no assurance that any such activity will
      generate funds for operations. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Summary of
      Significant Accounting Policies</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>a)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Use of
      Estimates</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The preparation of financial statements in accordance
      with United States generally accepted accounting principles requires
      management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities at the date of the financial statements
      and the reported amounts of revenue and expenses in the reporting period.
      The Company regularly evaluates estimates and assumptions related to
      deferred income tax asset valuations, asset impairment, conversion
      features embedded in convertible notes payable, derivative valuations,
      stock based compensation and loss contingencies. The Company bases its
      estimates and assumptions on current facts, historical experience and
      various other factors that it believes to be reasonable under the
      circumstances, the results of which form the basis for making judgments
      about the carrying values of assets and liabilities and the accrual of
      costs and expenses that are not readily apparent from other sources. The
      actual results experienced by the Company may differ materially and
      adversely from the Company&#146;s estimates. To the extent there are material
      differences between the estimates and the actual results, future results
      of operations will be affected.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-13></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 3</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Summary of
      Significant Accounting Policies &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>b)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Principles of
      Consolidation</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>These consolidated financial statements include the
      accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiary,
      Anavex Life Sciences (France) SA, a company incorporated under the laws of
      France. All inter-company transactions and balances have been
      eliminated.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>c)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Development Stage
      Company</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company is devoting substantially all of its present
      efforts to establish a new business and none of its planned principal
      operations have commenced. All losses accumulated since inception has been
      considered as part of the Company&#146;s development stage
      activities.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>d)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Equipment</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Equipment is recorded at cost and is depreciated at 33%
      per annum on the straight-line basis.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>e)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Impairment of Long-Lived
      Assets</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company reviews the recoverability of its long-lived
      assets whenever events or changes in circumstances indicate that the
      carrying amount of such assets may not be recoverable. The estimated
      future cash flows are based upon, among other things, assumptions about
      future operating performance, and may differ from actual cash flows.
      Long-lived assets evaluated for impairment are grouped with other assets
      to the lowest level for which identifiable cash flows are largely
      independent of the cash flows of other groups of assets and liabilities.
      If the sum of the projected undiscounted cash flows (excluding interest)
      is less than the carrying value of the assets, the assets will be written
      down to the estimated fair value in the period in which the determination
      is made.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>f)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Financial
      Instruments</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The carrying value of the Company&#146;s financial
      instruments, consisting of cash and accounts payable and accrued
      liabilities approximate their fair value due to the short-term maturity of
      such instruments. Based on borrowing rates currently available to the
      Company for similar terms and based on the short term duration of the debt
      instruments, the carrying value of the promissory notes payable
      approximate their fair value. Unless otherwise noted, it is management&#146;s
      opinion that the Company is not exposed to significant interest, currency
      or credit risks arising from these financial
      instruments.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-14></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 4</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Summary of
      Significant Accounting Policies &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>g)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Foreign Currency
      Translation</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The functional currency of the Company is the US dollar.
      Monetary items denominated in a foreign currency are translated into US
      dollars at exchange rates prevailing at the balance sheet date and
      non-monetary items are translated at exchange rates prevailing when the
      assets were acquired or obligations incurred. Foreign currency denominated
      expense items are translated at exchange rates prevailing at the
      transaction date. Unrealized gains or losses arising from the translations
      are credited or charged to income in the period in which they
      occur.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>h)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Research and Development
      Expenses</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Research and developments costs are expensed as incurred.
      These expenses are comprised of the costs of the Company&#146;s proprietary
      research and development efforts, including salaries, facilities costs,
      overhead costs and other related expenses as well as costs incurred in
      connection with third-party collaboration efforts. Milestone payments made
      by the Company to third parties are expensed when the specific milestone
      has been achieved.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In addition, the Company incurs expenses in respect of
      the acquisition of intellectual property relating to patents and
      trademarks. The probability of success and length of time to developing
      commercial applications of the drugs subject to the acquired patents and
      trademarks is difficult to determine and numerous risks and uncertainties
      exist with respect to the timely completion of the development projects.
      There is no assurance the acquired patents and trademarks will ever be
      successfully commercialized. Due to these risks and uncertainties, the
      acquisition of patents and trademarks does not meet the definition of an
      asset and thus are expensed as incurred.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>i)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Income Taxes</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company has adopted the asset and liability method of
      accounting for income taxes. Under the asset and liability method,
      deferred tax assets and liabilities are recognized for the future tax
      consequences attributable to temporary differences between the financial
      statements carrying amounts of existing assets and liabilities and their
      respective tax bases. Deferred tax assets and liabilities are measured
      using enacted tax rates expected to apply to taxable income in the years
      in which those temporary differences are expected to be recovered or
      settled.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-15></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 5</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Summary of
      Significant Accounting Policies &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>i)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Income Taxes &#150;
      (cont&#146;d)</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company has adopted the provisions of FASB ASC 740
      "Income Taxes" regarding accounting for uncertainty in income taxes. The
      Company initially recognizes tax positions in the financial statements
      when it is more likely than not the position will be sustained upon
      examination by the tax authorities. Such tax positions are initially and
      subsequently measured as the largest amount of tax benefit that is greater
      than 50% likely of being realized upon ultimate settlement with the tax
      authority assuming full knowledge of the position and all relevant facts.
      Application requires numerous estimates based on available information.
      The Company considers many factors when evaluating and estimating our tax
      positions and tax benefits, and our recognized tax positions and tax
      benefits may not accurately anticipate actual outcomes. As additional
      information is obtained, there may be a need to periodically adjust the
      recognized tax positions and tax benefits. These periodic adjustments may
      have a material impact on the consolidated statements of
      operations.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>j)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Basic and Diluted Loss per
      Share</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The basic loss per common share is computed by dividing
      net loss available to common stockholders by the weighted average number
      of common shares outstanding. Diluted loss per common share is computed
      similar to basic loss per common share except that the denominator is
      increased to include the number of additional common shares that would
      have been outstanding if the potential common shares had been issued and
      if the additional common shares were dilutive. For the year ended
      September 30, 2012, loss per share excludes 6,025,141 (2011 &#150; 5,030,479)
      potentially dilutive common shares (related to convertible notes payable
      and outstanding options and warrants) as their effect was
      anti-dilutive.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-16></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 6</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Summary of
      Significant Accounting Policies &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>k)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Stock-based
      Compensation</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for all stock-based payments and
      awards under the fair value based method.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Stock-based payments to non-employees are measured at the
      fair value of the consideration received, or the fair value of the equity
      instruments issued, or liabilities incurred, whichever is more reliably
      measurable. The fair value of stock-based payments to non-employees is
      periodically re-measured until the counterparty performance is complete,
      and any change therein is recognized over the vesting period of the award
      and in the same manner as if the Company had paid cash instead of paying
      with or using equity based instruments. Compensation costs for stock-based
      payments with graded vesting are recognized on a straight-line basis. The
      cost of the stock-based payments to non- employees that are fully vested
      and non-forfeitable as at the grant date is measured and recognized at
      that date, unless there is a contractual term for services in which case
      such compensation would be amortized over the contractual term.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for the granting of share purchase
      options to employees using the fair value method whereby all awards to
      employees will be recorded at fair value on the date of the grant. The
      fair value of all share purchase options are expensed over their vesting
      period with a corresponding increase to additional paid-in
      capital.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company uses the Black-Scholes option valuation model
      to calculate the fair value of share purchase options at the date of the
      grant. Option pricing models require the input of highly subjective
      assumptions, including the expected price volatility. Changes in these
      assumptions can materially affect the fair value estimates.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>l)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Fair Value
      Measurements</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The fair value hierarchy under GAAP is based on three
      levels of inputs, of which the first two are considered observable and the
      last unobservable, that may be used to measure fair value which are the
      following:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>Level 1 - </TD>
    <TD width="75%" align=left ><P align=justify>quoted prices (unadjusted) in active markets for
      identical assets or liabilities; </P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="75%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left>Level 2 - </TD>
    <TD  width="75%" align=left ><P align=justify>observable inputs other than Level I, quoted prices for
      similar assets or liabilities in active markets, quoted prices for
      identical or similar assets and liabilities in markets that are not
      active, and model-derived prices whose inputs are observable or whose
      significant value drivers are observable; and </P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="75%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left>Level 3 - </TD>
    <TD width="75%" align=left ><P align=justify>assets and liabilities whose significant value drivers
      are unobservable by little or no market activity and that are significant
      to the fair value of the assets or liabilities. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-17></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 7</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Summary of
      Significant Accounting Policies &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>l)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Fair Value Measurements &#150;
      (cont&#146;d)</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The book value of cash and accounts payable and accrued
      liabilities approximate their fair values due to the short term maturity
      of those instruments. Based on borrowing rates currently available to the
      Company under similar terms, the book value of promissory notes payable
      approximates their fair values. The Company&#146;s promissory notes payable are
      based on Level 2 inputs in the ASC 820 fair value hierarchy.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company&#146;s Level 3 liability consisted of the
      bifurcated embedded conversion features in the Company&#146;s convertible
      promissory notes. This Level 3 liability had no active market and was
      required to be measured at its fair value at each reporting period based
      on information that is unobservable.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the Company&#146;s Level 3 liabilities for the
      years ended June 30, 2012 and 2011 is as
      follows:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2012 </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2011 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Balance, beginning of the period </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;67,500 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Fair value of embedded conversion feature of convertible
      promissory notes </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>167,500 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Change in fair value of derivative
      liability </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>(67,500</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>(100,000</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Balance, end of the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>&nbsp;- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>&nbsp;67,500 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>Certain assets and liabilities are
  measured at fair value on a nonrecurring basis; that is, the instruments are not
  measured at fair value on an ongoing basis but are subject to fair value
  adjustments only in certain circumstances (for example, when there is evidence
  of impairment). There were no assets or liabilities measured at fair value on a
  nonrecurring basis during the periods ended September 30, 2012 and 2011. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-18></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 8</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 2</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Summary of Significant
      Accounting Policies &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>m)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Recent Accounting
      Pronouncements</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>On June 16, 2011, the FASB issued ASU No. 2011-05,
      Comprehensive Income (Topic 220): <I>Presentation of Comprehensive
        Income</I>, or ASU 2011-05. ASU 2011-05 requires entities to report items
      of other comprehensive income on either part of a single contiguous
      statement of comprehensive income or in a separate statement of
      comprehensive income immediately following the statement of income. On
      December 23, 2011, the FASB issued an update to this pronouncement, ASU
      No. 2011-12, Comprehensive Income (Topic 220): <i>Deferral of the Effective Date for Amendments to the
        Presentation of Reclassifications of Items Out of Accumulated Other
        Comprehensive Income in Accounting Standards Update No. 2011-05</i>, or
      ASU 2011-12. ASU 2011-12 defers the specific requirement to present items
      that are reclassified from accumulated other comprehensive income to net
      income separately with their respective components of net income and other
      comprehensive income. The Company has not recorded any components of
      comprehensive income (loss) for the years ended September 30, 2012 and
      2011 and, as at September 30, 2012, the Company does not have a balance
      recorded in respect of accumulated comprehensive income
      (loss).</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 3</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Equipment</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="80%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>September 30, 2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center>Accumulated </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center><U>Cost</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center><U>Depreciation</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center><U>Net</U> </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="15%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="15%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="15%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Computer equipment </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>&nbsp;5,631 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>&nbsp;5,055 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>&nbsp;576 </TD>
      <TD bgColor=#e6efff width="2%"
align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="80%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>September 30, 2011 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center>Accumulated </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center><U>Cost</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center><U>Depreciation</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="15%" align=center><U>Net</U> </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="15%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="15%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="15%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Computer equipment </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>&nbsp;5,631 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>&nbsp;3,197 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>&nbsp;2,434 </TD>
      <TD bgColor=#e6efff width="2%"
align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-19></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 9</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 4</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Derivative
      Liability</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left><P align=justify>Derivative liability, consisting of the embedded
      conversion features in the Company&#146;s convertible promissory notes, is
      accounted for as a separate liability measured at its respective fair
      value, as follows: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2012 </TD>
    <TD width="2%" align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2011 </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Balance, beginning of the period </TD>
    <TD bgColor=#e6efff width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;67,500 </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;- </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Fair value of embedded conversion feature of convertible
      promissory notes </TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>- </TD>
    <TD width="2%" align=left>&nbsp;</TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>167,500 </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Change in fair value of derivative
      liability </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>(67,500</TD>
    <TD bgColor=#e6efff width="2%" align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>(100,000</TD>
    <TD bgColor=#e6efff width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Balance, end of the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>&nbsp;- </TD>
    <TD width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>&nbsp;67,500 </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The fair values of the convertible
  promissory notes embedded call options have been determined using the binomial
  pricing model using the following weighted average assumptions:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2012 </TD>
    <TD width="2%" align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2011 </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Risk-free interest rate </TD>
    <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>0.05% </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>0.13% </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Expected life of derivative liability </TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>0.05 years </TD>
    <TD width="2%" align=left>&nbsp;</TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>0.56 years </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Annualized volatility </TD>
    <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>57.99% </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>93.45% </TD>
    <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Dividend rate </TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>0.00% </TD>
    <TD width="2%" align=left>&nbsp;</TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>0.00% </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-20></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 10</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 5</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Promissory
      Notes Payable</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Convertible interest bearing promissory
      notes payable </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;750,000 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Interest bearing promissory notes payable </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>299,000 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>216,000 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Less: fair value of derivative liabilities
      on date of issuance </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>(167,500</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Add: accumulated accretion </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>69,419 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>299,000 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>867,919 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Less: current portion </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>(299,000</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=right>(867,919</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Convertible interest bearing
  promissory notes </P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company issued unsecured
  convertible interest bearing promissory notes totaling $750,000 during the year
  ended September 30, 2011 consisting of a promissory note in the amount of
  $250,000 maturing on April 20, 2012 and a promissory note in the amount of
  $500,000 maturing on May 4, 2012, each bearing interest at 8% per annum. These
  notes were convertible at any time at the option of the holder into units of the
  Company at $3.00 per unit with each unit consisting of one common share and one
  common share purchase warrant entitling the holder thereof to purchase an
  additional common share for $4.00 for a period of 2 years from the date of
  issuance. </P>
<P style="MARGIN-LEFT: 10%" align=justify>In connection with the issuance of
  these notes, the Company paid a finder&#146;s fee totaling $100,000 which was
  deferred and amortized to income using the effective interest method over the
  terms of the notes. As at September 30, 2012, there remained no unamortized
  balance in respect of this deferred financing charge (2011: $55,464). </P>
<P style="MARGIN-LEFT: 10%" align=justify>Pursuant to the guidance of ASC
  815-40, the Company determined that the embedded conversion feature of the notes
  failed to meet the &#147;fixed for fixed&#148; criteria contained within the guidance.
  Accordingly, the Company bifurcated the embedded conversion features as a
  separate derivative liability having a fair value of $167,500 at inception. The
  corresponding debt discount was accreted over the term of the note. During the
  year ended September 30, 2012, the Company recorded accretion expense of $98,081
  (2011: $69,419) in respect of this debt discount.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On April 20, 2012, the $500,000
  convertible promissory note with accrued interest thereon of $40,000 along with
  an interest bearing $250,000 promissory note with accrued interest thereon of
  $9,389 that had been issued on November 1, 2011 were exchanged for a new
  non-convertible 12% interest bearing promissory note having a principal amount
  of $799,389 maturing on June 19, 2012. Subsequent to this exchange of promissory
  notes, on May 31, 2012, the Company extinguished this note along with accrued
  interest of $10,925 thereon by issuing 1,620,628 equity units having a fair
  value of $3,108,365. As a result of this extinguishment, the Company recorded a
  loss on debt extinguishment in the amount of $2,298,051.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-21></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 11</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 5</FONT></I> </TD>
    <TD width="90%" align=left ><P align=justify><I><FONT color=#4f81bd>Promissory Notes Payable &#150;
      (cont&#146;d)</FONT></I> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On May 31, 2012, the Company extinguished the $250,000
      convertible promissory note along with accrued interest of $22,333 thereon
      by issuing 544,667 equity units having a fair value of $1,044,671. As a
      result of this extinguishment, the Company recorded a loss on debt
      extinguishment in the amount of $772,338. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left ><P align=justify>Interest bearing promissory notes </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>During the year ended September 30, 2010, the Company
      issued a promissory note having a principal balance of $200,000 with terms
      that included interest at 8% per annum and maturing on May 4, 2011. On May
      4, 2011, this note, including accrued interest of $16,000 thereon, was
      exchanged for a new 8% interest bearing promissory note having a principal
      balance of $216,000 maturing May 4, 2012. On May 31, 2012, the Company
      extinguished this note along with accrued interest of $18,576 thereon by
      issuing 469,152 equity units having a fair value of $899,833. As a result
      of this extinguishment, the Company recorded a loss on debt extinguishment
      in the amount of $665,257. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On April 2, 2012, the Company issued a promissory note
      having a principal balance of $32,500 with terms that included interest at
      10% per annum maturing on April 2, 2013. The Company paid a finders fee totalling $3,250 which was deferred and amortized to income from the date of issuance to the date of extinguishment. On May 31, 2012, the Company
      extinguished this note along with accrued interest of $533 thereon by
      issuing 66,066 equity units having a fair value of $126,715. As a result
      of this extinguishment, the Company recorded a loss on debt extinguishment
      in the amount of $93,682. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 6, 2012, the Company issued a promissory note
      having a principal balance of $49,000 with terms that include interest at
      8% per annum and maturing on December 3, 2012. In connection with the
      issuance of this note, the Company paid a finder&#146;s fee totaling $4,900
      which was deferred and amortized to income using the effective interest
      method over the terms of the note. As at September 30, 2012, there
      remained an unamortized balance of $1,215 in respect of this deferred
      financing charge. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 26, 2012, the Company issued a promissory note
      having a principal balance of $250,000 with terms that include interest at
      8% per annum and maturing on March 31, 2013. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left ><P align=justify>Extinguishment of promissory notes payable </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>As noted above, on May 31, 2012, the Company issued
      equity units in settlement of certain of its promissory notes outstanding.
      Each unit consisted of one common share and common share purchase warrant
      entitling the holder to purchase an additional common share at $0.75 until
      November 30, 2013. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-22></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 12</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 5</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Promissory
      Notes Payable &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left >The promissory note settlements
      are summarized as follows: </TD>
  </TR>
</TABLE>
<BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD width="10%"  >&nbsp;</TD>
      <TD colspan="6" align=center style="BORDER-BOTTOM: #000000 1px solid"
      >Promissory note settled </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD colspan="4"
      align=center style="BORDER-BOTTOM: #000000 1px solid">Units issued </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="12%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD width="10%" >&nbsp;</TD>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="12%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="10%" align=center >Accrued </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="12%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="12%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="12%" align=center>Loss on </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD width="10%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      >Maturity date </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=center>Principal </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="10%" align=center
    >Interest </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=center>Number </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%" align=center>Fair
        Value </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="12%"
      align=center>Settlement </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify><I>Convertible interest bearing
  promissory note</I></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD width="10%"  >&nbsp;</TD>
      <TD bgColor=#e6efff align=left >April 20, 2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>&nbsp;250,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>&nbsp;22,333 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>544,667 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>&nbsp;1,044,671 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>&nbsp;(772,338</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify><I>Interest bearing promissory
  notes</I></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
    <TR vAlign=top>
      <TD width="10%"  >&nbsp;</TD>
      <TD bgColor=#e6efff align=left >&nbsp;May 4, 2012 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="11%" align=right>216,000 </TD>
      <TD bgColor=#e6efff  width="3%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="11%" align=right>18,571</TD>
      <TD bgColor=#e6efff  width="3%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="11%" align=right>469,152 </TD>
      <TD bgColor=#e6efff  width="3%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="11%" align=right>899,833 </TD>
      <TD bgColor=#e6efff  width="3%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="11%" align=right>(665,262</TD>
      <TD bgColor=#e6efff  width="3%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD width="10%" >&nbsp;</TD>
      <TD align=left >June 19, 2012 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="11%" align=right>799,389 </TD>
      <TD  width="3%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="11%" align=right>10,925 </TD>
      <TD  width="3%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="11%" align=right>1,620,628 </TD>
      <TD  width="3%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="11%" align=right>3,108,365 </TD>
      <TD  width="3%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="11%" align=right>(2,298,051</TD>
      <TD  width="3%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD width="10%" >&nbsp;</TD>
      <TD bgColor=#e6efff align=left >&nbsp;April 2, 2013 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>32,500 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>533 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>66,066 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>126,715 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>(93,682</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="3%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD width="10%" >&nbsp;</TD>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>1,047,889 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>30,029 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>2,155,846 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>4,134,913 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>(3,056,995</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="3%"
    align=left>) </TD>
    </TR>
    <TR>
      <TD width="10%" >&nbsp;</TD>
      <TD bgColor=#e6efff >&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="11%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="11%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="11%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="11%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="11%">&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD width="10%" >&nbsp;</TD>
      <TD align=left ></TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="11%"
      align=right>1,297,889 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="11%"
      align=right>&nbsp;52,362 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="11%"
      align=right>2,700,513 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="11%"
      align=right>&nbsp;5,179,584 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="3%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="11%"
      align=right>&nbsp;(3,829,333</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="3%"
    align=left>) </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>The fair value of each unit issued was
  determined to be $1.918 determined by aggregating (i) the fair value of $1.25
  for the Company&#146;s common shares based on their quoted market price on the date
  of settlement and (ii) the fair value of $0.668 for each warrant included in the
  Company&#146;s units. The fair value of the Company&#146;s warrants was determined using
  the binomial model with the following assumptions: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="30%">
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Stock price </TD>
      <TD bgColor=#e6efff width="35%" align=right >$1.25 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Exercise price </TD>
      <TD width="35%" align=right >$0.75 </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Expected volatility </TD>
      <TD bgColor=#e6efff width="35%" align=right >78.89% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Risk-free discount rate </TD>
      <TD width="35%" align=right >0.23% </TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 6</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On May 24, 2006, the board of directors approved a six
      (6) for one (1) forward split of the authorized issued and outstanding
      common stock. The Company&#146;s authorized capital increased from 25,000,000
      shares of common stock to 150,000,000 shares of common stock. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 24, 2007, the Company issued 222,222 common
      shares common shares at $3.60 per share for a total of $800,000 for
      research and development expenses. The common shares were recorded based
      upon the quoted market price of the Company&#146;s common stock on the
      agreement date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 25, 2007, the Company settled a loan payable
      in the amount of $333,000 by issuing 92,500 common shares at $3.60 per
      share, being the quoted market price of the Company&#146;s common stock on the
      settlement date. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-23></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 13</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 6</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On December 10, 2007, the Company issued 150,000 units at
      $3.50 per unit for proceeds of $525,000. Each unit consisted of one common
      share and one common share purchase warrant entitling the holder to
      purchase an additional common share at $5.00 per share until December 10,
      2009. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On December 18, 2007, the Company issued 10,000 shares at
      $4.50 per share for a total of $45,000 pursuant to an agreement to settle
      a debt and issued 50,000 shares at $3.86 per share for a total of $193,000
      pursuant to a consulting agreement. The Company recorded compensation
      expense of $65,000 in respect of these issuances based on the excess of
      the fair value of these shares over the balances at which they were
      recorded by the Company. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On May 15, 2008, the Company issued 65,000 common shares
      at $5.24 per share for a total of $340,600 to its former CEO in accordance
      with the terms of a severance agreement upon the termination of his
      services. The common shares were recorded based upon the quoted market
      price of the Company&#146;s common stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On August 19, 2008, the Company issued 25,000 common
      shares at $5.07 per share for a total of $ 126,750 to a director of the
      Company pursuant to an agreement to provide consulting services. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On August 19, 2008, the Company issued 142,698 units at
      $4.25 per unit for proceeds of $606,467 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $5.00 per share until August 19, 2009. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 20, 2008, the Company issued 25,000 common
      shares at $2.63 per share for a total of $65,750 to a director of the
      Company pursuant to an agreement to provide consulting services. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the issuance date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On February 20, 2009, the Company issued 25,000 common
      shares at $2.50 per share for a total of $62,500 to a director of the
      Company pursuant to an agreement to provide consulting services. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the issuance date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On March 6, 2009, the Company issued 89,148 units at
      $2.25 per unit for proceeds of $200,583 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $4.00 per share until March 6, 2010. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On March 20, 2009, the Company issued 10,800 units at
      $2.25 per unit for proceeds of $24,300 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $4.00 per share until March 20, 2010. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-24></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 14</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 6</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On March 20, 2009, the Company issued 2,500 common shares
      at $2.00 per share for a total of $5,000 to a public relations consultant
      pursuant to an agreement to provide consulting services. The common shares
      were recorded based upon the quoted market price of the Company&#146;s common
      stock on the issuance date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On May 14, 2009, the Company entered into a revised
      consulting agreement with a director whereby the consultant returned
      75,000 common shares to the Company for cancellation. The return of shares
      was recorded in the same amount at which they were originally issued. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 11, 2009 the Company issued 36,000 units at $2.25
      per unit for proceeds of $81,000 pursuant to private placement agreements.
      Each unit consisted of one common share and one common share purchase
      warrant entitling the holder to purchase an additional common share at
      $4.00 per share until June 11, 2010. The Company paid finders&#146; fees in the
      amount of $8,100 in relation to this private placement. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 11, 2009 the Company issued 29,227 common shares
      at $2.25 per share for service rendered by consultants. The common shares
      were recorded based upon the fair value of the Company&#146;s common stock on
      the issuance date of the shares. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 19, 2009, the Company issued 495,556 units at
      $2.25 per unit for total proceeds of $1,115,000 pursuant to private
      placement agreements. Each unit consisted on one common share and one and
      one-half of a common share purchase warrant entitling the holder to
      purchase additional common shares at $2.25 per share until June 19, 2011. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 26, 2009, the Company issued 22,222 common shares
      at $2.51 per share for finder&#146;s fees related to the issuance of a $500,000
      note payable. The common shares were recorded based upon the quoted market
      price of the Company&#146;s common stock on the issue date. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On August 19, 2009, the Company issued 128,888 units at
      $2.25 per Unit for total proceeds of $289,998. Of these placements, 40,000
      Units consisted of one common share and one share purchase warrant
      entitling the holder to purchase an additional common share at $4.00 per
      share until July 9, 2010 and 88,888 Units consisted on one common share
      and one and one- eighth share purchase warrant entitling the holder to
      purchase an additional common shares at $2.25 per share until August 4,
      2011. The Company paid finders&#146; fees totalling $19,000 in respect of these
      private placements. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On October 2, 2009 the Company issued 266,666 units at
      $2.25 per unit for proceeds of $600,000 pursuant to private placement
      agreement. Each unit consisted of one common share and one and one-eighth
      common share purchase warrant entitling the holder to purchase an
      additional common share at $2.25 per share until October 2, 2011. The
      Company had received $300,000 of this amount in the year ended September
      30, 2010. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On February 2, 2010 the Company issued 49,505 common
      shares of the Company, at their fair value of $2.02 per share pursuant to
      an agreement with a former officer to settle an outstanding amount owed. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-25></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 15</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 6</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On April 9, 2010, the Company issued 92,499 units at
      $2.60 per unit for proceeds of $240,498 pursuant to private placement
      agreement. Each unit consisted of one common share and one- half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $3.50 per share until April 9, 2011. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On April 30, 2010, the Company issued 9,825 common shares
      of the Company, at $2.85 per share as consideration for terminating a
      consulting agreement and for services rendered under the agreement. The
      common shares were recorded based upon the quoted market price of the
      Company&#146;s common stock on the date of the termination of the agreement. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 29, 2010, the Company issued 941,000 units at
      $2.50 per unit for total proceeds of $2,352,500 pursuant to private
      placement agreements. Each unit consisted on one common share and one-half
      of a common share purchase warrant entitling the holder to purchase
      additional common shares at $3.50 per share until December 29, 2011. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On July 5, 2010, the Company issued 400,000 units in
      settlement of $1,000,000 owing to a creditor. Each unit consisted of one
      common share and one-half common share purchase warrant entitling the
      holder to purchase an additional common share at 3.50 per share until
      January 5, 2012. The fair value of the units issued was determined to be
      $1,444,000 on the date they were issued and thus the Company recorded a
      loss on settlement of accounts payable of $444,000 with a corresponding
      credit to additional paid-in capital of the same amount on date of
      issuance. The fair value of the shares included in the units was
      determined with reference to their quoted market price and the value of
      the warrants was determined using the Black-Scholes model with the
      following assumptions: exercise price - $3.50, stock price - $3.15,
      expected volatility &#150; 68.45%, expected life &#150; 1.5 years, dividend yield &#150;
      0.00%. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 3, 2010, the Company issued 163,000 units at
      $2.75 per unit for proceeds of $448,250 pursuant to private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $3.75 per share until March 3, 2012. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 3, 2010, the Company issued 9,000 units at
      $2.75 per unit for finder&#146;s fees related to the private placement of the
      same date. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $3.75 per share until March 3, 2012. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 30, 2010, the Company issued 510,638 common
      shares at $2.35 per share pursuant to the terms of a convertible note
      payable. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 30, 2010, the Company issued 82,310 units at
      $2.25 per unit pursuant to the terms of convertible notes payable. Each
      unit consisted of one common share and one-half common share purchase
      warrant entitling the holder to purchase an additional common share at
      $3.50 per share until September 30, 2011. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 30, 2010, the Company issued 245,748 units
      at $2.25 per unit pursuant to the terms of convertible notes payable. Each
      unit consisted of one common share and one common share purchase warrant
      entitling the holder to purchase an additional common share at $3.00 per
      share until September 30, 2012. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-26></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 16</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD  align=left><EM><FONT color=#4f81bd>Note 6&nbsp; </FONT></EM></TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 18, 2010, the Company issued 393,846 units at
      $2.75 per unit for proceeds of $1,083,075 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $4.50 per share until May 18, 2012. The Company paid a
      finder&#146;s fee totalling $65,363 in respect of this private placement. </P></TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 18, 2010, the Company issued 3,636 units at
      $2.75 per unit for finder&#146;s fees related to the private placement of the
      same date. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $4.50 per share until May 18, 2012. </P></TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 18, 2010, the Company issued 853,075 units in
      the conversion of two notes payable originally convertible at $2.50. The
      Company recorded debt conversion expense of $504,160, related to the fair
      value of the additional units issued as a result of converting at the
      lower conversion price. Each unit consisted of one common share and one
      common share purchase warrant entitling the holder to purchase an
      additional common share at $3.00 per share until November 18, 2012. The
      fair value of the shares included in the units was determined with
      reference to their quoted market price and the value of the warrants was
      determined using the Black-Scholes model with the following assumptions:
      exercise price - $3.00, stock price - $4.12, expected volatility &#150; 78.33%,
      expected life &#150; 2.0 years, dividend yield &#150; 0.00%, risk-free rate &#150; 0.52%. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 18, 2010, the Company issued 145,063 shares
      of common stock at their fair value of $4.12 per share based on their
      quoted market price pursuant to settling non- convertible interest bearing
      notes payable outstanding in the amount of $398,922, including accrued
      interest of $26,032. The Company recorded a loss on settlement of debt of
      $198,738 based on the difference between the carrying value of the debt
      settled and the fair value of the shares issued. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 18, 2010, the Company issued 181,818 shares
      of common stock at their fair value of $4.12 per share based on the quoted
      value of units issued in a private placement on the same date to one
      creditor in settlement of $500,000 of debt owing. The Company recorded a
      loss on settlement of accounts payable of $249,090 based on the difference
      of the carrying value of the account payable and the fair value of the
      shares issued. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 25, 2010, the Company issued 29,851 units at
      $3.35 per unit for proceeds of $100,000 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $4.50 per share until November 25, 2012. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD  align=left></TD>
    <TD width="90%" align=left ><P align=justify>On November 25, 2010, the Company issued 2,985 units at
      $3.35 per unit for finder&#146;s fees related to the private placement of the
      same date. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $4.50 per share until November 25, 2012. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-27></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 17</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 6</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On February 1, 2011, the Company issued 61,014 units at
      $3.75 per unit for proceeds of $228,800 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $5.25 per share until August 1, 2012. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On May 3, 2011, the Company issued 33,334 units at $3.00
      per unit for proceeds of $100,000 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $4.00 per share until April 20, 2013. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On June 19, 2011, the Company issued 700,000 common
      shares at $2.25 per share for proceeds of $1,575,000 pursuant to the
      exercise of warrants. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On September 26, 2011, the Company issued 650,000 units
      in settlement of $975,000 of debt owing. Each unit consisted of one common
      share and one-half common share purchase warrant entitling the holder to
      purchase an additional common share at $2.00 per share until September 26,
      2012. The Company recorded a loss on settlement of account payable in the
      amount of $84,963 based on the fair value of shares being $975,000 at
      their issuance and the fair value of the warrants determined to be
      $84,963. The fair value of the shares included in the units was determined
      with reference to their quoted market price and the value of the warrants
      was determined using the Black-Scholes model with the following
      assumptions: exercise price - $2.00, stock price - $1.50, expected
      volatility &#150; 69%, expected life &#150; 1.0 years, dividend yield &#150; 0.00%,
      risk-free interest rate &#150; 0.10%. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On December 6, 2011, the Company issued 615,600 units at
      $1.25 per unit for proceeds of $769,500 pursuant to private placement
      agreements. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $2.00 per share until December 6, 2012. The Company paid
      finder&#146;s fees of $77,000 in connection with this private placement. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On February 9, 2012 the Company issued 8,000 units for
      service rendered by a director and officer of the Company. Each unit
      consisted of one common share and one-half common share purchase warrant
      entitling the holder to purchase an additional common share at $2.00 per
      share until February 9, 2013. The fair value of the units issued was
      determined to be $15,896 on the date they were issued and the Company
      recorded consulting fees of $15,896 on the statement of operations for the
      year ended September 30, 2012. The fair value of the shares included in
      the units was determined with reference to their quoted market price and
      the value of the warrants was determined using the Black-Scholes model
      with the following assumptions: exercise price - $2.00, stock price -
      $1.74, expected volatility &#150; 84.88%, expected life &#150; 1.0 years, risk free
      interest rate &#150; 0.15%, dividend yield &#150; 0.00%. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On February 9, 2012, the Company issued 270,000 units at
      $1.25 per unit for proceeds of $337,500 pursuant to private placement
      agreements. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $2.00 per share until February 9, 2013. The Company paid a
      finder&#146;s fee of $33,750 in connection with this private placement. </P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-28></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 18</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 6</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Capital
      Stock &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On May 31, 2012, the Company issued 2,700,513
    equity units determined to have a fair value of $5,179,584 in
      settlement of promissory notes totaling $1,297,889 and of $52,367  accrued
      interest thereon. Each unit consisted of one common share and one common
      share purchase warrant entitling the holder to purchase an additional
      common share at $0.75 per share until November 30, 2013. (Note 5). </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>On July 12, 2012, the Company issued
    75,000 common shares having a fair value of $75,000 based on their quoted
    market price to the former president of the Company for past services and in
    final settlement of a consulting agreement dated February 1, 2007. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 7</FONT></I> </TD>
    <TD width="90%" align=left ><P align=justify><I><FONT color=#4f81bd>Related Party
      Transactions</FONT></I> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left ><P align=justify>The following amounts have been donated to the Company by
      the directors: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD colspan="4" align=center>Years ended </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center>January 23, 2004 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center>(Date of Inception) </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=center>2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=center>2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=center>to September
      30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="15%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="15%" align=center>&nbsp;</TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left >Management fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="15%" align=right>&nbsp;- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="15%" align=right>&nbsp;- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="15%" align=right>&nbsp;14,625 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >Rent </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right>3,750 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left >Debt forgiven by directors </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=right>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=right>33,666 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" width="15%"
      align=right>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" width="15%"
      align=right>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" width="15%"
      align=right>&nbsp;52,041 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2012, the Company was charged consulting fees totaling $479,434 (2011: $674,917)
  by directors, officers and a significant shareholder of the Company. As at
  September 30, 2012, included in accounts payable and accrued liabilities is
  $127,452 (2011: $20,833) owing to directors and officers of the Company and a
  former director and officer of the Company.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-29></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 19</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 8</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT
      color=#4f81bd>Commitments</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>a)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Share Purchase
      Warrants</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the Company&#146;s share purchase warrants
      outstanding is presented below:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="60%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=left>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="8%" align=right>&nbsp;</TD>
      <TD width="14%" align=center nowrap>Weighted </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="8%" align=right>&nbsp;</TD>
      <TD width="14%" align=center>Average </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=center>&nbsp;</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="8%" align=right>&nbsp;</TD>
      <TD width="14%" align=center>Exercise </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=center>Number of Shares </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="8%"
    align=right>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="14%"
      align=center>Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD >&nbsp;</TD>
      <TD  width="1%">&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
      <TD  width="8%" align="right">&nbsp;</TD>
      <TD width="14%" align=center>&nbsp;</TD>
      <TD  width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2010 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>2,047,151 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="8%" align=right>$</TD>
      <TD bgColor=#e6efff width="14%" align=center>&nbsp;2.87 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expired </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=right>(148,749</TD>
      <TD  width="2%" align=left>) </TD>
      <TD  width="8%" align=right>$</TD>
      <TD width="14%" align=center>&nbsp;2.64 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Exercised </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>(700,000</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="8%" align=right>$</TD>
      <TD bgColor=#e6efff width="14%" align=center>&nbsp;2.25 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=right>1,457,077 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="8%"
    align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="14%"
      align=center>&nbsp;3.07 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Balance, September 30, 2011 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>2,655,479 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="8%" align=right>$</TD>
      <TD bgColor=#e6efff width="14%" align=center>&nbsp;3.16 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expired </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=right>(1,552,651</TD>
      <TD  width="2%" align=left>) </TD>
      <TD  width="8%" align=right>$</TD>
      <TD width="14%" align=center>&nbsp;3.16 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="17%"
    align=right>3,147,313 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="8%" align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="14%"
    align=center>&nbsp;0.93 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Balance, September 30, 2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="17%"
      align=right>4,250,141 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="8%"
    align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="14%"
      align=center>&nbsp;1.16 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2012, the Company has
  4,250,141 currently exercisable share purchase warrants outstanding as
  follows:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="60%">
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>Number </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="7%"
    align=right >&nbsp;</TD>
      <TD colspan="2"
    align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Exercise Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="29%"
      align=right>Expiry Date </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>853,075 </TD>
      <TD bgColor=#e6efff  width="7%" align=right
    >&nbsp;</TD>
      <TD bgColor=#e6efff  width="6%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center >&nbsp;3.00 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="29%" align=right>November 18, 2012 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>16,419 </TD>
      <TD  width="7%" align=right >&nbsp;</TD>
      <TD  width="6%" align=right>$</TD>
      <TD width="15%" align=center >&nbsp;4.50 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="29%" align=right>November 25, 2012 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>307,800 </TD>
      <TD bgColor=#e6efff  width="7%" align=right
    >&nbsp;</TD>
      <TD bgColor=#e6efff  width="6%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center >&nbsp;2.00 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="29%" align=right>December 6, 2012 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>200,000 </TD>
      <TD  width="7%" align=right >&nbsp;</TD>
      <TD  width="6%" align=right>$</TD>
      <TD width="15%" align=center >&nbsp;1.50 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="29%" align=right>January 5, 2013 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>135,000 </TD>
      <TD bgColor=#e6efff  width="7%" align=right
    >&nbsp;</TD>
      <TD bgColor=#e6efff  width="6%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center >&nbsp;2.00 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="29%" align=right>February 9, 2013 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>4,000 </TD>
      <TD  width="7%" align=right >&nbsp;</TD>
      <TD  width="6%" align=right>$</TD>
      <TD width="15%" align=center >&nbsp;2.00 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="29%" align=right>February 9, 2013 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>33,334 </TD>
      <TD bgColor=#e6efff  width="7%" align=right
    >&nbsp;</TD>
      <TD bgColor=#e6efff  width="6%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center >&nbsp;4.00 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="29%" align=right>April 20, 2013 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>2,700,513 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="7%"
    align=right >&nbsp;</TD>
      <TD  width="6%" align=right>$</TD>
      <TD width="15%" align=center >&nbsp;0.75 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="29%" align=right>November 30, 2013 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
      align=right>4,250,141 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="7%" align=right >&nbsp;</TD>
      <TD bgColor=#e6efff  width="6%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff width="15%" align=center >&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="29%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%"
  align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>During the year ended September 30,
  2012, the exercise price and expiry of 200,000 warrants exercisable at $3.50 and
  expiring January 5, 2012 were modified and extended such that these warrants are
  now exercisable at $1.50 until January 5, 2013. The fair value of this
  modification was determined to be $80,200 and was determined using the
  Black-Scholes option pricing model using the following weighted average
  assumptions: risk-free interest rate: 0.11%, expected life: 1.0 year, annualized
  volatility: 79.46%, dividend rate: 0%.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-30></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 20</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 8</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Commitments &#150;
      (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>b)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Stock&#150;based Compensation
      Plan</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In April, 2007, the Company adopted a stock option plan
      which provides for the granting of stock options to selected directors,
      officers, employees or consultants in an aggregate amount of up to
      3,000,000 common shares of the Company and, in any case, the number of
      shares to be issued to any one individual pursuant to the exercise of
      options shall not exceed 10% of the issued and outstanding share capital.
      The granting of stock options, exercise prices and terms are determined by
      the Company's Board of Directors. If no vesting schedule is specified by
      the Board of Directors on the grant of options, then the options shall
      vest over a 4-year period with 25% the granted vesting each year
      commencing 1 year from the grant date. For stockholders who have greater
      than 10% of the outstanding common shares of the Company and who have
      granted options, the exercise price of their options shall not be less
      than 110% of the fair of the stock on grant date. Otherwise, options
      granted shall have an exercise price equal to their fair value on grant
      date.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>On February 2, 2011, the Company amended and restated the
      2007 stock option plan to increase the number of options authorized to
      4,000,000.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the status of Company&#146;s outstanding stock
      purchase options for the year ended September 30, 2012 is presented
      below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="5%" align=right>&nbsp;</TD>
    <TD width="10%" align=center>Weighted </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="5%" align=right>&nbsp;</TD>
    <TD width="10%" align=center>Average </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center>Weighted </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=center>&nbsp;</TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="5%" align=right>&nbsp;</TD>
    <TD width="10%" align=center>Exercise </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center nowrap>Average Grant </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>Number of Shares </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="10%"
      align=center>Price </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="4%"
    align=right>&nbsp;</TD>
    <TD width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Date
      fair value </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Outstanding at September 30, 2010 </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right>2,775,000 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="5%" align=right>$</TD>
    <TD bgColor=#e6efff width="10%" align=right>&nbsp;3.29 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="4%" align=right>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=center>&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Forfeited </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right>(1,000,000</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="5%" align=right>$</TD>
    <TD width="10%" align=right>&nbsp;3.93 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Cancelled </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right>(50,000</TD>
    <TD bgColor=#e6efff  width="2%" align=left>) </TD>
    <TD bgColor=#e6efff  width="5%" align=right>$</TD>
    <TD bgColor=#e6efff width="10%" align=right>&nbsp;2.75 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="4%" align=right>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=center>&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=right>650,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="10%"
      align=right>&nbsp;4.06 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>$</TD>
    <TD width="12%" align=center>&nbsp;2.95 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Outstanding at September 30, 2011 </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="15%" align=right>2,375,000 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="5%" align=right>$</TD>
    <TD bgColor=#e6efff width="10%" align=right>&nbsp;3.18 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="4%" align=right>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=center>&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Forfeited </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="15%" align=right>(1,100,000</TD>
    <TD  width="2%" align=left>) </TD>
    <TD  width="5%" align=right>$</TD>
    <TD width="10%" align=right>&nbsp;2.82 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=right>500,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="5%" align=right>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="10%"
    align=right>&nbsp;1.50 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="4%" align=right>$</TD>
    <TD bgColor=#e6efff width="12%" align=center>&nbsp;0.72 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Outstanding at September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" width="15%"
      align=right>1,775,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="5%"
    align=right>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" width="10%"
      align=right>&nbsp;2.94 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Exercisable at September 30, 2012 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="15%"
    align=right>905,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="5%" align=right>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;2.81 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="4%" align=right>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=center>&nbsp;</TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Exercisable at September 30, 2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=right>930,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="10%"
      align=right>&nbsp;2.90 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="4%" align=right>&nbsp;</TD>
    <TD width="12%" align=center>&nbsp;</TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-31></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 21</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 8</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT
      color=#4f81bd>Commitments &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>b)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Stock&#150;based Compensation Plan &#150;
      (cont&#146;d)</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2012, the following stock options were
      outstanding:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="85%">
    <TR vAlign=top>
      <TD colspan="6" align=center style="BORDER-BOTTOM: #000000 1px solid">Number
        of Shares </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD align=center >&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >Aggregate </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >Remaining </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="3%" align=center >&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="14%" align=center>Number </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD colspan="2" align=center>Exercise </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD align=center >&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >Intrinsic </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >Contractual </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center>Total </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="3%" align=center
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="14%"
      align=center>Vested </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD colspan="2"
    align=center style="BORDER-BOTTOM: #000000 1px solid">Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    >Expiry Date </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="9%" align=center
    >Value </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="9%" align=center
    >Life (yrs) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>50,000 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="3%" align=right >(1</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="14%" align=right>50,000 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%" align=right>$</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;3.75 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff align=right >November 1, 2012 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >- </TD>
      <TD bgColor=#e6efff  width="2%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >0.09</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>100,000 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="3%" align=right >(2</TD>
      <TD  width="2%" align=left>) </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="14%" align=right>- </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="3%" align=right>$</TD>
      <TD width="9%" align=center >&nbsp;3.86 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD align=right >December 1, 2012 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="9%" align=center >- </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >0.17</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>150,000 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="3%" align=right >(3</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="14%" align=right>150,000 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%" align=right>$</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;3.10 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff align=right >June 30, 2014 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >- </TD>
      <TD bgColor=#e6efff  width="2%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >1.75</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>400,000 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="3%" align=right >(4</TD>
      <TD  width="2%" align=left>) </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="14%" align=right>400,000 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="3%" align=right>$</TD>
      <TD width="9%" align=center >&nbsp;2.50 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD align=right >September 15, 2013 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="9%" align=center >- </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >0.96</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>500,000 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="3%" align=right >(5</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="14%" align=right>- </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%" align=right>$</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;2.50 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff align=right >October 19, 2013 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >- </TD>
      <TD bgColor=#e6efff  width="2%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >1.04</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>5,000 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="3%" align=right >(6</TD>
      <TD  width="2%" align=left>) </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="14%" align=right>5,000 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="3%" align=right>$</TD>
      <TD width="9%" align=center >&nbsp;2.50 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD align=right >March 2, 2014 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="9%" align=center >- </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >1.42</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>50,000 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="3%" align=right >(7</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="14%" align=right>50,000 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%" align=right>$</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;3.50 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff align=right >June 30, 2014 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >- </TD>
      <TD bgColor=#e6efff  width="2%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >1.75</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>150,000 </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="3%" align=right >(8</TD>
      <TD  width="2%" align=left>) </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="14%" align=right>150,000 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="3%" align=right>$</TD>
      <TD width="9%" align=center >&nbsp;3.72 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD align=right >February 24, 2016 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="9%" align=center >- </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >3.40</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=right>100,000 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="3%" align=right >(9</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="14%" align=right>100,000 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%" align=right>$</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;3.67 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff align=right >March 30, 2016 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >- </TD>
      <TD bgColor=#e6efff  width="2%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >3.50</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>270,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="3%" align=right
    >(10</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="14%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
      <TD  width="3%" align=right>$</TD>
      <TD width="9%" align=center >&nbsp;3.00 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD align=right >February 8, 2017 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="9%" align=center
    >- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD  width="1%" align=center>&nbsp;</TD>
      <TD width="9%" align=center >4.36</TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
      align=right>1,775,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="3%"
    align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="14%"
    align=right>905,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="3%" align=right>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff align=left >&nbsp;</TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="9%"
    align=center >- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff  width="1%" align=center>&nbsp;</TD>
      <TD bgColor=#e6efff width="9%" align=center >&nbsp;</TD>
      <TD bgColor=#e6efff  width="2%"
  align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>The aggregate intrinsic value is
  calculated as the difference between the exercise price of the underlying awards
  and the quoted market price of the Company&#146;s stock for the options that were
  in-the-money at September 30, 2012.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, these options had
      fully vested. The Company did not recognize any stock-based compensation
      for these options during the year ended September 30, 2012 (2011:
      $nil). Subsequent to September 30, 2012, these options expired unexercised.</P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, these options have not
      vested. The options vest upon the Company listing its shares on the
      American Stock Exchange or any other nationally recognized stock exchange
      by December 1, 2012 or in the event of a change of control a listing on a
      nationally recognized stock exchange is not required. No stock- based
      compensation has been recorded in the financial statements as the
    performance condition has not yet been met. Subsequent to September 30, 2012, these options expired unexercised.</P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(3)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, these options had
      fully vested. During the year ended September 30, 2012, the expiry of
      these options was extended from June 3, 2013 to June 30, 2014. The fair
      value of this modification was determined to be $18,600 and was determined
      using the Black-Scholes option pricing model using the following weighted
      average assumptions: risk-free interest rate: 0.31%, expected life: 2.0
      years, annualized volatility: 84.74%, dividend rate:
      0%.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-32></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 22<BR>
</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 8</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT
      color=#4f81bd>Commitments &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>b)</FONT></I> </TD>
    <TD colSpan=2><P align=justify><I><FONT color=#808080>Stock&#150;based Compensation Plan &#150;
      (cont&#146;d)</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(4)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, these options had
      fully vested. The Company did not recognize any stock-based compensation
      for these options during the year ended September 30, 2012 (2011:
      $500,000).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(5)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, none of these options
      have vested. The options vest as to 100,000 per compound entered into a
      phase II trial. The fair value of these options was calculated to be
      $740,000, which the Company has not yet recognized in the financial
      statements as the performance conditions have not yet been met.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(6)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, these options had
      fully vested. The Company did not recognize any stock-based compensation
      for these options in the year ended September 30, 2012 (2011:
      $nil).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(7)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011 these options had fully
      vested. The Company did not recognize any stock-based compensation for the
      year ended September 30, 2012 (2011: $125,000). During the year ended
      September 30, 2012, the expiry of these options was shortened from June
      29, 2015 to June 30, 2014. The Company did not recognize any stock based
      compensation expense in connection with this modification because the fair
      value of the modified options was less than the fair value of the options
      under the old terms.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(8)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012, these options had fully vested
      (2011: none of these options have vested). The options vested on February
      24, 2012. The fair value of these options was calculated to be $406,500,
      of which the Company recognized stock-based compensation in the amount of
      $163,415 for the year ended September 30, 2012 (2011: $243,084).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(9)</SUP> </TD>
    <TD><P align=justify>These options were granted during the year ended
      September 30, 2011. At September 30, 2011, 75,000 of these options had
      vested. The remaining 25,000 options vested during the year ended
      September 30, 2012. The fair value of these options at issuance was
      calculated to be $267,000, of which the Company has recognized $6,500 as
      stock based compensation during the year ended September 30, 2012 (2011:
      $120,250).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(10)</SUP> </TD>
    <TD><P align=justify>As at September 30, 2012 and 2011, these options have not
      vested. The options vest upon one or more compounds: entering Phase II
      trial &#150; 90,000 options; entering Phase III trial &#150; 90,000 options; and
      receiving FDA approval &#150; 90,000 options. No stock-based compensation has
      been recorded in the financial statements as none of the performance
      conditions have yet been met.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-33></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 23</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 8</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT
      color=#4f81bd>Commitments &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>b)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Stock&#150;based Compensation Plan &#150;
      (cont&#146;d)</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>During the year ended September 30, 2012, a total of
      1,100,000 options were forfeited for which the Company had recognized
      stock-based compensation of $158,493 in respect of these options. The
      Company recognized stock-based compensation of $33,493 in respect of these
      options during the year ended September 30, 2012 (2011: $Nil).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>During the year ended September 30, 2011, a total of
      1,000,000 options were forfeited for which the Company had recognized
      stock based compensation of $708,917 in respect of these options. Of this
      total, $284,828 of stock based compensation expense had been recognized
      during the year ended September 30, 2011.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The fair value of stock options granted has been
      determined using the Black-Scholes option pricing model using the
      following weighted average assumptions applied to stock options granted
      during the periods:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="60%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Risk-free interest rate </TD>
      <TD bgColor=#e6efff width="25%" align=right>0.83% - 2.19% </TD>
      <TD bgColor=#e6efff width="25%" align=right>0.96% - 2.21% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expected life of options </TD>
      <TD width="25%" align=right>4.25 - 5.0 years </TD>
      <TD width="25%" align=right>4.5 - 5.0 years </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Annualized volatility </TD>
      <TD bgColor=#e6efff width="25%" align=right>57.87% - 95.25% </TD>
      <TD bgColor=#e6efff width="25%" align=right>56.27% - 62.52% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Dividend rate </TD>
      <TD width="25%" align=right>0% </TD>
      <TD width="25%" align=right>0% </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2012, the following
  summarizes the unvested stock options:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="70%">
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="5%" align=right>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="5%" align=right>&nbsp;</TD>
      <TD width="15%" align=center>Weighted </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center>&nbsp;</TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="5%" align=right>&nbsp;</TD>
      <TD width="15%" align=center>Weighted </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="5%" align=right>&nbsp;</TD>
      <TD width="15%" align=center>Average </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=center>Number of </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="5%" align=right>&nbsp;</TD>
      <TD width="15%" align=center>Average </TD>
      <TD  width="2%" align=center>&nbsp;</TD>
      <TD  width="5%" align=right>&nbsp;</TD>
      <TD width="15%" align=center>Grant-Date </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>Shares </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>&nbsp;</TD>
      <TD width="15%"
      align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Exercise Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%" align=center>Fair
        Value </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Unvested options at September
        30, 2010 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="15%" align=right>1,161,667 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;2.98 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;1.80 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Granted </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=right>650,000 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="5%" align=right>$</TD>
      <TD width="15%" align=center>&nbsp;4.06 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="5%" align=right>$</TD>
      <TD width="15%" align=center>&nbsp;2.61 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Forfeited/Cancelled </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="15%" align=right>(225,000</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;3.47 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;2.51 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Vested </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=right>(141,667</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>) </TD>
      <TD  width="5%" align=right>$</TD>
      <TD width="15%" align=center>&nbsp;3.57 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="5%" align=right>$</TD>
      <TD width="15%" align=center>&nbsp;2.59 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Unvested options at September
        30, 2011 </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="15%" align=right>1,445,000 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;3.33 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;2.17 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Granted </TD>
      <TD  width="1%" align=left>&nbsp;</TD>
      <TD width="15%" align=right>500,000 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="5%" align=right>$</TD>
      <TD width="15%" align=center>&nbsp;1.50 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
      <TD  width="5%" align=right>$</TD>
      <TD width="15%" align=center>&nbsp;0.72 </TD>
      <TD  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Forfeited </TD>
      <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="15%" align=right>(900,000</TD>
      <TD bgColor=#e6efff  width="2%" align=left>) </TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;2.74 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff  width="5%" align=right>$</TD>
      <TD bgColor=#e6efff width="15%" align=center>&nbsp;1.60 </TD>
      <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Vested </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=right>(175,000</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>&nbsp;3.71 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="5%"
    align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="15%"
      align=center>&nbsp;2.70 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left >Unvested options at September
        30, 2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=right>870,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="5%" align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=center>&nbsp;2.81 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="5%" align=right>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="15%"
    align=center>&nbsp;1.82 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-34></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 24</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 8</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Commitments &#150;
      (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><I><FONT color=#808080>b)</FONT></I> </TD>
    <TD><P align=justify><I><FONT color=#808080>Stock&#150;based Compensation Plan &#150;
      (cont&#146;d)</FONT></I></P></TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>As at September 30, 2012, there was no unrecognized
      compensation cost associated with unvested share-based compensation awards
      that will become vested exclusive of achieving any performance milestones
      that is expected to be recognized in current fiscal year. There has been
      no stock-based compensation recognized in the financial statements for the
      year ended September 30, 2012 (2011: $nil) for options that will vest upon
      the achievement of performance milestones because the Company has
      determined that satisfaction of the performance milestones was not
      probable. Compensation relating to stock options exercisable upon
      achieving performance milestones will be recognized in the period the
      milestones are achieved.</P></TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Stock-based compensation amounts, including those
      relating to shares issued for services during the years ended September
      30, 2012 and 2011 are classified in the Company&#146;s Statement of Operations
      as follows:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="70%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD colspan="4" align=center>Years ended September 30, </TD>
      <TD width="2%" align=right>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%" align=center>2012 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=center>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%" align=center>2011 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Consulting fees </TD>
      <TD bgColor=#e6efff width="1%" align=left>$</TD>
      <TD bgColor=#e6efff width="17%" align=right>&nbsp;312,903 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%" align=left>$</TD>
      <TD bgColor=#e6efff width="17%" align=right>&nbsp;1,273,162 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Research and development </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=right>80,200 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%" align=right>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="2%"
    align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="17%"
    align=right>&nbsp;393,103 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="2%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="17%"
    align=right>&nbsp;1,273,162 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="2%"
    align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 9</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Income Taxes</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left><P align=justify>The tax effects of the temporary differences that give
      rise to the Company&#146;s estimated deferred tax assets and liabilities are as
      follows: </P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="70%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=center><U>2012</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="17%" align=center><U>2011</U> </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=center><U>34%</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="17%" align=center><U>34%</U> </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Net operating loss carryforwards </TD>
      <TD bgColor=#e6efff width="1%" align=left>$</TD>
      <TD bgColor=#e6efff width="17%" align=right>&nbsp;6,775,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%" align=left>$</TD>
      <TD bgColor=#e6efff width="17%" align=right>&nbsp;5,508,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Research and development tax credits </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=right>741,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=right>476,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Foreign exchange </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>28,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>15,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Accrued bonuses </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=right>34,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="17%" align=right>- </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Intangible asset costs </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>34,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="17%" align=right>38,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Valuation allowance for deferred tax assets </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=right>(7,612,000</TD>
      <TD width="2%" align=left>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="17%"
      align=right>(6,037,000</TD>
      <TD width="2%" align=left>) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="17%">&nbsp;</TD>
      <TD bgColor=#e6efff width="2%">&nbsp;</TD>
      <TD bgColor=#e6efff width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="17%">&nbsp;</TD>
      <TD bgColor=#e6efff width="2%">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Net deferred tax assets </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="17%"
    align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="17%"
    align=right>&nbsp;- </TD>
      <TD bgColor=#e6efff width="2%"
align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-35></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 25</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 9</FONT></I> </TD>
    <TD width="90%" align=left><I><FONT color=#4f81bd>Income Taxes &#150;
      (cont&#146;d)</FONT></I> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left><P align=justify>The provision for income taxes differ from the amount
      established using the statutory income tax rate as follows: </P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="70%">
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=center><U>2012</U> </TD>
      <TD width="2%" align=center>&nbsp;</TD>
      <TD width="1%" align=center>&nbsp;</TD>
      <TD width="16%" align=center><U>2011</U> </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Income benefit at statutory rate </TD>
      <TD bgColor=#e6efff width="1%" align=left>$</TD>
      <TD bgColor=#e6efff width="16%" align=right>&nbsp;(2,823,000</TD>
      <TD bgColor=#e6efff width="2%" align=left>) </TD>
      <TD bgColor=#e6efff width="1%" align=left>$</TD>
      <TD bgColor=#e6efff width="16%" align=right>&nbsp;(2,484,000</TD>
      <TD bgColor=#e6efff width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Stock-based compensation </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>103,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>433,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Foreign income taxed at foreign statutory
        rate </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>(2,000</TD>
      <TD bgColor=#e6efff width="2%" align=left>) </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>1,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Debt extinguishment </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>1,302,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>181,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Research and development tax credit </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>(175,000</TD>
      <TD bgColor=#e6efff width="2%" align=left>) </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>(95,000</TD>
      <TD bgColor=#e6efff width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Fair value of derivative liability </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>(23,000</TD>
      <TD width="2%" align=left>) </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>(34,000</TD>
      <TD width="2%" align=left>) </TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Debt accretion </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>33,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>24,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Debt conversion </TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>- </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD width="1%" align=left>&nbsp;</TD>
      <TD width="16%" align=right>170,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff align=left>Other permanent differences </TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>10,000 </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%" align=left>&nbsp;</TD>
      <TD bgColor=#e6efff width="16%" align=right>- </TD>
      <TD bgColor=#e6efff width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Change in valuation allowance </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="16%"
      align=right>1,575,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="1%"
    align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="16%"
      align=right>1,804,000 </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp;</TD>
      <TD bgColor=#e6efff width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="16%">&nbsp;</TD>
      <TD bgColor=#e6efff width="2%">&nbsp;</TD>
      <TD bgColor=#e6efff width="1%">&nbsp;</TD>
      <TD bgColor=#e6efff width="16%">&nbsp;</TD>
      <TD bgColor=#e6efff width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Deferred income tax recovery </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="1%" align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="16%"
      align=right>&nbsp;- </TD>
      <TD width="2%" align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="1%" align=left>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" width="16%"
      align=right>&nbsp;- </TD>
      <TD width="2%" align=left>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>As of September 30, 2012, the Company
  had net operating loss carry-forwards of approximately $19,945,000 (2011:
  $16,300,000) available to offset future taxable income. The carry-forwards will
  begin to expire in 2027 unless utilized in earlier years. The Company has not
  yet filed any tax returns in France as they are not yet due.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company evaluates its valuation
  allowance requirements based on projected future operations. When circumstances
  change and this causes a change in management&#146;s judgment about the
  recoverability of deferred tax assets, the impact of the change on the valuation
  allowance is reflected in current income. Because management of the Company does
  not currently believe that it is more likely than not that the Company will
  receive the benefit of these assets, a valuation allowance equal to the deferred
  tax asset has been established at both September 30, 2012 and 2011.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Uncertain Tax Positions</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company files income tax returns
  in the U.S. federal jurisdiction, various state and foreign jurisdictions. The
  Company&#146;s tax returns are subject to tax examinations by U.S. federal and state
  tax authorities, or examinations by foreign tax authorities until respective
  statute of limitation. The Company is subject to tax examinations by tax
  authorities for all taxation years commencing on or after 2004.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Provisions have not been made for U.S.
  or additional foreign taxes on undistributed earnings of foreign subsidiaries.
  Such earnings have been and will continue to be reinvested but could become
  subject to additional tax if they were remitted as dividends, or were loaned to
  the Company affiliate. It is not practicable to determine the amount of
  additional tax, if any, that might be payable on the undistributed foreign
  earnings.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-36></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 26</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 10</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT
      color=#4f81bd>Supplemental Cash Flow Information</FONT></I> </TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD width="90%" align=left ><P align=justify>Investing and financing activities that do not have a
      direct impact on current cash flows are excluded from the statement of
      cash flows. </P></TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left >During the year ended September
      30, 2012: </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued 544,667 units of the Company at their
      fair value of $1.918 per unit to settle a convertible interest bearing
      note payable outstanding in the amount of $272,333, including accrued
      interest of $22,333 included in accounts payable and accrued liabilities
      and 2,155,846 units of the Company at their fair value of $1.918 per unit
      to settle non- convertible interest bearing notes payable outstanding in
      the amount of $1,077,923 including accrued interest of $30,034 included in
      accounts payable and accrued liabilities. Each unit consisted of one
      common share and one common share purchase warrant exercisable into one
      additional common share for $0.75 per share until November 30, 2013. The
      Company recorded a loss on debt settlement of $3,829,333 as a result of
      this transaction.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=top>b) </TD>
    <TD><P align=justify>The Company issued 75,000 common shares at their fair
      value of $1.00 per share for a total of $75,000 to the former President of
      the Company pursuant to a severance agreement.</P></TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify>The Company issued 8,000 units for services performed by director. Each unit consisted of one common share and one-half common share purchase warrant. The fair value of this issuance was determined to be $15,896.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2011:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued 3,636 units at $2.75 per unit for
      finder&#146;s fees related to the private placement. Each unit consisted of one
      common share and one-half common share purchase warrant entitling the
      holder to purchase an additional common share at $4.50 per share until May
      18, 2012.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued 853,075 units at the calculated fair
      value of $6.24 per unit in the conversion of two notes payable. The
      Company recorded debt conversion expense of $504,160 related to the fair
      value of the additional units issued based on the difference between the
      fair value of the units issued and the carrying value of the debt. Each
      unit consisted of one common share and one common share purchase warrant
      entitling the holder to purchase an additional common share at $3.00 per
      share until November 18, 2012.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify>The Company issued 145,063 shares of common stock at
      their fair value of $4.12 per share to settle non-convertible interest
      bearing notes payable outstanding in the amount of $398,923, including
      accrued interest of $26,032 (included in accounts payable and accrued
      liabilities). The Company recorded a loss on debt settlement of $198,738
      as a result of this transaction.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-37></A>
<P align=justify>Anavex Life Sciences Corp.<BR>
  (A Development Stage
  Company)<BR>
  Notes to the Consolidated Financial Statements<BR>
  September 30, 2012
  and 2011<BR>
  (<U>Stated in US Dollars</U>) &#150; Page 27</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD  align=left><EM><FONT color=#4f81bd>Note 10 </FONT></EM></TD>
    <TD width="90%" align=left ><I><FONT
      color=#4f81bd>Supplemental Cash Flow Information &#150; (cont&#146;d)</FONT></I> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD><P align=justify>The Company issued 181,818 shares of common stock at
      their fair value of $4.12 per share based on their quoted market price to
      one creditor in settlement of $500,000 of accounts payable. The Company
      recorded a loss on settlement of accounts payable of $249,090 as a result
      of the difference between the carrying value of the account payable and
      the fair value of the shares issued.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD><P align=justify>The Company issued 2,985 units at $3.35 per unit for
      finder&#146;s fees related to the private placement of the same date. Each unit
      consisted of one common share and one-half common share purchase warrant
      entitling the holder to purchase an additional common share at $4.50 per
      share until November 25, 2012.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD><P align=justify>On September 26, 2011, the Company issued 650,000 units
      having a fair value of $1,059,963 to settle an account payable totaling
      $975,000 and thus recorded a loss of $84,963 on the settlement of account
      payable.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">g) </TD>
    <TD><P align=justify>The Company issued an 8% interest bearing promissory note
      having a principal balance of $216,000 in exchange for a promissory note
      that had a principal balance of $200,000 with accrued interest of $16,000
      thereon.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left><I><FONT color=#4f81bd>Note 11</FONT></I> </TD>
    <TD width="90%" align=left ><I><FONT color=#4f81bd>Subsequent
      Events</FONT></I> </TD>
  </TR>
  <TR>
    <TD  align=left>&nbsp;</TD>
    <TD  width="90%" align=left >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD width="90%" align=left >Subsequent to September 30, 2012; </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>the Company issued a promissory note having a principal
      balance of $150,000 with terms that include interest at 8% per annum and
      maturing on March 31, 2013.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>the Company issued a promissory note having a principal
      balance of $50,000 with terms that include interest at 8% per annum and
      maturing on March 31, 2013.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_38></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
      FINANCIAL MATTERS </FONT></TD></TR></TABLE>
<P align=justify>None.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      9A. CONTROLS AND PROCEDURES </FONT></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Disclosure Controls and
Procedures</FONT></I></P>
<P align=justify>As required by Rule 13a-15 under the Securities Exchange Act of
1934, our management, with the participation of our principal executive officer
and principal financial officer, evaluated our disclosure controls and
procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934)
as of the end of the period covered by this annual report.</P>
<P align=justify>Disclosure controls and procedures are controls and other
procedures that are designed to ensure that information required to be disclosed
in our reports filed or submitted under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported, within the time periods specified
in the Securities and Exchange Commission&#146;s rules and forms. Disclosure controls
and procedures include controls and procedures designed to ensure that
information required to be disclosed in our reports filed under the Securities
Exchange Act of 1934 is accumulated and communicated to our principal executive
officer and principal financial officer to allow timely decisions regarding
required disclosure. </P>
<P align=justify>Based on its evaluation, our management, with the participation
of our principal executive officer and principal financial officer, concluded
that as of the end of the period covered by this annual report, our disclosure
controls and procedures were not effective. The ineffectiveness of our
disclosure controls and procedures was due to internal control deficiencies
related to internal control over financial reporting.</P>
<P align=justify><I><FONT color=#4f81bd>Management&#146;s Annual Report on Internal
Control over Financial Reporting </FONT></I></P>
<P align=justify>Management is responsible for establishing and maintaining
adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our management
evaluated, under the supervision and with the participation of our principal
executive officer and principal financial officer, the effectiveness of our
internal control over financial reporting as of September 30, 2012. </P>
<P align=justify>Based on its evaluation under the framework in Internal
Control&#151;Integrated Framework, issued by the Committee of Sponsoring
Organizations of the Treadway Commission, our management, with the participation
of our principal executive officer and principal financial officer, concluded
that our internal </P>
<P align=center>33</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_39></A>
<P align=justify>control over financial reporting was not effective as of
September 30, 2012. The ineffectiveness of our internal control over financial
reporting was due to the existence of significant deficiencies constituting
material weaknesses, as described in greater detail below. A material weakness
is a control deficiency, or combination of control deficiencies, such that there
is a reasonable possibility that a material misstatement of the annual or
interim financial statements will not be prevented or detected on a timely
basis. </P>
<P align=justify><I><FONT color=#4f81bd>Material Weaknesses
Identified</FONT></I></P>
<P align=justify>Based on our management&#146;s evaluation required by Rule 13a-15 of
the Securities Exchange Act of 1934, certain significant deficiencies in
internal control are evident to our management and our management believes these
deficiencies represent material weaknesses, including:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>Insufficient segregation of duties in our finance and
      accounting functions due to limited personnel. During the fiscal year
      ended September 30, 2012, we had limited staff that performed nearly all
      aspects of our financial reporting process, including, but not limited to,
      access to the underlying accounting records and systems, the ability to
      post and record journal entries and responsibility for the preparation of
      the financial statements. This creates certain incompatible duties and a
      lack of review over the financial reporting process that would likely
      result in a failure to detect errors in spreadsheets, calculations, or
      assumptions used to compile the financial statements and related
      disclosures as filed with the Securities and Exchange Commission. These
      control deficiencies could result in a material misstatement to our
      interim or annual financial statements that would not be prevented or
      detected; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>There has been a lack of sufficient supervision and
      review by our management as a product of limited
  personnel.</P></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Plan for Remediation of Material
Weaknesses</FONT></I></P>
<P align=justify>We intend to take appropriate and reasonable steps to make
improvements to remediate these deficiencies as a product of a larger strategic
plan that incorporates partnership with a larger enterprise, or the sale of the
company. We intend to consider the results of our remediation efforts and
related testing as part of our year-end 2013 assessment of the effectiveness of
our internal control over financial reporting in light of our strategic plan.
</P>
<P align=justify>Due to our size and nature, segregation of all conflicting
duties has not always been possible and may not be economically feasible.
However, we are in the process of implementing processes and procedures intended
to mitigate any material weaknesses identified,</P>
<P align=justify>We believe that the foregoing steps will remediate the
deficiencies identified above, and we intend to continue to monitor the
effectiveness of these steps and make any changes that our management deems
appropriate. </P>
<P align=center>34</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_40></A>
<P align=justify><I><FONT color=#4f81bd>Limitations on Effectiveness of
Controls</FONT></I></P>
<P align=justify>Our principal executive officer and principal financial officer
do not expect that our disclosure controls and procedures or our internal
control over financial reporting will prevent all errors and all fraud. A
control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our company have been
detected. These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of a simple
error or mistake. Additional controls can be circumvented by the individual acts
of some persons, by collusion of two or more people, or by management override
of the controls. The design of any system of controls also is based in part upon
certain assumptions about the likelihood of future events, and there can be no
assurance that any design will succeed in achieving its stated goals under all
potential future conditions; over time, controls may become inadequate because
of changes in conditions, or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and
not be detected. </P>
<P align=justify><I><FONT color=#4f81bd>Changes in Internal Control over
Financial Reporting</FONT></I></P>
<P align=justify>During the fourth quarter ended September 30, 2012, we
undertook changes that have materially improved our internal control over
financial reporting. We appointed Robert Chisholm as our principal executive
officer and principal financial officer. Mr. Chisholm has significant experience
working with internal controls and accounting, and is an accredited accountant.
His experience and accreditation exceeds the experience and qualifications of
his predecessor. Mr. Chisholm has implemented procedures by which we have
greater clarity into our daily financial affairs including improved budgeting,
review by the directors of all invoices received by the company, transparent
cash management reporting and planning, and on-demand reporting of all banking
transactions.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      9B OTHER INFORMATION </FONT></TD></TR></TABLE>
<P align=justify>On October 17, 2012, we issued Akira International Limited a
promissory note having a principal balance of $150,000 with terms that include
interest at 8% per annum and maturing on March 31, 2013. On November 14, 2012,
we issued Akira International Limited another promissory note having a principal
balance of $50,000 with terms that include interest at 8% per annum and maturing
on March 31, 2013.</P>
<P align=center>35</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_41></A>
<P align=justify><B>PART III</B></P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
  </FONT></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Directors and Executive
Officers</FONT></I></P>
<P align=justify>Our directors are to be elected at our annual meeting and each
director elected is to hold office until his or her successor is elected and
qualified. Our board of directors may remove our officers at any time. </P>
<P align=justify>Our directors and executive officers, their age, positions
held, and duration of such, are as follows: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left>Name </TD>
    <TD width="25%" align=left>Position </TD>
    <TD width="25%" align=left>Age </TD>
    <TD width="25%" align=left>Date first appointed </TD></TR>
  <TR vAlign=top>
    <TD align=left>Sean Lowry </TD>
    <TD width="25%" align=left>Director </TD>
    <TD width="25%" align=left>40 </TD>
    <TD width="25%" align=left>February 24, 2011 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Robert Chisholm <BR><BR></TD>
    <TD width="25%" align=left>Director, President, <BR>Secretary, Treasurer,
      <BR>Chief Financial Officer </TD>
    <TD width="25%" align=left>50 <BR><BR></TD>
    <TD width="25%" align=left>May 13, 2011 <BR><BR></TD></TR></TABLE></DIV>
<P align=justify><I><FONT color=#4f81bd>Business Experience</FONT></I></P>
<P align=justify>The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed.</P>
<P align=justify>Sean Lowry </P>
<P align=justify>Mr. Lowry is executive director of Airframe Capital, an
advisory firm. Mr. Lowry was president of Wm. Lowry Consulting from 2001 until
its merger with Airframe Capital in 2012. Between 2006 and 2012, Mr. Lowry was
also a partner and portfolio manager in Gulfstream Ventures, a venture capital
firm. Mr. Lowry serves as an officer and director of private companies and is a
member of the Institute of Corporate Directors. </P>
<P align=justify>We believe Mr. Lowry is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from serving as our director since February 24,
2011, in addition to his business experiences described above.</P>
<P align=justify>Robert Chisholm </P>
<P align=justify>Mr. Chisholm has been our President, Secretary, Treasurer and
Chief Financial Officer since June 26, 2012 and a director of our company since
May 13, 2011.</P>
<P align=justify>Mr. Chisholm has been an officer and partner of Emprise Capital
Corp, a private company focused on advising portfolio companies on managing
finances, including development and implementation of </P>
<P align=center>36</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_42></A>
<P align=justify>comprehensive budgeting processes, public market listings and
oversight of contract negotiations since 2009.</P>
<P align=justify>Mr. Chisholm has been the Chief Financial Officer and a
director of OMT Inc. since July 2011. He has been the Chief Financial Officer of
T.M.T. Resources Inc. since November 2011 and a director since October 2012 and
the Chief Financial Officer of Ripper Oil and Gas Inc. since May 2012.</P>
<P align=justify>Mr. Chisholm&#146;s background includes previous appointments as
Chief Financial Officer and a director of Brookwater Ventures Inc., Ocean Park
Ventures Corp., Savary Capital Corp., Windamere Ventures Ltd. (formerly Advanced
Vision Systems Corp.) and PNI Digital Media Inc. (formerly PhotoChannel Networks
Inc.). Mr. Chisholm has also served as a member of the Board of Directors for
Rare Earth Industries Limited (formerly Seymour Ventures Corp.) and as Chief
Financial Officer of Chantrell Ventures Corp. (formerly Tiger Pacific Mining
Corp.). Mr. Chisholm holds a professional accounting designation from the
Certified Management Accountants of Canada and received his BBA with a major in
accounting from Saint Francis Xavier University in Nova Scotia. </P>
<P align=justify>We believe Mr. Chisholm is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from serving as our director since May 13, 2011, in
addition to his business experiences described above. </P>
<P align=justify><I><FONT color=#4f81bd>Family Relationships</FONT></I></P>
<P align=justify>There are no family relationships between any director or
executive officer.</P>
<P align=justify><I><FONT color=#4f81bd>Involvement in Certain Legal
Proceedings</FONT></I></P>
<P align=justify>There are no material proceedings to which any director or
executive officer or any associate of any such director or officer is a party
adverse to our company or has a material interest adverse to our company. </P>
<P align=justify>No director or executive officer has been involved in any of
the following events during the past ten years: </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>any bankruptcy petition filed by or against any business
      of which such person was a general partner or executive officer either at
      the time of the bankruptcy or within two years prior to that
  time;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>any conviction in a criminal proceeding or being subject
      to a pending criminal proceeding (excluding traffic violations and other
      minor offences);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>being subject to any order, judgment, or decree, not
      subsequently reversed, suspended or vacated, of any court of competent
      jurisdiction, permanently or temporarily enjoining, barring, suspending or
      otherwise limiting his involvement in any type of business, securities or
      banking activities;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>being found by a court of competent jurisdiction (in a
      civil action), the Securities and Exchange Commission or the Commodity
      Futures Trading Commission to have violated a federal or state securities
      or commodities law, and the judgment has not been reversed, suspended, or
      vacated;</P></TD></TR></TABLE>
<P align=center>37</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_43></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any federal or state
      judicial or administrative order, judgment, decree, or finding, not
      subsequently reversed, suspended or vacated, relating to an alleged
      violation of: (i) any federal or state securities or commodities law or
      regulation; or (ii) any law or regulation respecting financial
      institutions or insurance companies including, but not limited to, a
      temporary or permanent injunction, order of disgorgement or restitution,
      civil money penalty or temporary or permanent cease- and- desist order, or
      removal or prohibition order; or (iii) any law or regulation prohibiting
      mail or wire fraud or fraud in connection with any business entity;
    or</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any sanction or
      order, not subsequently reversed, suspended or vacated, of any
      self-regulatory organization (as defined in Section 3(a)(26) of the
      Securities Exchange Act of 1934), any registered entity (as defined in
      Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
      exchange, association, entity or organization that has disciplinary
      authority over its members or persons associated with a
  member.</P></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Compliance with Section 16(a) of the
Securities Exchange Act of 1934 </FONT></I></P>
<P align=justify>Section 16(a) of the Securities Exchange Act of 1934 requires
our executive officers and directors and persons who own more than 10% of our
common stock to file with the Securities and Exchange Commission initial
statements of beneficial ownership, reports of changes in ownership and annual
reports concerning their ownership of our common stock and other equity
securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and
greater than 10% shareholders are required by the Securities and Exchange
Commission regulations to furnish us with copies of all Section 16(a) reports
that they file. </P>
<P align=justify>Based solely on our review of the copies of such forms received
by us, or written representations from certain reporting persons, we believe
that during fiscal year ended September 30, 2012, all filing requirements
applicable to our officers, directors and greater than 10% percent beneficial
owners were complied.</P>
<P align=justify><I><FONT color=#4f81bd>Code of Ethics</FONT></I></P>
<P align=justify>We have adopted a code of ethics that applies to our principal
executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions. We have posted our policy
on our website at www.anavex.com.</P>
<P align=justify><I><FONT color=#4f81bd>Audit Committee and Audit Committee
Financial Experts </FONT></I></P>
<P align=justify>We have an audit committee, comprised of two directors, Robert
Chisholm, and Sean Lowry. During the fiscal year ended September 30, 2012, our
audit committee held 12 meetings. The audit committee represents our board of
directors in discharging its responsibility relating to the accounting,
reporting and financial practices of our company, and has general responsibility
for oversight of internal controls, accounting and audit activities and legal
compliance of our company. However, the audit committee&#146;s function is one of
oversight only and does not relieve our management of its responsibilities for
preparing financial statements which accurately and fairly present our financial
results and conditions or </P>
<P align=center>38</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_44></A>
<P align=justify>the responsibilities of the independent registered public
accounting firm relating to the audit or review of financial statements.</P>
<P align=justify>Sean Lowry, and Robert Chisholm are each considered an &#147;audit
committee financial expert&#148; as defined in Item 407(d)(5)(ii) of Regulation S-K.
Sean Lowry is Chairman of the audit committee. </P>
<P align=justify><I><FONT color=#4f81bd>Nominating and Compensation
Committees</FONT></I></P>
<P align=justify>We do not have standing nominating or compensation committees,
or committees performing similar functions. Our board of directors believes that
it is not necessary to have a standing compensation committee at this time
because the functions of such committee are adequately performed by our board of
directors. Our board of directors has not adopted a charter for the compensation
committee. </P>
<P align=justify>Our board of directors also is of the view that it is
appropriate for us not to have a standing nominating committee because our board
of directors has performed and is expected to perform adequately the functions
of a nominating committee. Our board of directors has not adopted a charter for
the nominating committee. There has not been any defined policy or procedure
requirements for stockholders to submit recommendations or nomination for
directors. Our board of directors does not believe that a defined policy with
regard to the consideration of candidates recommended by stockholders is
necessary at this time because we believe that, at this stage of our
development, a specific nominating policy would be premature and of little
assistance until our business operations are at a more advanced level. There are
no specific, minimum qualifications that our board of directors believes must be
met by a candidate recommended by our board of directors. There is neither a
defined, nor a typical process of identifying and evaluating nominees for
director. </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      11. EXECUTIVE COMPENSATION </FONT></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Summary Compensation </FONT></I></P>
<P align=justify>The particulars of compensation paid to the following
persons:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>our principal executive officers;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>each of our two most highly compensated executive
      officers who were serving as executive officers at the end of the fiscal
      year ended September 30, 2012 who had total compensation exceeding
      $100,000; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>up to two additional individuals for whom disclosure
      would have been provided under (b) but for the fact that the individual
      was not serving as our executive officer at the end of the most recently
      completed financial year, who we will collectively refer to as the named
      executive officers, for our fiscal years ended September 30, 2012 and
      2011, are set out in the following summary compensation
  table:</P></TD></TR></TABLE>
<P align=center>39</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_45></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=left><BR><BR><BR><B>Name and Principal</B> <BR><B>Position</B>
    </TD>
    <TD width="12%" align=center><BR><BR><BR><BR><B>Year</B> </TD>
    <TD width="12%" align=center><BR><BR><BR><B>Salary</B> <BR><B>($)</B> </TD>
    <TD width="12%" align=center><BR><BR><BR><B>Bonus</B> <BR><B>($)</B> </TD>
    <TD width="12%" align=center><BR><BR><B>Stock</B> <BR><B>Awards</B>
      <BR><B>($)</B> </TD>
    <TD width="12%" align=center><BR><BR><B>Option</B> <BR><B>Awards</B>
      <BR><B>($)</B><B><SUP>(1)</SUP></B> </TD>
    <TD width="12%" align=center><B>Other</B> <BR><B>Annual</B>
      <BR><B>Compen-</B> <BR><B>sation</B> <BR><B>($)</B><B><SUP>(2)</SUP></B>
    </TD>
    <TD width="12%" align=center><BR><BR><BR><B>Total</B> <BR><B>($)</B>
</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Robert Chisholm<SUP>(1)</SUP>
      <BR>President, Chief <BR>Financial Officer and <BR>Director </TD>
    <TD bgColor=#e6efff width="12%" align=center>2012 <BR>2011 <BR><BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>96,217 <BR>Nil <BR><BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil <BR>Nil <BR><BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil <BR>Nil <BR><BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil <BR>Nil <BR><BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil <BR>Nil <BR><BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>96,217 <BR>Nil <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Harvey Lalach <SUP>(2)</SUP> <BR>Former President,
      <BR>Former Chief <BR>Operating, Former <BR>Director </TD>
    <TD width="12%" align=center>2012 <BR>2011 <BR><BR><BR></TD>
    <TD width="12%" align=center>130,000 <BR>150,000 <BR><BR><BR></TD>
    <TD width="12%" align=center>Nil <BR>Nil <BR><BR><BR></TD>
    <TD width="12%" align=center>75,000 <BR>Nil <BR><BR><BR></TD>
    <TD width="12%" align=center>18,600 <BR>
      Nil <BR>
      <BR><BR></TD>
    <TD width="12%" align=center>Nil <BR>Nil <BR><BR><BR></TD>
    <TD width="12%" align=center>223,600 <BR>
      150,000<BR>
      <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>George Tidmarsh <SUP>(3)</SUP> <BR>Former
      Executive <BR>Director </TD>
    <TD bgColor=#e6efff width="12%" align=center>2012 <BR>2011 <BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>42,012 <BR>Nil <BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil <BR>Nil <BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>15,896 <BR>Nil <BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>33,493 <BR>Nil <BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil <BR>Nil <BR></TD>
    <TD bgColor=#e6efff width="12%" align=center>91,401 <BR>Nil
  <BR></TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Robert Chisholm was appointed President and Chief
      Financial Officer on June 26, 2012. Prior to that date, Mr. Chisholm
      served as a director to the company.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Harvey Lalach was appointed President and Secretary on
      April 25, 2006. On August 27, 2011, Mr. Lalach was appointed Chief
      Operating Officer and on May 13, 2011 he was appointed interim Chief
      Financial Officer. Mr. Lalach resigned as an officer and director of our
      company on June 26, 2012.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>George Tidmarsh was appointed as an executive director on
      October 12, 2011 and received consulting fees and stock option awards in
      his capacity as Executive Director. Mr. Tidmarsh resigned on March 17,
      2012</P></TD></TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Consulting Agreements </FONT></I></P>
<P align=justify>Robert Chisholm</P>
<P align=justify>Effective June 26, 2012, Robert Chisholm was appointed
President and Chief Financial Officer of the company. Mr. Chisholm is
remunerated at the rate of CDN$7,500 per month through a company with which he
is associated.</P>
<P align=justify>Harvey Lalach</P>
<P align=justify>We had a consulting agreement dated February 1, 2007 with
Harvey Lalach to provide management services to our company for consideration of
$7,000 per month. The contract had a two year term, and was extended for an
additional two year term expiring January 31, 2011. During the fiscal year ended
September 30, 2008, we agreed to increase the compensation of Mr. Lalach to
$12,500 per month. Effective February 1, 2011 we entered into a consulting
agreement with Mr. Lalach whereby Mr. Lalach agreed to continue to provide
management services to our company in return for compensation of $12,500 per
month for an additional two years.</P>
<P align=justify>Effective June 26, 2012 Mr. Lalach resigned his positions as
both an officer and a director. Mr. Lalach continued to consult for the company
until September 30, 2012 and was paid $15,000. In addition, we issued an
aggregate of 75,000 shares of our common stock at a deemed value of $1.00 per
share to </P>
<P align=center>40</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_46></A>
<P align=justify>Mr. Lalach for his past services and in final settlement of his
Consulting Agreement dated February 1, 2007 and we extended the expiry date to
June 30, 2014 of 200,000 stock options held by Mr. Lalach.</P>
<P align=justify>Dr. George Tidmarsh</P>
<P align=justify>Effective October 10, 2011 we entered into a consulting
agreement with Dr. Tidmarsh to act as our executive director for the following
consideration: </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>a monthly consulting fee of $10,000;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>500,000 Share purchase options exercisable at $1.50 per
      option share until October 10, 2016 (subject to certain vesting
      provisions);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>reimbursement of all reasonable
  expenditures.</P></TD></TR></TABLE>
<P align=justify>On February 9, 2012 we issued an aggregate of 8,000 units of
our securities at a price of $1.25 per unit to George Tidmarsh, a former
director of our company, for his services during the month of January, 2012.
Each unit consisted of one share of our common stock and one-half of one share
purchase warrant. Each whole warrant is exercisable at $2.00 for one share of
common stock for a period of 12 months.</P>
<P align=justify>On March 18, 2012 Dr. Tidmarsh delivered notice to us of his
resignation as both an officer and a director. On March 21, 2012, Dr. Tidmarsh
withdrew his original notice, and issued an amended notice of resignation.</P>
<P align=justify><I><FONT color=#4f81bd>Outstanding Equity Awards at Fiscal
Year-End </FONT></I></P>
<P align=justify>The following table sets forth for each named executive officer
and director certain information concerning the outstanding equity awards as of
September 30, 2012.</P>
<P align=center>41</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_47></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top bgcolor="#EEEEEE">
    <TD rowSpan=2 align=center vAlign=bottom>Name </TD>
    <TD colspan="5" align=center vAlign=bottom> Option Awards </TD>
    <TD colspan="4" align=center vAlign=bottom> Stock Awards </TD>
  </TR>
  <TR>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"><BR> Number <BR>
      of <BR>
      Securities <BR>
      Underlying<BR>
      Exercisable <BR>
      Options <BR>
      (#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Number of <BR>
      Securities <BR>
      Underlying <BR>
      Unexercisable<BR>
      Options <BR>
      (#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Equity <BR> Incentive
      <BR>
      Plan <BR>
      Awards: <BR>
      Number of <BR>
      Securities <BR>
      Underlying <BR>
      Unexercised<BR>
      Unearned <BR>
      Options <BR>
      (#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Option <BR> Exercise
      <BR>
      Price <BR>
      ($) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Option <BR> Expiration
      <BR>
      Date </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"><BR> Number <BR>
      of <BR>
      Shares <BR>
      of <BR>
      Units <BR>
      of <BR>
      Stock <BR>
      that <BR>
      have <BR>
      not <BR>
      Vested <BR>
      (#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Market <BR> Value
      of <BR>
      Shares or <BR>
      Units of <BR>
      Stock that <BR>
      have not <BR>
      Vested <BR>
      ($) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Equity <BR> Incentive<BR>
      Plan <BR>
      Awards: <BR>
      Number <BR>
      of <BR>
      Unearned <BR>
      Shares, <BR>
      Units or <BR>
      Other <BR>
      Rights <BR>
      that <BR>
      have <BR>
      not <BR>
      Vested <BR>
      (#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Equity <BR> Incentive
      <BR>
      Plan <BR>
      Awards: <BR>
      Market or <BR>
      Payout <BR>
      Value of <BR>
      Unearned <BR>
      Shares, <BR>
      Units or <BR>
      Other <BR>
      Rights that <BR>
      have not <BR>
      Vested <BR>
      ($) </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Robert Chisholm </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Sean Lowry </TD>
    <TD bgColor=#e6efff width="10%" align=center>150,000 </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>3.72 </TD>
    <TD bgColor=#e6efff width="10%" align=center>Feb 24, 2016 </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Harvey <BR>
      Lalach </TD>
    <TD bgColor=#e6efff width="10%" align=center>150,000 <BR>
      50,000 </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil <BR>
      Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil <BR>
      Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>3.10 <BR>
      3.50 </TD>
    <TD bgColor=#e6efff width="10%" align=center>June 30, 2014 <BR>
      June 30, 2014 </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil <BR></TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A <BR></TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil <BR></TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A <BR></TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD width="10%" align=center>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>George Tidmarsh </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
    <TD bgColor=#e6efff width="10%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="10%" align=center>N/A </TD>
  </TR>
</TABLE>
<P align=justify>We have not adopted any other equity compensation plan other
than our 2007 Stock Option Plan.</P>
<P align=justify><I><FONT color=#4f81bd>Compensation of Directors
</FONT></I></P>
<P align=justify>The table below shows the compensation of our directors who
were not our named executive officers for the fiscal year ended September 30,
2012:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD width="12%" align=left>&nbsp; </TD>
    <TD width="12%" align=left>&nbsp; </TD>
    <TD width="12%" align=left>&nbsp; </TD>
    <TD width="12%" align=center><B>Non-Equity</B> </TD>
    <TD width="12%" align=center><B>Nonqualified</B> </TD>
    <TD width="12%" align=left>&nbsp; </TD>
    <TD width="12%" align=left>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD width="12%" align=center><B>Fees Earned or</B> </TD>
    <TD width="12%" align=center><B>Stock</B> </TD>
    <TD width="12%" align=center><B>Option</B> </TD>
    <TD width="12%" align=center><B>Incentive Plan</B> </TD>
    <TD width="12%" align=center><B>Deferred</B> </TD>
    <TD width="12%" align=center><B>All Other</B> </TD>
    <TD width="12%" align=left>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD width="12%" align=center><B>Paid in Cash</B> </TD>
    <TD width="12%" align=center><B>Awards</B> </TD>
    <TD width="12%" align=center><B>Awards</B> </TD>
    <TD width="12%" align=center><B>Compensation</B> </TD>
    <TD width="12%" align=center><B>Compensation</B> </TD>
    <TD width="12%" align=center><B>Compensation</B> </TD>
    <TD width="12%" align=center><B>Total</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Name</B> </TD>
    <TD width="12%" align=center><B>($)</B> </TD>
    <TD width="12%" align=center><B>($)</B> </TD>
    <TD width="12%" align=center><B>($)</B> </TD>
    <TD width="12%" align=center><B>($)</B> </TD>
    <TD width="12%" align=center><B>Earnings ($)</B> </TD>
    <TD width="12%" align=center><B>($)</B> </TD>
    <TD width="12%" align=center><B>($)</B> </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Sean Lowry <SUP>(1)</SUP> </TD>
    <TD bgColor=#e6efff width="12%" align=center>95,000 </TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="12%" align=center>Nil </TD>
    <TD bgColor=#e6efff width="12%" align=center>95,000
</TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="10%">(1) </TD>
    <TD >
      <P align=justify>Sean Lowry is paid a fee for his service as chairman of
      the company&#146;s audit committee.</P></TD></TR></TABLE>
<P align=justify>We reimburse our directors for expenses incurred in connection
with attending board meetings.</P>
<P align=center>42</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_48></A>
<P align=justify>During the fiscal year ended September 30, 2012, there were no
standard arrangements pursuant to which any of our directors were compensated
for services provided in their capacity as directors. </P>
<P align=justify>We currently have no formal plan for compensating our directors
for their services in their capacity as directors, although we may elect to
issue stock options to such persons in the future. Directors are entitled to
reimbursement for reasonable travel and other out-of-pocket expenses incurred in
connection with attendance at meetings of our board of directors. Our board of
directors may award special remuneration to any director undertaking any special
services on our behalf other than services ordinarily required of a
director.</P>
<P align=justify><I><FONT color=#4f81bd>Retirement or Similar Benefit
Plans</FONT></I></P>
<P align=justify>There are no arrangements or plans in which we provide
retirement or similar benefits for our directors or executive officers.</P>
<P align=justify><I><FONT color=#4f81bd>Resignation, Retirement, Other
Termination, or Change in Control Arrangements</FONT></I></P>
<P align=justify>We have no contract, agreement, plan or arrangement, whether
written or unwritten, that provides for payments to our directors or executive
officers at, following, or in connection with the resignation, retirement or
other termination of our directors or executive officers, or a change in control
of our company or a change in our directors&#146; or executive officers&#146;
responsibilities following a change in control. </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT
      color=#004080 size="4">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
      OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </FONT></TD>
  </TR></TABLE>
<P align=justify>The following table sets forth, as of December 28, 2012,
certain information with respect to the beneficial ownership of our common stock
by each stockholder known by us to be the beneficial owner of more than 5% of
our common stock and by each of our current directors and our named executive
officers and by our current directors and executive officers as a group. We have
determined the number and percentage of shares beneficially owned by such person
in accordance with Rule 13d-3 under the Securities Exchange Act of 1934. This
information does not necessarily indicate beneficial ownership for any other
purpose. </P>
<P align=center>43</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_49></A><BR>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="90%">

  <TR vAlign=top>
    <TD align=center><BR><B>Title of class</B> <BR></TD>
    <TD width="25%" align=center><B>Name and address of</B> <BR><B>beneficial
      owner</B> <BR></TD>
    <TD width="25%" align=center><B>Amount and nature of</B> <BR><B>beneficial
      ownership</B> <BR></TD>
    <TD width="25%" align=center><B>Percent of</B> <BR><B>class
      </B><B><SUP>1</SUP></B> <BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>Athanasios Skarpelos</B> <BR>2, Place du
      Port <BR>Geneva, Switzerland CH 1204 <BR></TD>
    <TD width="25%" align=right>6,725,832&nbsp;&nbsp;&nbsp;&nbsp; Direct
      <BR><BR><BR></TD>
    <TD width="25%" align=center>22.24% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>Sean Lowry</B> <BR>300-1172 Bay Street
      <BR>Toronto, Ontario M5S 1L9 <BR>Canada </TD>
    <TD width="25%"
      align=right>150,000<SUP>2</SUP>&nbsp;&nbsp;&nbsp;&nbsp;Direct
    <BR><BR><BR></TD>
    <TD width="25%" align=center>0.49% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>Robert Chisholm</B> <BR>c/o 1600 &#150; 609
      Granville <BR>Street Vancouver, BC V7Y 1C3 <BR>Canada </TD>
    <TD width="25%" align=right>0&nbsp;&nbsp;&nbsp;&nbsp; Direct
    <BR><BR><BR></TD>
    <TD width="25%" align=center>0% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>Harvey Lalach</B><SUP>3</SUP> <BR>4837
      Canyon Ridge Crescent <BR>Kelowna, British Columbia <BR>Canada </TD>
    <TD width="25%" align=right>825,000<SUP>4&nbsp;&nbsp; </SUP>&nbsp;Direct
      <BR><BR><BR></TD>
    <TD width="25%" align=center>2.71% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>George Tidmarsh</B><SUP>5</SUP> <BR>951
      Gateway Blvd., Suite 3A <BR>South, San Francisco, CA, <BR>94060, USA </TD>
    <TD width="25%" align=right>12,000<SUP>6&nbsp;&nbsp;&nbsp; </SUP>Direct
      <BR><BR><BR></TD>
    <TD width="25%" align=center>0.40% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left><BR><BR></TD>
    <TD width="25%" align=left><B>Directors &amp; Executive</B>
      <BR><B>Officers as a group (2</B> <BR><B>persons) </B><B><SUP>7</SUP></B>
    </TD>
    <TD width="25%" align=right><B>150,000</B>&nbsp;&nbsp;&nbsp;&nbsp; Direct
      <BR><BR></TD>
    <TD width="25%" align=center>0.49% <BR><BR></TD></TR></TABLE></DIV>
<P align=justify>1 Percentage of ownership is based on 30,240,687 shares of our
common stock issued and outstanding as of December 28, 2012. Except as otherwise
indicated, we believe that the beneficial owners of the common stock listed
above, based on information furnished by such owners, have sole investment and
voting power with respect to such shares, subject to community property laws
where applicable. Beneficial ownership is determined in accordance with the
rules of the Securities and Exchange Commission and generally includes voting or
investment power with respect to securities. Shares of common stock subject to
options or warrants currently exercisable, or exercisable within 60 days, are
deemed outstanding for purposes of computing the percentage ownership of the
person holding such option or warrants, but are not deemed outstanding for
purposes of computing the percentage ownership of any other person.</P>
<P align=center>44</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_50></A>
<P align=justify>2 Includes 150,000 stock options exercisable within 60 days.
</P>
<P align=justify>3 Mr. Lalach resigned as director and officer on June 26, 2012.
</P>
<P align=justify>4 Includes 625,000 shares of common stock and 200,000 stock
options exercisable within 60 days. </P>
<P align=justify>5 Dr. Tidmarsh resigned as executive chairman on March 21,
2012.</P>
<P align=justify>6 Includes 8,000 shares of common stock and 4,000 shares of
common stock issuable upon exercise of warrants.</P>
<P align=justify>7 Does not include Mr. Lalach, who resigned as director and
officer on June 26, 2012 and Dr. Tidmarsh who resigned as executive chairman on
March 21, 2012.</P>
<P align=justify><I><FONT color=#4f81bd>Changes in Control</FONT></I></P>
<P align=justify>We are unaware of any contract or other arrangement the
operation of which may at a subsequent date result in a change of control of our
company.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT color="#004080" size=4>ITEM
      13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
      </FONT></TD>
  </TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Transactions with related
persons</FONT></I></P>
<P align=justify>There has been no transaction, since October 1, 2010, or
currently proposed transaction, in which we were or are to be a participant and
the amount involved exceeds the lesser of $120,000 or one percent of the average
of our total assets at year end for the last two completed fiscal years, and in
which any of the following persons had or will have a direct or indirect
material interest. </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD vAlign=top width="4%" align=right>i. </TD>
    <TD vAlign=top width="4%" align=right>&nbsp;</TD>
    <TD>
      <P align=justify>any director or executive officer of our
  company;</P></TD></TR>
  <TR>
    <TD vAlign=top width="4%" align=right>ii. </TD>
    <TD vAlign=top width="4%" align=right>&nbsp;</TD>
    <TD>
      <P align=justify>any beneficial owner of shares carrying more than 5% of
      the voting rights attached to our outstanding shares of common stock;
      and</P></TD></TR>
  <TR>
    <TD vAlign=top width="4%" align=right>iii. </TD>
    <TD vAlign=top width="4%" align=right>&nbsp;</TD>
    <TD>
      <P align=justify>any member of the immediate family (including spouse,
      parents, children, siblings and in-laws) of any of the foregoing
      persons.</P></TD></TR></TABLE>
<P align=justify>Cameron Durrant</P>
<P align=justify>On May 20, 2008, we entered into a consulting agreement with
Cameron Durrant, a former director of our company, to provide certain management
and consulting services to our company. Consideration for his services included:
</P>
<P align=center>45</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_51></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>the issuance of 200,000 shares of common stock to be paid
      installments of 25,000 shares every quarter;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>the issuance of 400,000 stock options exercisable at
      $5.25 per share for a period of three years, subject to vesting
      provisions; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>a payment of a finder&#146;s fee for any financing our company
      receives in the amount of 4% on the first $100,000,000 and 2% on the
      balance.</P></TD></TR></TABLE>
<P align=justify>On May 14, 2009, we signed an amended consulting agreement with
Cameron Durrant, whereby the consideration of 200,000 common shares to be paid
in installments of 25,000 common shares every quarter was replaced with a grant
of 400,000 options at an exercise price of $2.50 per share until May 12, 2014
and vest as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>200,000 options upon the execution of the amended
      consulting agreement;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>50,000 options on August 14, 2009</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>50,000 options on November 14, 2009</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>50,000 on February 14, 2010</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(e) </TD>
    <TD>
      <P align=justify>50,000 options on May 14, 2010</P></TD></TR></TABLE>
<P align=justify>Dr. Durrant received 75,000 shares of common stock pursuant to
the consulting agreement dated May 20, 2008 and subsequently returned these
75,000 shares to our company for cancellation as a result of the award
modification.</P>
<P align=justify>On January 2, 2010 we signed a second amended consulting
agreement with Dr. Durrant, whereby we retained his services as our Executive
Chairman commencing as of January 2, 2010. In consideration of Dr. Durrant&#146;s
services, we agreed to pay him a monthly fee of $25,000, which equates to
$300,000 over the course of one year. The term of this agreement was for a
period of two years commencing on January 2, 2010 and expiring on January 1,
2012. Effective September 16, 2011, Dr. Durrant resigned from our board of
directors and as an officer of our company. </P>
<P align=justify><I><FONT color=#4f81bd>Compensation of Named Executive Officers
and Directors</FONT></I></P>
<P align=justify>For information regarding compensation of named executive
officers and directors, please see &#147;Item 11. Executive Compensation.&#148; </P>
<P align=justify><I><FONT color=#4f81bd>Director Independence</FONT></I></P>
<P align=justify>Under NASDAQ Rule 5605(a)(2), a director is not considered to
be independent if he or she is also an executive officer or employee of the
company or accepted any compensation from the company in excess of $120,000
during any period of twelve consecutive months within the three years preceding
the determination of independence.</P>
<P align=justify>We determined that Robert Chisholm is not independent as that
term is defined by NASDAQ 5605(a)(2) because Mr. Chisholm serves as our
President, Secretary, Treasurer and Chief Financial Officer. We determined that
Sean Lowry is independent as that term is defined by NASDAQ Rule 5605(a)(2).</P>
<P align=center>46</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_52></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT
      color=#17365d size="4">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</FONT></TD>
  </TR></TABLE>
<P align=justify><I><FONT color=#4f81bd>Fees Paid to Our Independent Registered
Public Accounting Firm </FONT></I></P>
<P align=justify>The following table sets forth the aggregate fees billed or
expected to be billed to our company for professional services rendered by our
independent registered public accounting firms, for the fiscal years ended
September 30, 2012 and 2011: </P>
<P align=justify>BDO Canada LLP</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="80%">

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="20%" align=right>2012
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="20%" align=right>2011
    </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=center >Audit Fees </TD>
    <TD bgColor=#e6efff width="20%" align=right>$87,231 </TD>
    <TD bgColor=#e6efff width="20%" align=right>$87,570 </TD></TR>
  <TR vAlign=top>
    <TD align=center >Audit Related Fees </TD>
    <TD width="20%" align=right>Nil </TD>
    <TD width="20%" align=right>Nil </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=center >Tax Fees </TD>
    <TD bgColor=#e6efff width="20%" align=right>$5,161 </TD>
    <TD bgColor=#e6efff width="20%" align=right>$7,349 </TD></TR>
  <TR vAlign=top>
    <TD align=center >All Other Fees </TD>
    <TD width="20%" align=right>Nil </TD>
    <TD width="20%" align=right>Nil </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=center >Total Fees </TD>
    <TD bgColor=#e6efff width="20%" align=right>$92,392 </TD>
    <TD bgColor=#e6efff width="20%" align=right>$94,919
</TD></TR></TABLE></DIV>
<P align=justify>Audit Fees. Consist of fees billed for professional services
rendered for the audits of our financial statements, reviews of our interim
financial statements included in quarterly reports, services performed in
connection with filings with the Securities and Exchange Commission and other
services that are normally provided by BDO Canada LLP for the fiscal years ended
September 30, 2012 and 2011, in connection with statutory and regulatory filings
or engagements.</P>
<P align=justify><I><FONT color=#4f81bd>Policy on Pre-Approval by Audit
Committee of Services Performed by Independent Registered Public Accounting Firm
</FONT></I></P>
<P align=justify>Our audit committee pre-approves all services provided by our
independent registered public accounting firm. All of the above services and
fees were reviewed and approved by our audit committee before the respective
services were rendered. </P>
<P align=justify>Our audit committee has considered the nature and amount of fees billed by BDO Canada LLP and believes that the provision of services for activities unrelated to the audit was compatible with maintaining BDO Canada LLP&rsquo;s independence.</P>
<P align=center>47</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_53></A>
<P align=justify><B>PART IV</B></P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><FONT
      color=#004080 size="4">ITEM 15. EXHIBITS, SCHEDULES FINANCIAL STATEMENT </FONT></TD>
  </TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Exhibit </B><BR><B>Number </B></TD>
    <TD width="90%" align=left ><BR><B>Description </B></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(3) </B></TD>
    <TD width="90%" align=left >
      <P align=justify><B>Articles of Incorporation and Bylaws </B></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.1 </TD>
    <TD width="90%" align=left >
      <P align=justify>Articles of Incorporation (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.2 </TD>
    <TD width="90%" align=left >
      <P align=justify>Bylaws (incorporated by reference to an exhibit to our
      Registration Statement on Form SB-2 filed on January 13, 2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.3 </TD>
    <TD width="90%" align=left >
      <P align=justify>Articles of Merger filed with the Secretary of State of
      Nevada on January 10, 2007 and which is effective January 25, 2007
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on January 25, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(4) </B></TD>
    <TD width="90%" align=left >
      <P align=justify><B>Instruments defining rights of security holders,
      including indentures </B></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.1 </TD>
    <TD width="90%" align=left >
      <P align=justify>Specimen Stock Certificate (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.2 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.3 </TD>
    <TD width="90%" align=left >
      <P align=justify>8% Convertible Loan Agreement dated June 3, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.4 </TD>
    <TD width="90%" align=left >
      <P align=justify>8% Convertible Loan Agreement dated June 19, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(10) </B></TD>
    <TD width="90%" align=left >
      <P align=justify><B>Material Contracts </B></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.1 </TD>
    <TD width="90%" align=left >
      <P align=justify>Agreement between Anavex Life Sciences Corp. and Dr.
      Alexandre Vamvakides dated January 31, 2007 (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on February 7, 2007)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.2 </TD>
    <TD width="90%" align=left >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1002616
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.3 </TD>
    <TD width="90%" align=left >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004208
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.4 </TD>
    <TD width="90%" align=left >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004868
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.5 </TD>
    <TD width="90%" align=left >
      <P align=justify>Written description of Greek Patent Application Number
      20070100020 (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.6 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Stock Option Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on February 22,
      2007) </P></TD></TR></TABLE></DIV>
<P align=center>48</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_54></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD width="90%" align=left ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>10.7 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Services and Subscription Agreement dated
      September 11, 2007 between our company and Eurogenet Labs S.A.
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 27, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.8 </TD>
    <TD width="90%" align=left >
      <P align=justify>2007 Stock Option Plan (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on September 28, 2007)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.9 </TD>
    <TD width="90%" align=left >
      <P align=justify>Consulting Agreement with Cameron Durrant dated May 20,
      2008 (incorporated by reference to an exhibit to our Quarterly Report on
      Form 10-QSB filed on August 18, 2008 </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.10 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.11 </TD>
    <TD width="90%" align=left >
      <P align=justify>Consulting Agreement with Tariq Arshad dated March 2,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.13 </TD>
    <TD width="90%" align=left >
      <P align=justify>Consulting Agreement with Dr. Mark Smith dated January
      13, 2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.14 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.15 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.16 </TD>
    <TD width="90%" align=left >
      <P align=justify>Amended Consulting Agreement with Cameron Durrant dated
      May 14, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.17 </TD>
    <TD width="90%" align=left >
      <P align=justify>CEO Consulting Agreement with Dr. Herve de Kergrohen
      dated June 12, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.18 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Private Placement subscription agreement dated
      June 15, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.19 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Services Agreement with Andreas Eleuthariadis
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.20 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Services Agreement with Vasileios Kourafalos
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.21 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Services Agreement with George Kalkanis dated
      June 10, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.22 </TD>
    <TD width="90%" align=left >
      <P align=justify>Stock Option Agreement with Alexandre Vamvakides dated
      June 11, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.23 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Private Placement Subscription Agreement
      Convertible Loan (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.24 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Private Placement Subscription Agreement for
      Units (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.25 </TD>
    <TD width="90%" align=left >
      <P align=justify>Consultant Services Agreement with NAD Ltd. dated July 1,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on November 24, 2009) </P></TD></TR></TABLE></DIV>
<P align=center>49</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_55></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD width="90%" align=left >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.26 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 24,
      2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.27 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on August 12, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.28 </TD>
    <TD width="90%" align=left >
      <P align=justify>Stock Option Agreement with Alexander Vamvakides dated
      October 19, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.29 </TD>
    <TD width="90%" align=left >
      <P align=justify>Promissory note issued to Stonehedge Limited on January
      1, 2010 (incorporated by reference to an exhibit to our Quarterly Report
      on Form 10-Q filed on March 31, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.30 </TD>
    <TD width="90%" align=left >
      <P align=justify>Second Amended Consulting Agreement with Dr. Cameron
      Durrant dated January 2, 2010 (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.31 </TD>
    <TD width="90%" align=left >
      <P align=justify>Contract Lease Agreement with Euro Genet Labs SA dated
      February 1, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.32 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.33 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.34 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.35 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement for US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.36 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement for non-US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.37 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate for US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.38 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.39 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Services Agreement dated July 5, 2010 with
      Eurogenet Labs SA (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.40 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.41 </TD>
    <TD width="90%" align=left >
      <P align=justify>Agreement for Services with Genesis Biopharma Group LLC
      dated August 10, 2010 (incorporated by reference to an exhibit of our
      Current Report on Form 8-K filed on August 18, 2010) <I>(portions of the
      exhibit have been omitted pursuant to a request for confidential</I>
      <I>treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.42 </TD>
    <TD width="90%" align=left >
      <P align=justify>Agreement for Services with ABX-CRO Advanced
      Pharmaceutical Services dated August 10, 2010 (incorporated by reference
      to an exhibit of our Current Report on Form 8-K filed on August 18, 2010)
      <I>(portions of the exhibit have been omitted pursuant to a request
      for</I> <I>confidential treatment)</I> </P></TD></TR></TABLE></DIV>
<P align=center>50</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_56></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD width="90%" align=left >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.43 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.44 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (Canadian and Offshore
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.45 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (US warrant
      holders)(incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.46 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (Canadian and Offshore
      warrant holders) (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.47 </TD>
    <TD width="90%" align=left >
      <P align=justify>Consulting Agreement dated August 2, 2010 with Tom
      Skarpelos (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.48 </TD>
    <TD width="90%" align=left >
      <P align=justify>Independent Contractor Agreement dated September 1, 2010
      with David Tousley (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.49 </TD>
    <TD width="90%" align=left >
      <P align=justify>Sublease Contract with Genesis Research LLC dated
      September 15, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.50 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.51 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.52 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.53 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.54 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Service and Subscription Agreement dated
      November 1, 2010 with Eurogenet Labs SA (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on November 22, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.55 </TD>
    <TD width="90%" align=left >
      <P align=justify>Subscription Agreement with Stonehedge Limited dated
      November 17, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.56 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 30,
      2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.57 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.58 </TD>
    <TD width="90%" align=left >
      <P align=justify>Shares for Services Agreement Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.59 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.60 </TD>
    <TD width="90%" align=left >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR></TABLE></DIV>
<P align=center>51</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_57></A><BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">
    <TR vAlign=top>
      <TD align=left><B>Exhibit</B> <BR>
        <B>Number</B> </TD>
      <TD width="90%" align=left ><BR> <P align=justify><B>Description</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.61 </TD>
      <TD width="90%" align=left > <P align=justify>Termination Agreement dated
          February 2, 2011 with Genesis BioPharma Group, LLC (incorporated by
          reference to an exhibit to our Current Report on Form 8-K filed on February
          7, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.62 </TD>
      <TD width="90%" align=left > <P align=justify>Independent Contractor Agreement
          with Harvey Lalach dated February 1, 2011 (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on February 7,
          2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.63 </TD>
      <TD width="90%" align=left > <P align=justify>Independent Contractor Agreement
          with Dr. Angelos Stergiou dated February 1, 2011 (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on February 7,
          2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.64 </TD>
      <TD width="90%" align=left > <P align=justify>Amended and Restated 2007
          Stock Option Plan (incorporated by reference to an exhibit to our Current
          Report on Form 8-K filed on February 8, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.65 </TD>
      <TD width="90%" align=left > <P align=justify>Form of Advisory Board Consulting
          Agreement (incorporated by reference to an exhibit to our Current Report
          on Form 8-K filed on February 28, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.66 </TD>
      <TD width="90%" align=left > <P align=justify>Consulting Agreement dated
          March 30, 2011 with Shackleton Consulting Corp. (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on April 13, 2011)
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.67 </TD>
      <TD width="90%" align=left > <P align=justify>Form of subscription agreement
          for convertible debenture (incorporated by reference to an exhibit to
          our Current Report on Form 8-K filed on April 26, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.68 </TD>
      <TD width="90%" align=left > <P align=justify>Form of subscription agreement
          for convertible debenture (incorporated by reference to an exhibit to
          our Current Report on Form 8-K filed on May 9, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.69 </TD>
      <TD width="90%" align=left > <P align=justify>Form of warrant certificate
          (incorporated by reference to an exhibit to our Current Report on Form
          8-K filed on May 9, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.70 </TD>
      <TD width="90%" align=left > <P align=justify>Amended Stock Option Agreement
          dated September 16, 2011 with Cameron Durrant (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on September 21,
          2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.71 </TD>
      <TD width="90%" align=left > <P align=justify>Consulting Agreement dated
          effective October 10, 2011, with George Tidmarsh (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on October 14,
          2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.72 </TD>
      <TD width="90%" align=left > <P align=justify>Form of subscription agreement
          for services (US purchaser) (incorporated by reference to our current
          report on Form 8-K filed on February 10, 2012) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.73 </TD>
      <TD width="90%" align=left > <P align=justify>Form of subscription agreement
          for units (Offshore purchasers) (incorporated by reference to our current
          report on Form 8-K filed on February 10, 2012) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.74 </TD>
      <TD width="90%" align=left > <P align=justify>Unsecured Promissory Note
          dated April 20, 2012 issued to Georgia Georgopoulou (incorporated by
          reference to our quarterly report on Form 10-Q filed on May 15, 2012)
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.75 </TD>
      <TD width="90%" align=left > <P align=justify>Form of subscription agreements
          for convertible debenture and promissory notes (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on June 7, 2012)
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><a href="exhibit10-76.htm">10.76*
        </a></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left
    > <P align=justify><a href="exhibit10-76.htm">Promissory Note dated October
          17, 2012 issued to Akira International Limited </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><a href="exhibit10-77.htm">10.77*
        </a></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left
    > <P align=justify><a href="exhibit10-77.htm">Promissory Note dated November
          12, 2012 issued to Akira International Limited </a></P></TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>52</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_58></A><BR>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>Exhibit</B> <BR>
          <B>Number</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><BR>
          <B>Description</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(14)</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><B>Code of Ethics</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>14.1 </P></TD>
      <TD width="90%" align=left > <P align=justify>Code of Conduct (incorporated
          by reference to an exhibit to our Current Report on Form 8- K filed
          on September 28, 2007) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(21)</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><B>Subsidiaries</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>21.1 </P></TD>
      <TD width="90%" align=left > <P align=justify>Anavex Life Sciences (France)
          SA, incorporated under the laws of France </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(31)</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><B>Section 302 Certifications</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><a href="exhibit31-1.htm">31.1* </a></P></TD>
      <TD width="90%" align=left > <P align=justify><a href="exhibit31-1.htm">Section
          302 Certification of Robert Chisholm </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(32)</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><B>Section 906 Certifications</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><a href="exhibit32-1.htm">32.1* </a></P></TD>
      <TD width="90%" align=left > <P align=justify><a href="exhibit32-1.htm">Section
          906 Certification of Robert Chisholm </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(99)</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><B>Additional Exhibits</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>99.1 </P></TD>
      <TD width="90%" align=left > <P align=justify>Insider Trading Policy Adopted
          August 27, 2010 (incorporated by reference to an exhibit to our Current
          Report on Form 8-K filed on September 27, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(101)</B> </P></TD>
      <TD width="90%" align=left > <P align=justify><B>XBRL</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.INS* </P></TD>
      <TD width="90%" align=left > <P align=justify>XBRL INSTANCE DOCUMENT </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.SCH* </P></TD>
      <TD width="90%" align=left > <P align=justify>XBRL TAXONOMY EXTENSION SCHEMA
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.CAL* </P></TD>
      <TD width="90%" align=left > <P align=justify>XBRL TAXONOMY EXTENSION CALCULATION
          LINKBASE </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.DEF* </P></TD>
      <TD width="90%" align=left > <P align=justify>XBRL TAXONOMY EXTENSION DEFINITION
          LINKBASE </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.LAB* </P></TD>
      <TD width="90%" align=left > <P align=justify>XBRL TAXONOMY EXTENSION LABEL
          LINKBASE </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.PRE* </P></TD>
      <TD width="90%" align=left > <P align=justify>XBRL TAXONOMY EXTENSION PRESENTATION
          LINKBASE </P></TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>* Filed herewith. </P>
<P align=center>53</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_59></A>
<P align=center><B>SIGNATURES</B></P>
<P align=justify>Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP. </B></P>
<P align=justify>By:</P>
<P align=justify><u>/s/ Robert Chisholm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</u><BR>Robert Chisholm<BR>President, Secretary, Treasurer, Chief Financial Officer and
Director<BR>(Principal Executive Officer, Principal Financial Officer and
Principal Accounting Officer)<BR>Date: December 31, 2012
<BR></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.</P>
<P align=justify>By:</P>
<P align=justify><u>/s/ Robert Chisholm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</u><BR>Robert
Chisholm<BR>President, Secretary, Treasurer, Chief Financial Officer and
Director<BR>(Principal Executive Officer, Principal Financial Officer and
Principal Accounting Officer)<BR>Date: December 31, 2012 </P>
<P align=justify>By:<BR></P>
<P align=justify><u>/s/ Sean
Lowry&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</u><BR>Sean
Lowry<BR>Director<BR>Date: December 31, 2012 </P>
<P align=center>54</P>
<HR align=center color=black SIZE=5 width="100%" noShade>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
